Before_IN using_VBG this_DT medication_NN ,_, tell_VB your_PRP$ doctor_NN or_CC pharmacist_NN of_IN all_DT prescription_NN and_CC nonprescription_NN products_NNS you_PRP may_MD use_VB ,_, especially_RB of_IN :_: aminoglycosides_NNS -LRB-_-LRB- e.g._FW ,_, gentamicin_NN ,_, amikacin_NN -RRB-_-RRB- ,_, amphotericin_NN B_NN ,_, cyclosporine_NN ,_, non-steroidal_JJ anti-inflammatory_JJ drugs_NNS -LRB-_-LRB- e.g._FW ,_, ibuprofen_NN -RRB-_-RRB- ,_, tacrolimus_NN ,_, vancomycin_NN ._. Do_VB not_RB start_VB or_CC stop_VB any_DT medicine_NN without_IN doctor_NN or_CC pharmacist_NN approval_NN ._. Intravenous_JJ Adenocard_NN -LRB-_-LRB- adenosine_NN -RRB-_-RRB- has_VBZ been_VBN effectively_RB administered_VBN in_IN the_DT presence_NN of_IN other_JJ cardioactive_JJ drugs_NNS ,_, such_JJ as_IN quinidine_NN ,_, beta-adrenergic_JJ blocking_VBG agents_NNS ,_, calcium_NN channel_NN blocking_VBG agents_NNS ,_, and_CC angiotensin_NN converting_NN enzyme_NN inhibitors_NNS ,_, without_IN any_DT change_NN in_IN the_DT adverse_JJ reaction_NN profile_NN ._. Digoxin_NN and_CC verapamil_NN use_NN may_MD be_VB rarely_RB associated_VBN with_IN ventricular_JJ fibrillation_NN when_WRB combined_VBN with_IN Adenocard_NNP ._. Because_IN of_IN the_DT potential_NN for_IN additive_JJ or_CC synergistic_JJ depressant_NN effects_NNS on_IN the_DT SA_NNP and_CC AV_NNP nodes_NNS ,_, however_RB ,_, Adenocard_NNP should_MD be_VB used_VBN with_IN caution_NN in_IN the_DT presence_NN of_IN these_DT agents_NNS ._. The_DT use_NN of_IN Adenocard_NNP in_IN patients_NNS receiving_VBG digitalis_NN may_MD be_VB rarely_RB associated_VBN with_IN ventricular_JJ fibrillation_NN ._. The_DT effects_NNS of_IN adenosine_NN are_VBP antagonized_VBN by_IN methylxanthines_NNS such_JJ as_IN caffeine_NN and_CC theophylline_NN ._. In_IN the_DT presence_NN of_IN these_DT methylxanthines_NNS ,_, larger_JJR doses_NNS of_IN adenosine_NN may_MD be_VB required_VBN or_CC adenosine_NN may_MD not_RB be_VB effective_JJ ._. Adenosine_NN effects_NNS are_VBP potentiated_VBN by_IN dipyridamole_NN ._. Thus_RB ,_, smaller_JJR doses_NNS of_IN adenosine_NN may_MD be_VB effective_JJ in_IN the_DT presence_NN of_IN dipyridamole_NN ._. Carbamazepine_NNP has_VBZ been_VBN reported_VBN to_TO increase_VB the_DT degree_NN of_IN heart_NN block_NN produced_VBN by_IN other_JJ agents_NNS ._. As_IN the_DT primary_JJ effect_NN of_IN adenosine_NN is_VBZ to_TO decrease_VB conduction_NN through_IN the_DT A-V_NN node_NN ,_, higher_JJR degrees_NNS of_IN heart_NN block_NN may_MD be_VB produced_VBN in_IN the_DT presence_NN of_IN carbamazepine_NN ._. Co-administration_NN with_IN antifungal_JJ agents_NNS such_JJ as_IN ketoconazole_NN or_CC itraconazole_NN is_VBZ not_RB recommended_VBN ._. Nafazodone_NNP ,_, fluvoxamine_NN ,_, cimetidine_NN -LRB-_-LRB- consider_VB Xanax_NNP dose_NN reduction_NN -RRB-_-RRB- ._. Fluoxetine_NNP ,_, OCs_NNP ,_, sertraline_NN ,_, diltiazem_NN ,_, macrolide_NN antibiotics_NNS -LRB-_-LRB- exercise_NN caution_NN -RRB-_-RRB- ._. No_DT drug_NN interaction_NN studies_NNS were_VBD performed_VBN ._. No_DT in_FW vitro_FW metabolism_NN studies_NNS were_VBD performed_VBN ._. Dexamethasone_NN :_: Steady-state_JJ trough_NN concentrations_NNS of_IN albendazole_NN sulfoxide_NN were_VBD about_IN 56_CD %_NN higher_JJR when_WRB 8_CD mg_NN dexamethasone_NN was_VBD coadministered_VBN with_IN each_DT dose_NN of_IN albendazole_NN -LRB-_-LRB- 15_CD mg/kg/day_NN -RRB-_-RRB- in_IN eight_CD neurocysticercosis_NN patients_NNS ._. Praziquantel_NNP :_: In_IN the_DT fed_NN state_NN ,_, praziquantel_NN -LRB-_-LRB- 40_CD mg/kg_NN -RRB-_-RRB- increased_VBD mean_JJ maximum_NN plasma_NN concentration_NN and_CC area_NN under_IN the_DT curve_NN of_IN albendazole_NN sulfoxide_NN by_IN about_IN 50_CD %_NN in_IN healthy_JJ subjects_NNS -LRB-_-LRB- n_NN =_JJ 10_CD -RRB-_-RRB- compared_VBN with_IN a_DT separate_JJ group_NN of_IN subjects_NNS -LRB-_-LRB- n_NN =_JJ 6_CD -RRB-_-RRB- given_VBN albendazole_NN alone_RB ._. Mean_NN T_NN max_NN and_CC mean_VB plasma_NN elimination_NN half-life_NN of_IN albendazole_NN sulfoxide_NN were_VBD unchanged_JJ ._. The_DT pharmacokinetics_NNS of_IN praziquantel_NN were_VBD unchanged_JJ following_VBG coadministration_NN with_IN albendazole_NN -LRB-_-LRB- 400_CD mg_NN -RRB-_-RRB- ._. Cimetidine_NNP :_: Albendazole_NNP sulfoxide_NN concentrations_NNS in_IN bile_NN and_CC cystic_JJ fluid_NN were_VBD increased_VBN -LRB-_-LRB- about_IN 2-fold_JJ -RRB-_-RRB- in_IN hydatid_NN cyst_NN patients_NNS treated_VBN with_IN cimetidine_NN -LRB-_-LRB- 10_CD mg/kg/day_NN -RRB-_-RRB- -LRB-_-LRB- n_NN =_JJ 7_CD -RRB-_-RRB- compared_VBN with_IN albendazole_NN -LRB-_-LRB- 20_CD mg/kg/day_NN -RRB-_-RRB- alone_RB -LRB-_-LRB- n_NN =_JJ 12_CD -RRB-_-RRB- ._. Albendazole_NNP sulfoxide_NN plasma_NN concentrations_NNS were_VBD unchanged_JJ 4_CD hours_NNS after_IN dosing_NN ._. Theophylline_NNP :_: The_DT pharmacokinetics_NNS of_IN theophylline_NN -LRB-_-LRB- aminophylline_NN 5.8_CD mg/kg_NN infused_VBD over_IN 20_CD minutes_NNS -RRB-_-RRB- were_VBD unchanged_JJ following_VBG a_DT single_JJ oral_JJ dose_NN of_IN albendazole_NN -LRB-_-LRB- 400_CD mg_NN -RRB-_-RRB- in_IN 6_CD healthy_JJ subjects_NNS ._. No_DT information_NN provided_VBN ._. PROLEUKIN_NNP may_MD affect_VB central_JJ nervous_JJ function_NN ._. Therefore_RB ,_, interactions_NNS could_MD occur_VB following_VBG concomitant_JJ administration_NN of_IN psychotropic_JJ drugs_NNS -LRB-_-LRB- e.g._FW ,_, narcotics_NNS ,_, analgesics_NNS ,_, antiemetics_NNS ,_, sedatives_NNS ,_, tranquilizers_NNS -RRB-_-RRB- ._. Concurrent_JJ administration_NN of_IN drugs_NNS possessing_VBG nephrotoxic_JJ -LRB-_-LRB- e.g._FW ,_, aminoglycosides_NNS ,_, indomethacin_NN -RRB-_-RRB- ,_, myelotoxic_JJ -LRB-_-LRB- e.g._FW ,_, cytotoxic_JJ chemotherapy_NN -RRB-_-RRB- ,_, cardiotoxic_JJ -LRB-_-LRB- e.g._FW ,_, doxorubicin_NN -RRB-_-RRB- or_CC hepatotoxic_JJ -LRB-_-LRB- e.g._FW ,_, methotrexate_NN ,_, asparaginase_NN -RRB-_-RRB- effects_NNS with_IN PROLEUKIN_NN may_MD increase_VB toxicity_NN in_IN these_DT organ_NN systems_NNS ._. The_DT safety_NN and_CC efficacy_NN of_IN PROLEUKIN_NNP in_IN combination_NN with_IN any_DT antineoplastic_JJ agents_NNS have_VBP not_RB been_VBN established_VBN ._. In_IN addition_NN ,_, reduced_VBD kidney_NN and_CC liver_NN function_NN secondary_JJ to_TO PROLEUKIN_NN treatment_NN may_MD delay_VB elimination_NN of_IN concomitant_JJ medications_NNS and_CC increase_VB the_DT risk_NN of_IN adverse_JJ events_NNS from_IN those_DT drugs_NNS ._. Hypersensitivity_NN reactions_NNS have_VBP been_VBN reported_VBN in_IN patients_NNS receiving_VBG combination_NN regimens_NNS containing_VBG sequential_JJ high_JJ dose_NN PROLEUKIN_NN and_CC antineoplastic_JJ agents_NNS ,_, specifically_RB ,_, dacarbazine_NN ,_, cis-platinum_NN ,_, tamoxifen_NN and_CC interferon-alfa_NN ._. These_DT reactions_NNS consisted_VBD of_IN erythema_NN ,_, pruritus_NN ,_, and_CC hypotension_NN and_CC occurred_VBD within_IN hours_NNS of_IN administration_NN of_IN chemotherapy_NN ._. These_DT events_NNS required_VBN medical_JJ intervention_NN in_IN some_DT patients_NNS ._. Myocardial_JJ injury_NN ,_, including_VBG myocardial_JJ infarction_NN ,_, myocarditis_NN ,_, ventricular_JJ hypokinesia_NN ,_, and_CC severe_JJ rhabdomyolysis_NN appear_VBP to_TO be_VB increased_VBN in_IN patients_NNS receiving_VBG PROLEUKIN_NNP and_CC interferon-alfa_JJ concurrently_RB ._. Exacerbation_NN or_CC the_DT initial_JJ presentation_NN of_IN a_DT number_NN of_IN autoimmune_JJ and_CC inflammatory_JJ disorders_NNS has_VBZ been_VBN observed_VBN following_VBG concurrent_JJ use_NN of_IN interferon-alfa_NN and_CC PROLEUKIN_NN ,_, including_VBG crescentic_JJ IgA_NN glomerulonephritis_NN ,_, oculo-bulbar_JJ myasthenia_NN gravis_NN ,_, inflammatory_JJ arthritis_NN ,_, thyroiditis_NN ,_, bullous_JJ pemphigoid_NN ,_, and_CC Stevens-Johnson_NN syndrome_NN ._. Although_IN glucocorticoids_NNS have_VBP been_VBN shown_VBN to_TO reduce_VB PROLEUKIN-induced_JJ side_JJ effects_NNS including_VBG fever_NN ,_, renal_JJ insufficiency_NN ,_, hyperbilirubinemia_NN ,_, confusion_NN ,_, and_CC dyspnea_NN ,_, concomitant_JJ administration_NN of_IN these_DT agents_NNS with_IN PROLEUKIN_NN may_MD reduce_VB the_DT antitumor_NN effectiveness_NN of_IN PROLEUKIN_NNP and_CC thus_RB should_MD be_VB avoided_VBN ._. 12_CD Beta-blockers_NNS and_CC other_JJ antihypertensives_NNS may_MD potentiate_VB the_DT hypotension_NN seen_VBN with_IN PROLEUKIN_NN ._. Delayed_VBN Adverse_JJ Reactions_NNS to_TO Iodinated_NNP Contrast_NNP Media_NNP :_: A_NNP review_NN of_IN the_DT literature_NN revealed_VBD that_IN 12.6_CD %_NN -LRB-_-LRB- range_NN 11-28_CD %_NN -RRB-_-RRB- of_IN 501_CD patients_NNS treated_VBN with_IN various_JJ interleukin-2_NN containing_VBG regimens_NNS who_WP were_VBD subsequently_RB administered_VBN radiographic_JJ iodinated_VBN contrast_NN media_NNS experienced_VBD acute_JJ ,_, atypical_JJ adverse_JJ reactions_NNS ._. The_DT onset_NN of_IN symptoms_NNS usually_RB occurred_VBD within_IN hours_NNS -LRB-_-LRB- most_RBS commonly_RB 1_CD to_TO 4_CD hours_NNS -RRB-_-RRB- following_VBG the_DT administration_NN of_IN contrast_NN media_NNS ._. These_DT reactions_NNS include_VBP fever_NN ,_, chills_NNS ,_, nausea_NN ,_, vomiting_VBG ,_, pruritus_NN ,_, rash_NN ,_, diarrhea_NN ,_, hypotension_NN ,_, edema_NN ,_, and_CC oliguria_NN ._. Some_DT clinicians_NNS have_VBP noted_VBN that_IN these_DT reactions_NNS resemble_VBP the_DT immediate_JJ side_JJ effects_NNS caused_VBN by_IN interleukin-2_NN administration_NN ,_, however_RB the_DT cause_NN of_IN contrast_NN reactions_NNS after_IN interleukin-2_NN therapy_NN is_VBZ unknown_JJ ._. Most_JJS events_NNS were_VBD reported_VBN to_TO occur_VB when_WRB contrast_NN media_NNS was_VBD given_VBN within_IN 4_CD weeks_NNS after_IN the_DT last_JJ dose_NN of_IN interleukin-2_NN ._. These_DT events_NNS were_VBD also_RB reported_VBN to_TO occur_VB when_WRB contrast_NN media_NNS was_VBD given_VBN several_JJ months_NNS after_IN interleukin-2_NN treatment_NN ._. No_DT formal_JJ interaction_NN studies_NNS have_VBP been_VBN performed_VBN ._. The_DT duration_NN of_IN the_DT period_NN following_VBG treatment_NN with_IN AMEVIVE_NN before_IN one_CD should_MD consider_VB starting_VBG other_JJ immunosuppressive_JJ therapy_NN has_VBZ not_RB been_VBN evaluated_VBN ._. Carcinogenesis_NN ,_, Mutagenesis_NN ,_, and_CC Fertility_NN ._. In_IN a_DT chronic_JJ toxicity_NN study_NN ,_, cynomolgus_NN monkeys_NNS were_VBD dosed_VBN weekly_RB for_IN 52_CD weeks_NNS with_IN intravenous_JJ alefacept_NN at_IN 1_CD mg/kg/dose_NN or_CC 20_CD mg/kg/dose_NN ._. One_CD animal_NN in_IN the_DT high_JJ dose_NN group_NN developed_VBD a_DT B-cell_NN lymphoma_NN that_WDT was_VBD detected_VBN after_IN 28_CD weeks_NNS of_IN dosing_NN ._. Additional_JJ animals_NNS in_IN both_DT dose_NN groups_NNS developed_VBD B-cell_NN hyperplasia_NN of_IN the_DT spleen_NN and_CC lymph_NN nodes_NNS ._. All_DT animals_NNS in_IN the_DT study_NN were_VBD positive_JJ for_IN an_DT endemic_JJ primate_JJ gammaherpes_NNS virus_NN also_RB known_VBN as_IN lymphocryptovirus_NN -LRB-_-LRB- LCV_NN -RRB-_-RRB- ._. Latent_JJ LCV_NN infection_NN is_VBZ generally_RB asymptomatic_JJ ,_, but_CC can_MD lead_VB to_TO B-cell_NN lymphomas_NNS when_WRB animals_NNS are_VBP immune_JJ suppressed_VBN ._. In_IN a_DT separate_JJ study_NN ,_, baboons_NNS given_VBN 3_CD doses_NNS of_IN alefacept_NN at_IN 1_CD mg/kg_NN every_DT 8_CD weeks_NNS were_VBD found_VBN to_TO have_VB centroblast_NN proliferation_NN in_IN B-cell_NN dependent_JJ areas_NNS in_IN the_DT germinal_JJ centers_NNS of_IN the_DT spleen_NN following_VBG a_DT 116-day_JJ washout_NN period_NN ._. The_DT role_NN of_IN AMEVIVE_NNP in_IN the_DT development_NN of_IN the_DT lymphoid_JJ malignancy_NN and_CC the_DT hyperplasia_NN observed_VBN in_IN non-human_JJ primates_NNS and_CC the_DT relevance_NN to_TO humans_NNS is_VBZ unknown_JJ ._. Immunodeficiency-associated_JJ lymphocyte_NN disorders_NNS -LRB-_-LRB- plasmacytic_JJ hyperplasia_NN ,_, polymorphic_JJ proliferation_NN ,_, and_CC B-cell_NN lymphomas_NNS -RRB-_-RRB- occur_VBP in_IN patients_NNS who_WP have_VBP congenital_JJ or_CC acquired_VBN immunodeficiencies_NNS including_VBG those_DT resulting_VBG from_IN immunosuppressive_JJ therapy_NN ._. No_DT carcinogenicity_NN or_CC fertility_NN studies_NNS were_VBD conducted_VBN ._. Mutagenicity_NN studies_NNS were_VBD conducted_VBN in_FW vitro_FW and_CC in_FW vivo_FW ;_: ._. no_DT evidence_NN of_IN mutagenicity_NN was_VBD observed_VBN ._. Pregnancy_NN -LRB-_-LRB- Category_NN B_NN -RRB-_-RRB- ._. Women_NNS of_IN childbearing_JJ potential_JJ make_VB up_RP a_DT considerable_JJ segment_NN of_IN the_DT patient_NN population_NN affected_VBN by_IN psoriasis_NN ._. Since_IN the_DT effect_NN of_IN AMEVIVE_NNP on_IN pregnancy_NN and_CC fetal_JJ development_NN ,_, including_VBG immune_JJ system_NN development_NN ,_, is_VBZ not_RB known_VBN ,_, health_NN care_NN providers_NNS are_VBP encouraged_VBN to_TO enroll_VB patients_NNS currently_RB taking_VBG AMEVIVE_NNP who_WP become_VBP pregnant_JJ into_IN the_DT Biogen_NNP Pregnancy_NNP Registry_NNP by_IN calling_VBG 1-866-AMEVIVE_NN -LRB-_-LRB- 1-866-263-8483_CD -RRB-_-RRB- ._. Reproductive_NNP toxicology_NN studies_NNS have_VBP been_VBN performed_VBN in_IN cynomolgus_NN monkeys_NNS at_IN doses_NNS up_RB to_TO 5_CD mg/kg/week_NN -LRB-_-LRB- about_IN 62_CD times_NNS the_DT human_JJ dose_NN based_VBN on_IN body_NN weight_NN -RRB-_-RRB- and_CC have_VBP revealed_VBN no_DT evidence_NN of_IN impaired_JJ fertility_NN or_CC harm_NN to_TO the_DT fetus_NN due_JJ to_TO AMEVIVE_NNP ._. No_DT abortifacient_NN or_CC teratogenic_JJ effects_NNS were_VBD observed_VBN in_IN cynomolgus_NN monkeys_NNS following_VBG intravenous_JJ bolus_NN injections_NNS of_IN AMEVIVE_NNP administered_VBN weekly_RB during_IN the_DT period_NN of_IN organogenesis_NN to_TO gestation_NN ._. AMEVIVE_NNP underwent_VBD trans-placental_JJ passage_NN and_CC produced_VBN in_IN utero_NN exposure_NN in_IN the_DT developing_VBG monkeys_NNS ._. In_IN utero_NN ,_, serum_NN levels_NNS of_IN exposure_NN in_IN these_DT monkeys_NNS were_VBD 23_CD %_NN of_IN maternal_JJ serum_NN levels_NNS ._. No_DT evidence_NN of_IN fetal_JJ toxicity_NN including_VBG adverse_JJ effects_NNS on_IN immune_JJ system_NN development_NN was_VBD observed_VBN in_IN any_DT of_IN these_DT animals_NNS ._. Animal_NN reproduction_NN studies_NNS ,_, however_RB ,_, are_VBP not_RB always_RB predictive_JJ of_IN human_JJ response_NN and_CC there_EX are_VBP no_DT adequate_JJ and_CC well-controlled_JJ studies_NNS in_IN pregnant_JJ women_NNS ._. Because_IN the_DT risk_NN to_TO the_DT development_NN of_IN the_DT fetal_JJ immune_JJ system_NN and_CC postnatal_JJ immune_JJ function_NN in_IN humans_NNS is_VBZ unknown_JJ ,_, AMEVIVE_NNP should_MD be_VB used_VBN during_IN pregnancy_NN only_RB if_IN clearly_RB needed_VBN ._. If_IN pregnancy_NN occurs_VBZ while_IN taking_VBG AMEVIVE_NNP ,_, continued_VBD use_NN of_IN the_DT drug_NN should_MD be_VB assessed_VBN ._. Nursing_NNP Mothers_NNP ._. It_PRP is_VBZ not_RB known_VBN whether_IN AMEVIVE_NNP is_VBZ excreted_VBN in_IN human_JJ milk_NN ._. Because_IN many_JJ drugs_NNS are_VBP excreted_VBN in_IN human_JJ milk_NN ,_, and_CC because_IN there_EX exists_VBZ the_DT potential_NN for_IN serious_JJ adverse_JJ reactions_NNS in_IN nursing_NN infants_NNS from_IN AMEVIVE_NNP ,_, a_DT decision_NN should_MD be_VB made_VBN whether_IN to_TO discontinue_VB nursing_NN while_IN taking_VBG the_DT drug_NN or_CC to_TO discontinue_VB the_DT use_NN of_IN the_DT drug_NN ,_, taking_VBG into_IN account_NN the_DT importance_NN of_IN the_DT drug_NN to_TO the_DT mother_NN ._. Geriatric_NNP Use_NNP ._. Of_IN the_DT 1357_CD patients_NNS who_WP received_VBD AMEVIVE_NNP in_IN clinical_JJ trials_NNS ,_, a_DT total_NN of_IN 100_CD patients_NNS wer_NN ._. 65_CD years_NNS of_IN age_NN and_CC 13_CD patients_NNS were_VBD ._. 75_CD years_NNS of_IN age_NN ._. No_DT differences_NNS in_IN safety_NN or_CC efficacy_NN were_VBD observed_VBN between_IN older_JJR and_CC younger_JJR patients_NNS ,_, but_CC there_EX were_VBD not_RB sufficient_JJ data_NNS to_TO exclude_VB important_JJ differences_NNS ._. Because_IN the_DT incidence_NN of_IN infections_NNS and_CC certain_JJ malignancies_NNS is_VBZ higher_JJR in_IN the_DT elderly_JJ population_NN ,_, in_IN general_JJ ,_, caution_NN should_MD be_VB used_VBN in_IN treating_VBG the_DT elderly_JJ ._. Pediatric_NNP Use_NNP ._. The_DT safety_NN and_CC efficacy_NN of_IN AMEVIVE_NNP in_IN pediatric_JJ patients_NNS have_VBP not_RB been_VBN studied_VBN ._. AMEVIVE_NNP is_VBZ not_RB indicated_VBN for_IN pediatric_JJ patients_NNS ._. Drug/Laboratory_NNP Interactions_NNS No_DT formal_JJ drug_NN interaction_NN studies_NNS have_VBP been_VBN performed_VBN with_IN Campath_NNP ._. An_DT immune_JJ response_NN to_TO Campath_NNP may_MD interfere_VB with_IN subsequent_JJ diagnostic_JJ serum_NN tests_NNS that_WDT utilize_VBP antibodie_NN ._. Intravenous_JJ ranitidine_NN was_VBD shown_VBN to_TO double_VB the_DT bioavailability_NN of_IN oral_JJ alendronate_NN ._. The_DT clinical_JJ significance_NN of_IN this_DT increased_VBN bioavailability_NN and_CC whether_IN similar_JJ increases_NNS will_MD occur_VB in_IN patients_NNS given_VBN oral_JJ H2-antagonists_NNS is_VBZ unknown_JJ ._. no_DT other_JJ specific_JJ drug_NN interaction_NN studies_NNS were_VBD performed_VBN ._. Products_NNPS containing_VBG calcium_NN and_CC other_JJ multivalent_JJ cations_NNS likely_RB will_MD interfere_VB with_IN absorption_NN of_IN alendronate_NN ._. Both_CC the_DT magnitude_NN and_CC duration_NN of_IN central_JJ nervous_JJ system_NN and_CC cardiovascular_JJ effects_NNS may_MD be_VB enhanced_VBN when_WRB ALFENTA_NNP is_VBZ administered_VBN in_IN combination_NN with_IN other_JJ CNS_NN depressants_NNS such_JJ as_IN barbiturates_NNS ,_, tranquilizers_NNS ,_, opioids_NNS ,_, or_CC inhalation_NN general_JJ anesthetics_NNS ._. Postoperative_JJ respiratory_JJ depression_NN may_MD be_VB enhanced_VBN or_CC prolonged_VBN by_IN these_DT agents_NNS ._. In_IN such_JJ cases_NNS of_IN combined_JJ treatment_NN ,_, the_DT dose_NN of_IN one_CD or_CC both_DT agents_NNS should_MD be_VB reduced_VBN ._. Limited_JJ clinical_JJ experience_NN indicates_VBZ that_IN requirements_NNS for_IN volatile_JJ inhalation_NN anesthetics_NNS are_VBP reduced_VBN by_IN 30_CD to_TO 50_CD %_NN for_IN the_DT first_JJ sixty_NN -LRB-_-LRB- 60_CD -RRB-_-RRB- minutes_NNS following_VBG ALFENTA_NNP induction_NN The_DT concomitant_JJ use_NN of_IN erythromycin_NN with_IN ALFENTA_NN can_MD significantly_RB inhibit_VB ALFENTA_NN clearance_NN and_CC may_MD increase_VB the_DT risk_NN of_IN prolonged_JJ or_CC delayed_VBN respiratory_JJ depression_NN ._. Cimetidine_NNP reduces_VBZ the_DT clearance_NN of_IN ALFENTA_NNP ._. Therefore_RB smaller_JJR ALFENTA_NN doses_NNS will_MD be_VB required_VBN with_IN prolonged_JJ administration_NN and_CC the_DT duration_NN of_IN action_NN of_IN ALFENTA_NNP my_PRP$ be_VB extended_VBN ._. Perioperative_NNP administration_NN of_IN drugs_NNS affecting_VBG hepatic_JJ blood_NN flow_NN or_CC enzyme_NN function_NN may_MD reduce_VB plasma_NN clearance_NN and_CC prolong_VB recovery_NN ._. Drug-Drug_NNP Interactions_NNS :_: The_DT pharmacokinetic_JJ and_CC pharmacodynamic_JJ interactions_NNS between_IN UROXATRAL_NNP and_CC other_JJ alpha-blockers_NNS have_VBP not_RB been_VBN determined_VBN ._. However_RB ,_, interactions_NNS may_MD be_VB expected_VBN ,_, and_CC UROXATRAL_NNP should_MD NOT_RB be_VB used_VBN in_IN combination_NN with_IN other_JJ alpha-blockers_NNS ._. No_DT drug_NN interaction_NN studies_NNS have_VBP been_VBN performed_VBN ._. Effects_NNS of_IN Other_JJ Drugs_NNS on_IN Aliskiren_NNP Based_VBD on_IN in-vitro_FW studies_NNS ,_, aliskiren_NN is_VBZ metabolized_VBN by_IN CYP_NN 3A4_NN ._. Co-administration_NN of_IN lovastatin_NN ,_, atenolol_NN ,_, warfarin_NN ,_, furosemide_NN ,_, digoxin_NN ,_, celecoxib_NN ,_, hydrochlorothiazide_NN ,_, ramipril_NN ,_, valsartan_NN ,_, metformin_NN and_CC amlodipine_NN did_VBD not_RB result_VB in_IN clinically_RB significant_JJ increases_NNS in_IN aliskiren_JJ exposure_NN ._. Co-administration_NN of_IN irbesartan_NN reduced_VBD aliskiren_JJ Cmax_NN up_IN to_TO 50_CD %_NN after_IN multiple_JJ dosing_NN ._. Co-administration_NN of_IN atorvastatin_NN resulted_VBD in_IN about_IN a_DT 50_CD %_NN increase_NN in_IN aliskiren_NN Cmax_NN and_CC AUC_NN after_IN multiple_JJ dosing_NN ._. Ketoconazole_NN :_: Co-administration_NN of_IN 200_CD mg_NN twice-daily_JJ ketoconazole_NN with_IN aliskiren_NN resulted_VBD in_IN an_DT approximate_JJ 80_CD %_NN increase_NN in_IN plasma_NN levels_NNS of_IN aliskiren_NN ._. A_DT 400_CD mg_NN once-daily_JJ dose_NN was_VBD not_RB studied_VBN but_CC would_MD be_VB expected_VBN to_TO increase_VB aliskiren_JJ blood_NN levels_NNS further_RB ._. Effects_NNS of_IN Aliskiren_NN on_IN Other_JJ Drugs_NNS Aliskiren_NN does_VBZ not_RB inhibit_VB the_DT CYP450_NN isoenzymes_NNS -LRB-_-LRB- CYP1A2_NN ,_, 2C8_NN ,_, 2C9_NN ,_, 2C19_NN ,_, 2D6_NN ,_, 2E1_NN ,_, and_CC CYP_NN 3A_NN -RRB-_-RRB- or_CC induce_VB CYP_NN 3A4_NN ._. Co-administration_NN of_IN aliskiren_NN did_VBD not_RB significantly_RB affect_VB the_DT pharmacokinetics_NNS of_IN lovastatin_NN ,_, digoxin_NN ,_, valsartan_NN ,_, amlodipine_NN ,_, metformin_NN ,_, celecoxib_NN ,_, atenolol_NN ,_, atorvastatin_NN ,_, ramipril_NN or_CC hydrochlorothiazide_NN ._. Warfarin_NNP :_: The_DT effects_NNS of_IN aliskiren_NN on_IN warfarin_NN pharmacokinetics_NNS have_VBP not_RB been_VBN evaluated_VBN in_IN a_DT well-controlled_JJ clinical_JJ trial_NN ._. Furosemide_NNP :_: When_WRB aliskiren_NN was_VBD co-administered_VBN with_IN furosemide_NN ,_, the_DT AUC_NN and_CC Cmax_NN of_IN furosemide_NN were_VBD reduced_VBN by_IN about_IN 30_CD %_NN and_CC 50_CD %_NN ,_, respectively_RB ._. Patients_NNS who_WP are_VBP applying_VBG Panretin_NNP gel_NN should_MD not_RB concurrently_RB use_VB products_NNS that_WDT contain_VBP DEET_NN -LRB-_-LRB- N_NN ,_, N-diethyl-m-toluamide_NN -RRB-_-RRB- ,_, a_DT common_JJ component_NN of_IN insect_JJ repellent_NN products_NNS ._. Animal_NN toxicology_NN studies_NNS showed_VBD increased_VBN DEET_NNP toxicity_NN when_WRB DEET_NNP was_VBD included_VBN as_IN proof_NN of_IN the_DT formulation_NN ._. Although_IN there_EX was_VBD no_DT clinical_JJ evidence_NN in_IN the_DT vehicle-controlled_JJ studies_NNS of_IN drug_NN interactions_NNS with_IN systemic_JJ antiretroviral_JJ agents_NNS ,_, including_VBG protease_NN inhibitors_NNS ,_, macrolide_NN antibiotics_NNS ,_, and_CC azole_NN antifungals_NNS ,_, the_DT effect_NN of_IN Panretin_NNP gel_NN on_IN the_DT steady-state_JJ concentrations_NNS of_IN these_DT drugs_NNS is_VBZ not_RB known_VBN ._. No_DT drug_NN interaction_NN data_NNS are_VBP available_JJ on_IN concomitant_JJ administration_NN of_IN Panretin_NNP gel_NN and_CC systemic_JJ anti-KS_JJ agents_NNS ._. The_DT following_VBG drug_NN interactions_NNS were_VBD observed_VBN in_IN some_DT patients_NNS undergoing_VBG treatment_NN with_IN oral_JJ allopurinol_NN ._. Although_IN the_DT pattern_NN of_IN use_NN for_IN oral_JJ allopurinol_NN includes_VBZ longer_JJR term_NN therapy_NN ,_, particularly_RB for_IN gout_NN and_CC renal_JJ calculi_NNS ,_, the_DT experience_NN gained_VBD may_MD be_VB relevant_JJ ._. Mercaptopurine/Azathioprine_NNP :_: Allopurinol_NN inhibits_VBZ the_DT enzymatic_JJ oxidation_NN of_IN mercaptopurine_NN and_CC azathioprine_NN to_TO 6-thiouric_JJ acid_NN ._. This_DT oxidation_NN ,_, which_WDT is_VBZ catalyzed_VBN by_IN xanthine_NN oxidase_NN ,_, inactivates_VBZ mercaptopurine_NN ._. In_IN patients_NNS receiving_VBG mercaptopurine_NN -LRB-_-LRB- Purinethol_NN -RRB-_-RRB- or_CC azathioprine_NN -LRB-_-LRB- Imuran_NN -RRB-_-RRB- ,_, the_DT concomitant_JJ administration_NN of_IN 300-600_CD mg_NN of_IN allopurinol_NN per_IN day_NN will_MD require_VB a_DT reduction_NN in_IN dose_NN to_TO approximately_RB one-third_JJ to_TO one-fourth_NN of_IN the_DT usual_JJ dose_NN of_IN mercaptopurine_NN or_CC azathioprine_NN ._. Subsequent_JJ adjustment_NN of_IN doses_NNS of_IN mercaptopurine_NN or_CC azathioprine_NN should_MD be_VB made_VBN on_IN the_DT basis_NN of_IN therapeutic_JJ response_NN and_CC the_DT appearance_NN of_IN toxic_JJ effects_NNS ._. Dicumarol_NNP :_: It_PRP has_VBZ been_VBN reported_VBN that_IN allopurinol_NN prolongs_VBZ the_DT half-life_NN of_IN the_DT anticoagulant_NN ,_, dicumarol_NN ._. The_DT clinical_JJ basis_NN of_IN this_DT drug_NN interaction_NN has_VBZ not_RB been_VBN established_VBN but_CC should_MD be_VB noted_VBN when_WRB allopurinol_NN is_VBZ given_VBN to_TO patients_NNS already_RB on_IN dicumarol_NN therapy_NN ._. Consequently_RB ,_, prothrombin_NN time_NN should_MD be_VB reassessed_VBN periodically_RB in_IN patients_NNS receiving_VBG both_CC drugs_NNS ._. Uricosuric_NNP Agents_NNPS :_: Since_IN the_DT excretion_NN of_IN oxipurinol_NN is_VBZ similar_JJ to_TO that_DT of_IN urate_NN ,_, uricosuric_JJ agents_NNS ,_, which_WDT increase_VBP the_DT excretion_NN of_IN urate_NN ,_, are_VBP also_RB likely_JJ to_TO increase_VB the_DT excretion_NN of_IN oxipurinol_NN and_CC thus_RB lower_JJR the_DT degree_NN of_IN inhibition_NN of_IN xanthine_NN oxidase_NN ._. The_DT concomitant_JJ administration_NN of_IN uricosuric_JJ agents_NNS and_CC allopurinol_NN has_VBZ been_VBN associated_VBN with_IN a_DT decrease_NN in_IN the_DT excretion_NN of_IN oxypurines_NNS -LRB-_-LRB- hypoxanthine_NN and_CC xanthine_NN -RRB-_-RRB- and_CC an_DT increase_NN in_IN urinary_JJ uric_JJ acid_NN excretion_NN compared_VBN with_IN that_DT observed_VBN with_IN allopurinol_NN alone_RB ._. Although_IN clinical_JJ evidence_NN to_TO date_NN has_VBZ not_RB demonstrated_VBN renal_JJ precipitation_NN of_IN oxypurines_NNS in_IN patients_NNS either_CC on_IN allopurinol_NN alone_RB or_CC in_IN combination_NN with_IN uricosuric_JJ agents_NNS ,_, the_DT possibility_NN should_MD be_VB kept_VBN in_IN mind_NN ._. Thiazide_NNP Diuretics_NNPS :_: The_DT reports_NNS that_IN the_DT concomitant_JJ use_NN of_IN allopurinol_NN and_CC thiazide_JJ diuretics_NNS may_MD contribute_VB to_TO the_DT enhancement_NN of_IN allopurinol_NN toxicity_NN in_IN some_DT patients_NNS have_VBP been_VBN reviewed_VBN in_IN an_DT attempt_NN to_TO establish_VB a_DT cause-and-effect_JJ relationship_NN and_CC a_DT mechanism_NN of_IN causation_NN ._. Review_NN of_IN these_DT case_NN reports_VBZ indicates_VBZ that_IN the_DT patients_NNS were_VBD mainly_RB receiving_VBG thiazide_JJ diuretics_NNS for_IN hypertension_NN and_CC that_IN tests_NNS to_TO rule_VB out_RP decreased_VBN renal_JJ function_NN secondary_JJ to_TO hypertensive_JJ nephropathy_NN were_VBD not_RB often_RB performed_VBN ._. In_IN those_DT patients_NNS in_IN whom_WP renal_JJ insufficiency_NN was_VBD documented_VBN ,_, however_RB ,_, the_DT recommendation_NN to_TO lower_VB the_DT dose_NN of_IN allopurinol_NN was_VBD not_RB followed_VBN ._. Although_IN a_DT causal_JJ mechanism_NN and_CC a_DT cause-and-effect_JJ relationship_NN have_VBP not_RB been_VBN established_VBN ,_, current_JJ evidence_NN suggests_VBZ that_IN renal_JJ function_NN should_MD be_VB monitored_VBN in_IN patients_NNS on_IN thiazide_JJ diuretics_NNS and_CC allopurinol_NN even_RB in_IN the_DT absence_NN of_IN renal_JJ failure_NN ,_, and_CC dosage_NN levels_NNS should_MD be_VB even_RB more_RBR conservatively_RB adjusted_VBN in_IN those_DT patients_NNS on_IN such_JJ combined_JJ therapy_NN if_IN diminished_VBN renal_JJ function_NN is_VBZ detected_VBN ._. Ampicillin/Amoxicillin_NNP :_: An_DT increase_NN in_IN the_DT frequency_NN of_IN skin_NN rash_NN has_VBZ been_VBN reported_VBN among_IN patients_NNS receiving_VBG ampicillin_NN or_CC amoxicillin_NNP concurrently_RB with_IN allopurinol_NN compared_VBN to_TO patients_NNS who_WP are_VBP not_RB receiving_VBG both_CC drugs_NNS ._. The_DT cause_NN of_IN the_DT reported_VBN association_NN has_VBZ not_RB been_VBN established_VBN ._. Cytotoxic_JJ Agents_NNS :_: Enhanced_VBN bone_NN marrow_NN suppression_NN by_IN cyclophosphamide_NN and_CC other_JJ cytotoxic_JJ agents_NNS has_VBZ been_VBN reported_VBN among_IN patients_NNS with_IN neoplastic_JJ disease_NN ,_, except_IN leukemia_NN ,_, in_IN the_DT presence_NN of_IN allopurinol_NN ._. However_RB ,_, in_IN a_DT well-controlled_JJ study_NN of_IN patients_NNS with_IN lymphoma_NN on_IN combination_NN therapy_NN ,_, allopurinol_NN did_VBD not_RB increase_VB the_DT marrow_NN toxicity_NN of_IN patients_NNS treated_VBN with_IN cyclophosphamide_NN ,_, doxorubicin_NN ,_, bleomycin_NN ,_, procarbazine_NN and/or_CC mechlorethamine_NN ._. Chlorpropamide_NNP :_: Chlorpropamides_NNP plasma_NN half-life_NN may_MD be_VB prolonged_VBN by_IN allopurinol_NN ,_, since_IN allopurinol_NN and_CC chlorpropamide_NN may_MD compete_VB for_IN excretion_NN in_IN the_DT renal_JJ tubule_NN ._. The_DT risk_NN of_IN hypoglycemia_NN secondary_JJ to_TO this_DT mechanism_NN may_MD be_VB increased_VBN if_IN allopurinol_NN and_CC chlorpropamide_NN are_VBP given_VBN concomitantly_RB in_IN the_DT presence_NN of_IN renal_JJ insufficiency_NN ._. Cyclosporin_NN :_: Reports_NNS indicate_VBP that_IN cyclosporine_NN levels_NNS may_MD be_VB increased_VBN during_IN concomitant_JJ treatment_NN with_IN allopurinol_NN sodium_NN for_IN injection_NN ._. Monitoring_NN of_IN cyclosporine_NN levels_NNS and_CC possible_JJ adjustment_NN of_IN cyclosporine_NN dosage_NN should_MD be_VB considered_VBN when_WRB these_DT drugs_NNS are_VBP co-administered_JJ ._. Tolbutamides_NNS conversion_NN to_TO inactive_JJ metabolites_NNS has_VBZ been_VBN shown_VBN to_TO be_VB catalyzed_VBN by_IN xanthine_NN oxidase_NN from_IN rat_NN liver_NN ._. The_DT clinical_JJ significance_NN ,_, if_IN any_DT ,_, of_IN these_DT observations_NNS is_VBZ unknown_JJ ._. Ergot-Containing_JJ Drugs_NNS :_: These_DT drugs_NNS have_VBP been_VBN reported_VBN to_TO cause_VB prolonged_JJ vasospastic_JJ reactions_NNS ._. Because_IN there_EX is_VBZ a_DT theoretical_JJ basis_NN that_IN these_DT effects_NNS may_MD be_VB additive_JJ ,_, use_NN of_IN ergotamine-containing_JJ or_CC ergot-type_JJ medications_NNS -LRB-_-LRB- like_IN dihydroergotamine_NN or_CC methysergide_NN -RRB-_-RRB- and_CC AXERT_NN within_IN 24_CD hours_NNS of_IN each_DT other_JJ should_MD be_VB avoided_VBN ._. Monoamine_NNP Oxidase_NNP Inhibitors_NNS :_: Coadministration_NN of_IN moclobemide_NN resulted_VBD in_IN a_DT 27_CD %_NN decrease_NN in_IN almotriptan_NN clearance_NN and_CC an_DT increase_NN in_IN Cmax_NN of_IN approximately_RB 6_CD %_NN ._. No_DT dose_NN adjustment_NN is_VBZ necessary_JJ ._. Other_JJ 5-HT1B_NN /_: 1D_NN Agonists_NNS Concomitant_JJ use_NN of_IN other_JJ 5-HT1B_NN /_: 1D_NN agonists_NNS within_IN 24_CD hours_NNS of_IN treatment_NN with_IN AXERT_NN is_VBZ contraindicated_VBN ._. Propanolol_NNP :_: The_DT pharmacokinetics_NNS of_IN almotriptan_NN were_VBD not_RB affected_VBN by_IN coadministration_NN of_IN propranolol_NN ._. Selective_JJ Serotonin_NN Reuptake_NNP Inhibitors_NNS -LRB-_-LRB- SSRIs_NNS -RRB-_-RRB- :_: SSRIs_NNS -LRB-_-LRB- e.g._FW ,_, fluoxetine_NN ,_, fluvoxamine_NN ,_, paroxetine_NN ,_, sertraline_NN -RRB-_-RRB- have_VBP been_VBN rarely_RB reported_VBN to_TO cause_VB weakness_NN ,_, hyperreflexia_NN ,_, and_CC incoordination_NN when_WRB coadministered_VBN with_IN 5-HT1_NN agonists_NNS ._. If_IN concomitant_JJ treatment_NN with_IN AXERT_NN and_CC an_DT SSRI_NNP is_VBZ clinically_RB warranted_VBN ,_, appropriate_JJ observation_NN of_IN the_DT patient_NN is_VBZ advised_VBN ._. Verapamil_NNP :_: Coadministration_NNP of_IN almotriptan_NN and_CC verapamil_NN resulted_VBD in_IN a_DT 24_CD %_NN increase_NN in_IN plasma_NN concentrations_NNS of_IN almotriptan_NN ._. No_DT dose_NN adjustment_NN is_VBZ necessary_JJ ._. Coadministration_NN of_IN almotriptan_NN and_CC the_DT potent_JJ CYP3A4_NN inhibitor_NN ketoconazole_NN -LRB-_-LRB- 400_CD mg_NN q.d._NN for_IN 3_CD days_NNS -RRB-_-RRB- resulted_VBD in_IN an_DT approximately_RB 60_CD %_NN increase_NN in_IN the_DT area_NN under_IN the_DT plasma_NN concentration-time_NN curve_NN and_CC maximal_JJ plasma_NN concentrations_NNS of_IN almotriptan_NN ._. Although_IN the_DT interaction_NN between_IN almotriptan_NN and_CC other_JJ potent_JJ CYP3A4_NN inhibitors_NNS -LRB-_-LRB- e.g._FW ,_, itraconazole_NN ,_, ritonavir_NN ,_, and_CC erythromycin_NN -RRB-_-RRB- has_VBZ not_RB been_VBN studied_VBN ,_, increased_VBD exposures_NNS to_TO almotriptan_NN may_MD be_VB expected_VBN when_WRB almotriptan_NN is_VBZ used_VBN concomitantly_RB with_IN these_DT medications_NNS ._. AXERT_NNP is_VBZ not_RB known_VBN to_TO interfere_VB with_IN commonly_RB employed_VBN clinical_JJ laboratory_NN tests_NNS ._. Because_IN alosetron_NN is_VBZ metabolized_VBN by_IN a_DT variety_NN of_IN hepatic_JJ CYP_NN drug-metabolizing_JJ enzymes_NNS ,_, inducers_NNS or_CC inhibitors_NNS of_IN these_DT enzymes_NNS may_MD change_VB the_DT clearance_NN of_IN alosetron_NN ._. Fluvoxamine_NN is_VBZ a_DT known_JJ strong_JJ inhibitor_NN of_IN CYP1A2_NN and_CC also_RB inhibits_VBZ CYP3A4_NN ,_, CYP2C9_NN ,_, and_CC CYP2C19_NN ._. In_IN a_DT pharmacokinetic_JJ study_NN ,_, 40_CD healthy_JJ female_JJ subjects_NNS received_VBD fluvoxamine_NN in_IN escalating_VBG doses_NNS from_IN 50_CD to_TO 200_CD mg_NN per_IN day_NN for_IN 16_CD days_NNS ,_, with_IN coadministration_NN of_IN alosetron_NN 1_CD mg_NN on_IN the_DT last_JJ day_NN ._. Fluvoxamine_NN increased_VBD mean_JJ alosetron_NN plasma_NN concentrations_NNS -LRB-_-LRB- AUC_NN -RRB-_-RRB- approximately_RB 6-fold_RB and_CC prolonged_VBD the_DT half-life_NN by_IN approximately_RB 3-fold_RB ._. Concomitant_JJ administration_NN of_IN alosetron_NN and_CC fluvoxamine_NN is_VBZ contraindicated_VBN ._. Concomitant_JJ administration_NN of_IN alosetron_NN and_CC moderate_JJ CYP1A2_NN inhibitors_NNS ,_, including_VBG quinolone_JJ antibiotics_NNS and_CC cimetidine_NN ,_, has_VBZ not_RB been_VBN evaluated_VBN ,_, but_CC should_MD be_VB avoided_VBN unless_IN clinically_RB necessary_JJ because_IN of_IN similar_JJ potential_JJ drug_NN interactions_NNS ._. Ketoconazole_NN is_VBZ a_DT known_JJ strong_JJ inhibitor_NN of_IN CYP3A4_NN ._. In_IN a_DT pharmacokinetic_JJ study_NN ,_, 38_CD healthy_JJ female_JJ subjects_NNS received_VBD ketoconazole_NN 200_CD mg_NN twice_RB daily_RB for_IN 7_CD days_NNS ,_, with_IN coadministration_NN of_IN alosetron_NN 1_CD mg_NN on_IN the_DT last_JJ day_NN ._. Ketoconazole_NN increased_VBD mean_JJ alosetron_NN plasma_NN concentrations_NNS -LRB-_-LRB- AUC_NN -RRB-_-RRB- by_IN 29_CD %_NN ._. Caution_NN should_MD be_VB used_VBN when_WRB alosetron_NN and_CC ketoconazole_NN are_VBP administered_VBN concomitantly_RB ._. Coadministration_NN of_IN alosetron_NN and_CC strong_JJ CYP3A4_NN inhibitors_NNS ,_, such_JJ as_IN clarithromycin_NN ,_, telithromycin_NN ,_, protease_NN inhibitors_NNS ,_, voriconazole_NN ,_, and_CC itraconazole_NN has_VBZ not_RB been_VBN evaluated_VBN but_CC should_MD be_VB undertaken_VBN with_IN caution_NN because_IN of_IN similar_JJ potential_JJ drug_NN interactions_NNS ._. The_DT effect_NN of_IN induction_NN or_CC inhibition_NN of_IN other_JJ pathways_NNS on_IN exposure_NN to_TO alosetron_NN and_CC its_PRP$ metabolites_NNS is_VBZ not_RB known_VBN ._. In_FW vitro_FW human_JJ liver_NN microsome_NN studies_NNS and_CC an_DT in_FW vivo_FW metabolic_JJ probe_NN study_NN demonstrated_VBD that_IN alosetron_NN did_VBD not_RB inhibit_VB CYP_NN enzymes_NNS 2D6_NN ,_, 3A4_NN ,_, 2C9_NN ,_, or_CC 2C19_NN ._. In_FW vitro_FW ,_, at_IN total_JJ drug_NN concentrations_NNS 27-fold_RB higher_JJR than_IN peak_JJ plasma_NN concentrations_NNS observed_VBN with_IN the_DT 1-mg_JJ dosage_NN ,_, alosetron_NN inhibited_VBD CYP_NN enzymes_NNS 1A2_NN -LRB-_-LRB- 60_CD %_NN -RRB-_-RRB- and_CC 2E1_NN -LRB-_-LRB- 50_CD %_NN -RRB-_-RRB- ._. In_IN an_DT in_FW vivo_FW metabolic_JJ probe_NN study_NN ,_, alosetron_NN did_VBD not_RB inhibit_VB CYP2E1_NN but_CC did_VBD produce_VB 30_CD %_NN inhibition_NN of_IN both_CC CYP1A2_NN and_CC N-acetyltransferase_NN ._. Although_IN not_RB studied_VBN with_IN alosetron_NN ,_, inhibition_NN of_IN N-acetyltransferase_NN may_MD have_VB clinically_RB relevant_JJ consequences_NNS for_IN drugs_NNS such_JJ as_IN isoniazid_NN ,_, procainamide_NN ,_, and_CC hydralazine_NN ._. The_DT effect_NN on_IN CYP1A2_NN was_VBD explored_VBN further_RB in_IN a_DT clinical_JJ interaction_NN study_NN with_IN theophylline_NN and_CC no_DT effect_NN on_IN metabolism_NN was_VBD observed_VBN ._. Another_DT study_NN showed_VBD that_IN alosetron_NN had_VBD no_DT clinically_RB significant_JJ effect_NN on_IN plasma_NN concentrations_NNS of_IN the_DT oral_JJ contraceptive_JJ agents_NNS ethinyl_NN estradiol_NN and_CC levonorgestrel_NN -LRB-_-LRB- CYP3A4_NN substrates_NNS -RRB-_-RRB- ._. A_DT clinical_JJ interaction_NN study_NN was_VBD also_RB conducted_VBN with_IN alosetron_NN and_CC the_DT CYP3A4_NN substrate_NN cisapride_NN ._. No_DT significant_JJ effects_NNS on_IN cisapride_NN metabolism_NN or_CC QT_NN interval_NN were_VBD noted_VBN ._. The_DT effect_NN of_IN alosetron_NN on_IN monoamine_NN oxidases_NNS and_CC on_IN intestinal_JJ first_JJ pass_NN secondary_JJ to_TO high_JJ intraluminal_JJ concentrations_NNS have_VBP not_RB been_VBN examined_VBN ._. Based_VBN on_IN the_DT above_JJ data_NNS from_IN in_FW vitro_FW and_CC in_FW vivo_FW studies_NNS ,_, it_PRP is_VBZ unlikely_JJ that_IN alosetron_NN will_MD inhibit_VB the_DT hepatic_JJ metabolic_JJ clearance_NN of_IN drugs_NNS metabolized_VBN by_IN the_DT major_JJ CYP_NN enzyme_NN 3A4_NN ,_, as_RB well_RB as_IN the_DT CYP_NN enzymes_NNS 2D6_NN ,_, 2C9_NN ,_, 2C19_NN ,_, 2E1_NN ,_, or_CC 1A2_NN ._. Alosetron_NNP does_VBZ not_RB appear_VB to_TO induce_VB the_DT major_JJ cytochrome_NN P450_NN -LRB-_-LRB- CYP_NN -RRB-_-RRB- drug_NN metabolizing_VBG enzyme_NN 3A_NN ._. Alosetron_NNP also_RB does_VBZ not_RB appear_VB to_TO induce_VB CYP_NN enzymes_NNS 2E1_NN or_CC 2C19_NN ._. It_PRP is_VBZ not_RB known_VBN whether_IN alosetron_NN might_MD induce_VB other_JJ enzymes_NNS ._. The_DT benzodiazepines_NNS ,_, including_VBG alprazolam_NN ,_, produce_VBP additive_JJ CNS_NNS depressant_NN effects_NNS when_WRB co-administered_VBN with_IN other_JJ psychotropic_JJ medications_NNS ,_, anticonvulsants_NNS ,_, antihistaminics_NNS ,_, ethanol_NN ,_, and_CC other_JJ drugs_NNS which_WDT themselves_PRP produce_VBP CNS_NN depression_NN ._. The_DT steady_JJ state_NN plasma_NN concentrations_NNS of_IN imipramine_NN and_CC desipramine_NN have_VBP been_VBN reported_VBN to_TO be_VB increased_VBN an_DT average_NN of_IN 31_CD %_NN and_CC 20_CD %_NN ,_, respectively_RB ,_, by_IN the_DT concomitant_JJ administration_NN of_IN alprazolam_NN tablets_NNS in_IN doses_NNS up_RB to_TO 4_CD mg/day_NN ._. The_DT clinical_JJ significance_NN of_IN these_DT changes_NNS is_VBZ unknown_JJ ._. Drugs_NNS That_WDT Inhibit_VBP Alprazolam_NNP Metabolism_NNP Via_NNP Cytochrome_NNP P450_NN 3A_NN :_: The_DT initial_JJ step_NN in_IN alprazolam_NN metabolism_NN is_VBZ hydroxylation_NN catalyzed_VBN by_IN cytochrome_NN P450_NN 3A_NN -LRB-_-LRB- CYP_NN 3A_NN -RRB-_-RRB- ._. Drugs_NNS which_WDT inhibit_VBP this_DT metabolic_JJ pathway_NN may_MD have_VB a_DT profound_JJ effect_NN on_IN the_DT clearance_NN of_IN alprazolam_NN ._. Drugs_NNS Demonstrated_VBN to_TO be_VB CYP_NN 3A_NN Inhibitors_NNS of_IN Possible_JJ Clinical_JJ Significance_NN on_IN the_DT Basis_NN of_IN Clinical_JJ Studies_NNS Involving_VBG Alprazolam_NN -LRB-_-LRB- caution_NN is_VBZ recommended_VBN during_IN coadministration_NN with_IN alprazolam_NN -RRB-_-RRB- :_: Coadministration_NN of_IN fluoxetine_NN with_IN alprazolam_NN increased_VBD the_DT maximum_NN plasma_NN concentration_NN of_IN alprazolam_NN by_IN 46_CD %_NN ,_, decreased_VBD clearance_NN by_IN 21_CD %_NN ,_, increased_VBD half-life_NN by_IN 17_CD %_NN ,_, and_CC decreased_VBD measured_VBN psychomotor_NN performance_NN ._. Coadministration_NN of_IN propoxyphene_NN decreased_VBD the_DT maximum_NN plasma_NN concentration_NN of_IN alprazolam_NN by_IN 6_CD %_NN ,_, decreased_VBD clearance_NN by_IN 38_CD %_NN ,_, and_CC increased_VBD half-life_NN by_IN 58_CD %_NN ._. Coadministration_NN of_IN oral_JJ contraceptives_NNS increased_VBD the_DT maximum_NN plasma_NN concentration_NN of_IN alprazolam_NN by_IN 18_CD %_NN ,_, decreased_VBD clearance_NN by_IN 22_CD %_NN ,_, and_CC increased_VBD half-life_NN by_IN 29_CD %_NN ._. Drugs_NNS and_CC other_JJ substances_NNS demonstrated_VBD to_TO be_VB CYP_NN 3A_NN inhibitors_NNS on_IN the_DT basis_NN of_IN clinical_JJ studies_NNS involving_VBG benzodiazepines_NNS metabolized_VBN similarly_RB to_TO alprazolam_NN or_CC on_IN the_DT basis_NN of_IN in_FW vitro_FW studies_NNS with_IN alprazolam_NN or_CC other_JJ benzodiazepines_NNS -LRB-_-LRB- caution_NN is_VBZ recommended_VBN during_IN coadministration_NN with_IN alprazolam_NN -RRB-_-RRB- :_: Available_JJ data_NNS from_IN clinical_JJ studies_NNS of_IN benzodiazepines_NNS other_JJ than_IN alprazolam_NN suggest_VBP a_DT possible_JJ drug_NN interaction_NN with_IN alprazolam_NN for_IN the_DT following_NN :_: diltiazem_NN ,_, isoniazid_NN ,_, macrolide_NN antibiotics_NNS such_JJ as_IN erythromycin_NN and_CC clarithromycin_NN ,_, and_CC grapefruit_NN juice_NN ._. Data_NNS from_IN in_FW vitro_FW studies_NNS of_IN alprazolam_NN suggest_VBP a_DT possible_JJ drug_NN interaction_NN with_IN alprazolam_NN for_IN the_DT following_NN :_: sertraline_NN and_CC paroxetine_NN ._. Data_NNS from_IN in_FW vitro_FW studies_NNS of_IN benzodiazepines_NNS other_JJ than_IN alprazolam_NN suggest_VBP a_DT possible_JJ drug_NN interaction_NN for_IN the_DT following_NN :_: ergotamine_NN ,_, cyclosporine_NN ,_, amiodarone_NN ,_, nicardipine_NN ,_, and_CC nifedipine_NN ._. Caution_NN is_VBZ recommended_VBN during_IN the_DT coadministration_NN of_IN any_DT of_IN these_DT with_IN alprazolam_NN ._. No_DT drug_NN interactions_NNS have_VBP been_VBN reported_VBN between_IN Prostin_NNP VR_NN Pediatric_NNP and_CC the_DT therapy_NN standard_NN in_IN neonates_NNS with_IN restricted_JJ pulmonary_JJ or_CC systemic_JJ blood_NN flow_NN ._. Standard_JJ therapy_NN includes_VBZ antibiotics_NNS ,_, such_JJ as_IN penicillin_NN and_CC gentamicin_NN ._. vasopressors_NNS ,_, such_JJ as_IN dopamine_NN and_CC isoproterenol_NN ._. cardiac_JJ glycosides_NNS ._. and_CC diuretics_NNS ,_, such_JJ as_IN furosemide_NN ._. Caverject_NNP :_: The_DT potential_NN for_IN pharmacokinetic_JJ drug-drug_NN interactions_NNS between_IN alprostadil_NN and_CC other_JJ agents_NNS has_VBZ not_RB been_VBN formally_RB studied_VBN ._. The_DT interaction_NN of_IN Activase_NN with_IN other_JJ cardioactive_JJ or_CC cerebroactive_JJ drugs_NNS has_VBZ not_RB been_VBN studied_VBN ._. In_IN addition_NN to_TO bleeding_NN associated_VBN with_IN heparin_NN and_CC vitamin_NN K_NN antagonists_NNS ,_, drugs_NNS that_WDT alter_VBP platelet_NN function_NN -LRB-_-LRB- such_JJ as_IN acetylsalicylic_JJ acid_NN ,_, dipyridamole_NN and_CC Abciximab_NNP -RRB-_-RRB- may_MD increase_VB the_DT risk_NN of_IN bleeding_VBG if_IN administered_VBN prior_RB to_TO ,_, during_IN ,_, or_CC after_IN Activase_NN therapy_NN ._. Use_NN of_IN Antithrombotics_NNP Aspirin_NNP and_CC heparin_NN have_VBP been_VBN administered_VBN concomitantly_RB with_IN and_CC following_VBG infusions_NNS of_IN Activase_NNP in_IN the_DT management_NN of_IN acute_JJ myocardial_JJ infarction_NN or_CC pulmonary_JJ embolism_NN ._. Because_IN heparin_NN ,_, aspirin_NN ,_, or_CC Activase_NNP may_MD cause_VB bleeding_JJ complications_NNS ,_, careful_JJ monitoring_NN for_IN bleeding_NN is_VBZ advised_VBN ,_, especially_RB at_IN arterial_JJ puncture_NN sites_NNS ._. The_DT concomitant_JJ use_NN of_IN heparin_NN or_CC aspirin_NN during_IN the_DT first_JJ 24_CD hours_NNS following_VBG symptom_NN onset_NN were_VBD prohibited_VBN in_IN The_DT NINDS_NN t-PA_NN Stroke_NNP Trial_NNP ._. The_DT safety_NN of_IN such_JJ concomitant_JJ use_NN with_IN Activase_NN for_IN the_DT management_NN of_IN acute_JJ ischemic_JJ stroke_NN is_VBZ unknown_JJ ._. Concurrent_JJ administration_NN of_IN HEXALEN_NN and_CC antidepressants_NNS of_IN the_DT MAO_NNP inhibitor_NN class_NN may_MD cause_VB severe_JJ orthostatic_JJ hypotension.Cimetidine_NN ,_, an_DT inhibitor_NN of_IN microsomal_JJ drug_NN metabolism_NN ,_, increased_VBD altretamines_NNS half-life_NN and_CC toxicity_NN in_IN a_DT rat_NN model_NN ._. Data_NNS from_IN a_DT randomized_JJ trial_NN of_IN HEXALEN_NN and_CC cisplatin_NN plus_CC or_CC minus_CC pyridoxine_NN in_IN ovarian_JJ cancer_NN indicated_VBD that_IN pyridoxine_NN significantly_RB reduced_VBD neurotoxicity_NN ._. however_RB ,_, it_PRP adversely_RB affected_VBD response_NN duration_NN suggesting_VBG that_IN pyridoxine_NN should_MD not_RB be_VB administered_VBN with_IN HEXALEN_NN and/or_CC cisplatin_NN ._. Careful_JJ observation_NN is_VBZ required_VBN when_WRB amantadine_NN is_VBZ administered_VBN concurrently_RB with_IN central_JJ nervous_JJ system_NN stimulants_NNS ._. Coadministration_NN of_IN thioridazine_NN has_VBZ been_VBN reported_VBN to_TO worsen_VB the_DT tremor_NN in_IN elderly_JJ patients_NNS with_IN Parkinsons_NNPS disease_NN ._. however_RB ,_, it_PRP is_VBZ not_RB known_VBN if_IN other_JJ phenothiazines_NNS produce_VBP a_DT similar_JJ response_NN ._. Special_JJ consideration_NN should_MD be_VB given_VBN to_TO the_DT administration_NN of_IN ETHYOL_NNP in_IN patients_NNS receiving_VBG antihypertensive_JJ medications_NNS or_CC other_JJ drugs_NNS that_WDT could_MD cause_VB or_CC potentiate_VB hypotension_NN ._. When_WRB amiloride_NN HCl_NN is_VBZ administered_VBN concomitantly_RB with_IN an_DT angiotensin-converting_JJ enzyme_NN inhibitor_NN ,_, the_DT risk_NN of_IN hyperkalemia_NN may_MD be_VB increased_VBN ._. Therefore_RB ,_, if_IN concomitant_JJ use_NN of_IN these_DT agents_NNS is_VBZ indicated_VBN because_IN of_IN demonstrated_VBN hypokalemia_NN ,_, they_PRP should_MD be_VB used_VBN with_IN caution_NN and_CC with_IN frequent_JJ monitoring_NN of_IN serum_NN potassium_NN ._. Lithium_NN generally_RB should_MD not_RB be_VB given_VBN with_IN diuretics_NNS because_IN they_PRP reduce_VBP its_PRP$ renal_JJ clearance_NN and_CC add_VB a_DT high_JJ risk_NN of_IN lithium_NN toxicity_NN ._. Read_VB circulars_NNS for_IN lithium_NN preparations_NNS before_IN use_NN of_IN such_JJ concomitant_JJ therapy_NN ._. In_IN some_DT patients_NNS ,_, the_DT administration_NN of_IN a_DT non-steroidal_JJ anti-inflammatory_JJ agent_NN can_MD reduce_VB the_DT diuretic_JJ ,_, natriuretic_JJ ,_, and_CC antihypertensive_JJ effects_NNS of_IN loop_NN ,_, potassium-sparing_NN and_CC thiazide_JJ diuretics_NNS ._. Therefore_RB ,_, when_WRB MIDAMOR_NN and_CC non-steroidal_JJ anti-inflammatory_JJ agents_NNS are_VBP used_VBN concomitantly_RB ,_, the_DT patient_NN should_MD be_VB observed_VBN closely_RB to_TO determine_VB if_IN the_DT desired_VBN effect_NN of_IN the_DT diuretic_JJ is_VBZ obtained_VBN ._. Since_IN indomethacin_NN and_CC potassium-sparing_JJ diuretics_NNS ,_, including_VBG MIDAMOR_NNP ,_, may_MD each_DT be_VB associated_VBN with_IN increased_VBN serum_NN potassium_NN levels_NNS ,_, the_DT potential_JJ effects_NNS on_IN potassium_NN kinetics_NNS and_CC renal_JJ function_NN should_MD be_VB considered_VBN when_WRB these_DT agents_NNS are_VBP administered_VBN concurrently_RB ._. Drug_NNP Laboratory_NNP Test_NNP Interactions_NNS :_: Prolongation_NN of_IN the_DT template_NN bleeding_NN time_NN has_VBZ been_VBN reported_VBN during_IN continuous_JJ intravenous_JJ infusion_NN of_IN AMICAR_NN at_IN dosages_NNS exceeding_VBG 24_CD g/day_NN ._. Platelet_NN function_NN studies_NNS in_IN these_DT patients_NNS have_VBP not_RB demonstrated_VBN any_DT significant_JJ platelet_NN dysfunction_NN ._. However_RB ,_, in_FW vitro_FW studies_NNS have_VBP shown_VBN that_IN at_IN high_JJ concentrations_NNS -LRB-_-LRB- 7.4_CD mMol/L_NN or_CC 0.97_CD mg/mL_NN and_CC greater_JJR -RRB-_-RRB- EACA_NN inhibits_VBZ ADP_NN and_CC collagen-induced_JJ platelet_NN aggregation_NN ,_, the_DT release_NN of_IN ATP_NN and_CC serotonin_NN ,_, and_CC the_DT binding_NN of_IN fibrinogen_NN to_TO the_DT platelets_NNS in_IN a_DT concentration-response_JJ manner_NN ._. Following_VBG a_DT 10_CD g_NN bolus_NN of_IN AMICAR_NNP ,_, transient_JJ peak_NN plasma_NN concentrations_NNS of_IN 4.6_CD mMol/L_NN or_CC 0.60_CD mg/mL_NN have_VBP been_VBN obtained_VBN ._. The_DT concentration_NN of_IN AMICAR_NNP necessary_JJ to_TO maintain_VB inhibition_NN of_IN fibrinolysis_NN is_VBZ 0.99_CD mMol/L_NN or_CC 0.13_CD mg/mL_NN ._. Administration_NN of_IN a_DT 5_CD g_NN bolus_NN followed_VBN by_IN 1_CD to_TO 1.25_CD g/hr_NN should_MD achieve_VB and_CC sustain_VB plasma_NN levels_NNS of_IN 0.13_CD mg/mL_NN ._. Thus_RB ,_, concentrations_NNS which_WDT have_VBP been_VBN obtained_VBN in_FW vivo_FW clinically_RB in_IN patients_NNS with_IN normal_JJ renal_JJ function_NN are_VBP considerably_RB lower_JJR than_IN the_DT in_FW vitro_FW concentrations_NNS found_VBN to_TO induce_VB abnormalities_NNS in_IN platelet_NN function_NN tests_NNS ._. However_RB ,_, higher_JJR plasma_NN concentrations_NNS of_IN AMICAR_NN may_MD occur_VB in_IN patients_NNS with_IN severe_JJ renal_JJ failure_NN ._. Cytadren_NN accelerates_VBZ the_DT metabolism_NN of_IN dexamethasone_NN ._. therefore_RB ,_, if_IN glucocorticoid_NN replacement_NN is_VBZ needed_VBN ,_, hydrocortisone_NN should_MD be_VB prescribed_VBN ._. Aminoglutethimide_NNP diminishes_VBZ the_DT effect_NN of_IN coumarin_NN and_CC warfarin_NN ._. Renal_JJ clearance_NN measurements_NNS of_IN PAH_NN can_MD not_RB be_VB made_VBN with_IN any_DT significant_JJ accuracy_NN in_IN patients_NNS receiving_VBG sulfonamides_NNS ,_, procaine_NN ,_, or_CC thiazolesulfone_NN ._. These_DT compounds_NNS interfere_VBP with_IN chemical_NN color_NN development_NN essential_JJ to_TO the_DT analytical_JJ procedures_NNS ._. Probenecid_NNP depresses_VBZ tubular_JJ secretion_NN of_IN certain_JJ weak_JJ acids_NNS such_JJ as_IN PAH_NN ._. Therefore_RB ,_, patients_NNS receiving_VBG probenecid_NN will_MD have_VB erroneously_RB low_JJ ERPF_NN and_CC Tm_NN PAH_NN values_NNS ._. There_EX have_VBP been_VBN no_DT formal_JJ studies_NNS of_IN the_DT interaction_NN of_IN LEVULAN_NNP KERASTICK_NNP for_IN Topical_NNP Solution_NN with_IN any_DT other_JJ drugs_NNS ,_, and_CC no_DT drug-specific_JJ interactions_NNS were_VBD noted_VBN during_IN any_DT of_IN the_DT controlled_JJ clinical_JJ trials_NNS ._. It_PRP is_VBZ ,_, however_RB ,_, possible_JJ that_IN concomitant_JJ use_NN of_IN other_JJ known_JJ photosensitizing_JJ agents_NNS such_JJ as_IN griseofulvin_NN ,_, thiazide_JJ diuretics_NNS ,_, sulfonylureas_NNS ,_, phenothiazines_NNS ,_, sulfonamides_NNS and_CC tetracyclines_NNS might_MD increase_VB the_DT photosensitivity_NN reaction_NN of_IN actinic_JJ keratoses_NNS treated_VBN with_IN the_DT LEVULAN_NNP KERASTICK_NNP for_IN Topical_NNP Solution_NN ._. Aminosalicylic_JJ acid_NN may_MD decrease_VB the_DT amount_NN of_IN digoxin_NN -LRB-_-LRB- Lanoxin_NN ,_, Lanoxicaps_NN -RRB-_-RRB- that_WDT gets_VBZ absorbed_VBN into_IN your_PRP$ body_NN ._. In_IN the_DT case_NN that_IN you_PRP are_VBP taking_VBG digoxin_NN while_IN taking_VBG aminosalicylic_JJ acid_NN ,_, higher_JJR doses_NNS of_IN digoxin_NN may_MD be_VB needed_VBN ._. Aminosalicylic_JJ acid_NN may_MD also_RB decrease_VB the_DT absorption_NN of_IN vitamin_NN B12_NN ,_, which_WDT can_MD lead_VB to_TO a_DT deficiency_NN ._. Therefore_RB you_PRP may_MD need_VB to_TO take_VB a_DT vitamin_NN B12_NN supplement_NN while_IN taking_VBG aminosalicylic_JJ acid_NN ._. Amiodarone_NNP is_VBZ metabolized_VBN to_TO desethylamiodarone_VBN by_IN the_DT cytochrome_NN P450_NN -LRB-_-LRB- CYP450_NN -RRB-_-RRB- enzyme_NN group_NN ,_, specifically_RB cytochromes_VBZ P450_NN 3A4_NN -LRB-_-LRB- CYP3A4_NN -RRB-_-RRB- and_CC CYP2C8_NN ._. The_DT CYP3A4_NN isoenzyme_NN is_VBZ present_JJ in_IN both_CC the_DT liver_NN and_CC intestines_NNS ._. Amiodarone_NNP is_VBZ also_RB known_VBN to_TO be_VB an_DT inhibitor_NN of_IN CYP3A4_NN ._. Therefore_RB ,_, amiodarone_NN has_VBZ the_DT potential_NN for_IN interactions_NNS with_IN drugs_NNS or_CC substances_NNS that_WDT may_MD be_VB substrates_NNS ,_, inhibitors_NNS or_CC inducers_NNS of_IN CYP3A4_NN ._. While_IN only_RB a_DT limited_JJ number_NN of_IN in_FW vivo_FW drug-drug_JJ interactions_NNS with_IN amiodarone_NN have_VBP been_VBN reported_VBN ,_, chiefly_RB with_IN the_DT oral_JJ formulation_NN ,_, the_DT potential_NN for_IN other_JJ interactions_NNS should_MD be_VB anticipated_VBN ._. This_DT is_VBZ especially_RB important_JJ for_IN drugs_NNS associated_VBN with_IN serious_JJ toxicity_NN ,_, such_JJ as_IN other_JJ antiarrhythmics_NNS ._. If_IN such_JJ drugs_NNS are_VBP needed_VBN ,_, their_PRP$ dose_NN should_MD be_VB reassessed_VBN and_CC ,_, where_WRB appropriate_JJ ,_, plasma_NN concentration_NN measured_VBN ._. In_IN view_NN of_IN the_DT long_JJ and_CC variable_JJ half-life_NN of_IN amiodarone_NN ,_, potential_NN for_IN drug_NN interactions_NNS exists_VBZ not_RB only_RB with_IN concomitant_JJ medication_NN but_CC also_RB with_IN drugs_NNS administered_VBN after_IN discontinuation_NN of_IN amiodarone_NN ._. Since_IN amiodarone_NN is_VBZ a_DT substrate_NN for_IN CYP3A4_NN and_CC CYP2C8_NN ,_, drugs/substances_NNS that_WDT inhibit_VBP these_DT isoenzymes_NNS may_MD decrease_VB the_DT metabolism_NN and_CC increase_NN serum_NN concentration_NN of_IN amiodarone_NN ._. Reported_VBN examples_NNS include_VBP the_DT following_NN :_: Protease_NN Inhibitors_NNS :_: Protease_NN inhibitors_NNS are_VBP known_VBN to_TO inhibit_VB CYP3A4_NN to_TO varying_VBG degrees_NNS ._. A_DT case_NN report_NN of_IN one_CD patient_NN taking_VBG amiodarone_NN 200_CD mg_NN and_CC indinavir_NN 800_CD mg_NN three_CD times_NNS a_DT day_NN resulted_VBD in_IN increases_NNS in_IN amiodarone_NN concentrations_NNS from_IN 0.9_CD mg/L_NN to_TO 1.3_CD mg/L_NN ._. DEA_NNP concentrations_NNS were_VBD not_RB affected_VBN ._. There_EX was_VBD no_DT evidence_NN of_IN toxicity_NN ._. Monitoring_VBG for_IN amiodarone_NN toxicity_NN and_CC serial_NN measurement_NN of_IN amiodarone_NN serum_NN concentration_NN during_IN concomitant_JJ protease_NN inhibitor_NN therapy_NN should_MD be_VB considered_VBN ._. Histamine_NN H2_NN antagonists_NNS :_: Cimetidine_NN inhibits_VBZ CYP3A4_NN and_CC can_MD increase_VB serum_NN amiodarone_NN levels_NNS ._. Other_JJ substances_NNS :_: Grapefruit_NN juice_NN given_VBN to_TO healthy_JJ volunteers_NNS increased_VBD amiodarone_NN AUC_NN by_IN 50_CD %_NN and_CC Cmax_NN by_IN 84_CD %_NN ,_, resulting_VBG in_IN increased_VBN plasma_NN levels_NNS of_IN amiodarone_NN ._. Grapefruit_NN juice_NN should_MD not_RB be_VB taken_VBN during_IN treatment_NN with_IN oral_JJ amiodarone_NN ._. This_DT information_NN should_MD be_VB considered_VBN when_WRB changing_VBG from_IN intravenous_JJ amiodarone_NN to_TO oral_JJ amiodarone_NN ._. Amiodarone_NNP may_MD suppress_VB certain_JJ CYP450_NN enzymes_NNS ,_, including_VBG CYP1A2_NN ,_, CYP2C9_NN ,_, CYP2D6_NN ,_, and_CC CYP3A4_NN ._. This_DT inhibition_NN can_MD result_VB in_IN unexpectedly_RB high_JJ plasma_NN levels_NNS of_IN other_JJ drugs_NNS which_WDT are_VBP metabolized_VBN by_IN those_DT CYP450_NN enzymes_NNS ._. Reported_VBN examples_NNS of_IN this_DT interaction_NN include_VBP the_DT following_NN :_: Immunosuppressives_NNS :_: Cyclosporine_NN -LRB-_-LRB- CYP3A4_NN substrate_NN -RRB-_-RRB- administered_VBN in_IN combination_NN with_IN oral_JJ amiodarone_NN has_VBZ been_VBN reported_VBN to_TO produce_VB persistently_RB elevated_JJ plasma_NN concentrations_NNS of_IN cyclosporine_NN resulting_VBG in_IN elevated_JJ creatinine_NN ,_, despite_IN reduction_NN in_IN dose_NN of_IN cyclosporine_NN ._. HMG-CoA_NN Reductase_NN Inhibitors_NNS :_: Simvastatin_NN -LRB-_-LRB- CYP3A4_NN substrate_NN -RRB-_-RRB- in_IN combination_NN with_IN amiodarone_NN has_VBZ been_VBN associated_VBN with_IN reports_NNS of_IN myopathy/rhabdomyolysis_NN ._. Cardiovasculars_NNP :_: Cardiac_JJ glycosides_NNS :_: In_IN patients_NNS receiving_VBG digoxin_NN therapy_NN ,_, administration_NN of_IN oral_JJ amiodarone_NN regularly_RB results_VBZ in_IN an_DT increase_NN in_IN serum_NN digoxin_NN concentration_NN that_WDT may_MD reach_VB toxic_JJ levels_NNS with_IN resultant_JJ clinical_JJ toxicity_NN ._. Amiodarone_NNP taken_VBN concomitantly_RB with_IN digoxin_NN increases_VBZ the_DT serum_NN digoxin_NN concentration_NN by_IN 70_CD %_NN after_IN one_CD day_NN ._. On_IN administration_NN of_IN oral_JJ amiodarone_NN ,_, the_DT need_NN for_IN digitalis_NN therapy_NN should_MD be_VB reviewed_VBN and_CC the_DT dose_NN reduced_VBN by_IN approximately_RB 50_CD %_NN or_CC discontinued_VBN ._. If_IN digitalis_NN treatment_NN is_VBZ continued_VBN ,_, serum_NN levels_NNS should_MD be_VB closely_RB monitored_VBN and_CC patients_NNS observed_VBN for_IN clinical_JJ evidence_NN of_IN toxicity_NN ._. These_DT precautions_NNS probably_RB should_MD apply_VB to_TO digitoxin_NN administration_NN as_RB well_RB ._. Antiarrhythmics_NNS :_: Other_JJ antiarrhythmic_JJ drugs_NNS ,_, such_JJ as_IN quinidine_NN ,_, procainamide_NN ,_, disopyramide_NN ,_, and_CC phenytoin_NN ,_, have_VBP been_VBN used_VBN concurrently_RB with_IN amiodarone_NN ._. There_EX have_VBP been_VBN case_NN reports_NNS of_IN increased_VBN steady-state_JJ levels_NNS of_IN quinidine_NN ,_, procainamide_NN ,_, and_CC phenytoin_NN during_IN concomitant_JJ therapy_NN with_IN amiodarone_NN ._. Phenytoin_NN decreases_VBZ serum_NN amiodarone_NN levels_NNS ._. Amiodarone_NNP taken_VBN concomitantly_RB with_IN quinidine_NN increases_VBZ quinidine_NN serum_NN concentration_NN by_IN 33_CD %_NN after_IN two_CD days_NNS ._. Amiodarone_NNP taken_VBN concomitantly_RB with_IN procainamide_NN for_IN less_JJR than_IN seven_CD days_NNS increases_VBZ plasma_NN concentrations_NNS of_IN procainamide_NN and_CC n-acetyl_NN procainamide_NN by_IN 55_CD %_NN and_CC 33_CD %_NN ,_, respectively_RB ._. Quinidine_NN and_CC procainamide_NN doses_NNS should_MD be_VB reduced_VBN by_IN one-third_NN when_WRB either_CC is_VBZ administered_VBN with_IN amiodarone_NN ._. Plasma_NN levels_NNS of_IN flecainide_NN have_VBP been_VBN reported_VBN to_TO increase_VB in_IN the_DT presence_NN of_IN oral_JJ amiodarone_NN ._. because_IN of_IN this_DT ,_, the_DT dosage_NN of_IN flecainide_NN should_MD be_VB adjusted_VBN when_WRB these_DT drugs_NNS are_VBP administered_VBN concomitantly_RB ._. In_IN general_JJ ,_, any_DT added_VBD antiarrhythmic_JJ drug_NN should_MD be_VB initiated_VBN at_IN a_DT lower_JJR than_IN usual_JJ dose_NN with_IN careful_JJ monitoring_NN ._. Combination_NN of_IN amiodarone_NN with_IN other_JJ antiarrhythmic_JJ therapy_NN should_MD be_VB reserved_VBN for_IN patients_NNS with_IN life-threatening_JJ ventricular_JJ arrhythmias_NNS who_WP are_VBP incompletely_RB responsive_JJ to_TO a_DT single_JJ agent_NN or_CC incompletely_RB responsive_JJ to_TO amiodarone_NN ._. During_IN transfer_NN to_TO oral_JJ amiodarone_NN ,_, the_DT dose_NN levels_NNS of_IN previously_RB administered_VBN agents_NNS should_MD be_VB reduced_VBN by_IN 30_CD to_TO 50_CD %_NN several_JJ days_NNS after_IN the_DT addition_NN of_IN oral_JJ amiodarone_NN ._. The_DT continued_JJ need_NN for_IN the_DT other_JJ antiarrhythmic_JJ agent_NN should_MD be_VB reviewed_VBN after_IN the_DT effects_NNS of_IN amiodarone_NN have_VBP been_VBN established_VBN ,_, and_CC discontinuation_NN ordinarily_RB should_MD be_VB attempted_VBN ._. If_IN the_DT treatment_NN is_VBZ continued_VBN ,_, these_DT patients_NNS should_MD be_VB particularly_RB carefully_RB monitored_VBN for_IN adverse_JJ effects_NNS ,_, especially_RB conduction_NN disturbances_NNS and_CC exacerbation_NN of_IN tachyarrhythmias_NNS ,_, as_IN amiodarone_NN is_VBZ continued_VBN ._. In_IN amiodarone-treated_JJ patients_NNS who_WP require_VBP additional_JJ antiarrhythmic_JJ therapy_NN ,_, the_DT initial_JJ dose_NN of_IN such_JJ agents_NNS should_MD be_VB approximately_RB half_NN of_IN the_DT usual_JJ recommended_VBN dose_NN ._. Antihypertensives_NNS :_: Amiodarone_NN should_MD be_VB used_VBN with_IN caution_NN in_IN patients_NNS receiving_VBG -_: receptor_NN blocking_VBG agents_NNS -LRB-_-LRB- e.g._FW ,_, propranolol_NN ,_, a_DT CYP3A4_NN inhibitor_NN -RRB-_-RRB- or_CC calcium_NN channel_NN antagonists_NNS -LRB-_-LRB- e.g._FW ,_, verapamil_NN ,_, a_DT CYP3A4_NN substrate_NN ,_, and_CC diltiazem_NN ,_, a_DT CYP3A4_NN inhibitor_NN -RRB-_-RRB- because_IN of_IN the_DT possible_JJ potentiation_NN of_IN bradycardia_NN ,_, sinus_NN arrest_NN ,_, and_CC AV_NN block_NN ._. if_IN necessary_JJ ,_, amiodarone_NN can_MD continue_VB to_TO be_VB used_VBN after_IN insertion_NN of_IN a_DT pacemaker_NN in_IN patients_NNS with_IN severe_JJ bradycardia_NN or_CC sinus_NN arrest_NN ._. Anticoagulants_NNPS :_: Potentiation_NN of_IN warfarin-type_JJ -LRB-_-LRB- CYP2C9_NN and_CC CYP3A4_NN substrate_NN -RRB-_-RRB- anticoagulant_JJ response_NN is_VBZ almost_RB always_RB seen_VBN in_IN patients_NNS receiving_VBG amiodarone_NN and_CC can_MD result_VB in_IN serious_JJ or_CC fatal_JJ bleeding_NN ._. Since_IN the_DT concomitant_JJ administration_NN of_IN warfarin_NN with_IN amiodarone_NN increases_VBZ the_DT prothrombin_NN time_NN by_IN 100_CD %_NN after_IN 3_CD to_TO 4_CD days_NNS ,_, the_DT dose_NN of_IN the_DT anticoagulant_NN should_MD be_VB reduced_VBN by_IN one-third_NN to_TO one-half_NN ,_, and_CC prothrombin_NN times_NNS should_MD be_VB monitored_VBN closely_RB ._. Some_DT drugs/substances_NNS are_VBP known_VBN to_TO accelerate_VB the_DT metabolism_NN of_IN amiodarone_NN by_IN stimulating_VBG the_DT synthesis_NN of_IN CYP3A4_NN -LRB-_-LRB- enzyme_NN induction_NN -RRB-_-RRB- ._. This_DT may_MD lead_VB to_TO low_JJ amiodarone_NN serum_NN levels_NNS and_CC potential_JJ decrease_NN in_IN efficacy_NN ._. Reported_VBN examples_NNS of_IN this_DT interaction_NN include_VBP the_DT following_NN :_: Antibiotics_NNS :_: Rifampin_NNP is_VBZ a_DT potent_JJ inducer_NN of_IN CYP3A4_NN ._. Administration_NN of_IN rifampin_NN concomitantly_RB with_IN oral_JJ amiodarone_NN has_VBZ been_VBN shown_VBN to_TO result_VB in_IN decreases_NNS in_IN serum_NN concentrations_NNS of_IN amiodarone_NN and_CC desethylamiodarone_NN ._. Other_JJ substances_NNS ,_, including_VBG herbal_JJ preparations_NNS :_: St._NNP John_NNP s_VBZ Wort_NNP -LRB-_-LRB- Hypericum_NNP perforatum_NN -RRB-_-RRB- induces_VBZ CYP3A4_NN ._. Since_IN amiodarone_NN is_VBZ a_DT substrate_NN for_IN CYP3A4_NN ,_, there_EX is_VBZ the_DT potential_NN that_IN the_DT use_NN of_IN St._NNP John_NNP s_VBZ Wort_NNP in_IN patients_NNS receiving_VBG amiodarone_NN could_MD result_VB in_IN reduced_VBN amiodarone_NN levels_NNS ._. Other_JJ reported_VBN interactions_NNS with_IN amiodarone_NN :_: Fentanyl_NN -LRB-_-LRB- CYP3A4_NN substrate_NN -RRB-_-RRB- in_IN combination_NN with_IN amiodarone_NN may_MD cause_VB hypotension_NN ,_, bradycardia_NN ,_, and_CC decreased_VBD cardiac_JJ output_NN ._. Sinus_NN bradycardia_NN has_VBZ been_VBN reported_VBN with_IN oral_JJ amiodarone_NN in_IN combination_NN with_IN lidocaine_NN -LRB-_-LRB- CYP3A4_NN substrate_NN -RRB-_-RRB- given_VBN for_IN local_JJ anesthesia_NN ._. Seizure_NN ,_, associated_VBN with_IN increased_VBN lidocaine_NN concentrations_NNS ,_, has_VBZ been_VBN reported_VBN with_IN concomitant_JJ administration_NN of_IN intravenous_JJ amiodarone_NN ._. Dextromethorphan_NNP is_VBZ a_DT substrate_NN for_IN both_DT CYP2D6_NN and_CC CYP3A4_NN ._. Amiodarone_NN inhibits_VBZ CYP2D6_NN ._. Cholestyramine_NNP increases_VBZ enterohepatic_JJ elimination_NN of_IN amiodarone_NN and_CC may_MD reduce_VB its_PRP$ serum_NN levels_NNS and_CC t1/2_NN ._. Disopyramide_NNP increases_VBZ QT_NNP prolongation_NN which_WDT could_MD cause_VB arrhythmia_NN ._. Fluoroquinolones_NNP ,_, macrolide_NN antibiotics_NNS ,_, and_CC azoles_NNS are_VBP known_VBN to_TO cause_VB QTc_NN prolongation_NN ._. There_EX have_VBP been_VBN reports_NNS of_IN QTc_NN prolongation_NN ,_, with_IN or_CC without_IN TdP_NN ,_, in_IN patients_NNS taking_VBG amiodarone_NN when_WRB fluoroquinolones_NNS ,_, macrolide_NN antibiotics_NNS ,_, or_CC azoles_NNS were_VBD administered_VBN concomitantly_RB ._. Hemodynamic_JJ and_CC electrophysiologic_JJ interactions_NNS have_VBP also_RB been_VBN observed_VBN after_IN concomitant_JJ administration_NN with_IN propranolol_NN ,_, diltiazem_NN ,_, and_CC verapamil_NN ._. Volatile_JJ Anesthetic_NNP Agents_NNPS :_: ._. In_IN addition_NN to_TO the_DT interactions_NNS noted_VBD above_RB ,_, chronic_JJ -LRB-_-LRB- 2_CD weeks_NNS -RRB-_-RRB- oral_JJ Cordarone_NNP administration_NN impairs_VBZ metabolism_NN of_IN phenytoin_NN ,_, dextromethorphan_NN ,_, and_CC methotrexate_NN ._. Electrolyte_NNP Disturbances_NNPS Patients_NNPS with_IN hypokalemia_NN or_CC hypomagnesemia_NN should_MD have_VB the_DT condition_NN corrected_VBN whenever_WRB possible_JJ before_IN being_VBG treated_VBN with_IN Cordarone_JJ I.V._NNP ,_, as_IN these_DT disorders_NNS can_MD exaggerate_VB the_DT degree_NN of_IN QTc_NN prolongation_NN and_CC increase_VB the_DT potential_NN for_IN TdP_NN ._. Special_JJ attention_NN should_MD be_VB given_VBN to_TO electrolyte_NN and_CC acid-base_NN balance_NN in_IN patients_NNS experiencing_VBG severe_JJ or_CC prolonged_JJ diarrhea_NN or_CC in_IN patients_NNS receiving_VBG concomitant_JJ diuretics_NNS ._. Drugs_NNS Metabolized_VBN by_IN P450_NN 2D6_NN -_: The_DT biochemical_JJ activity_NN of_IN the_DT drug_NN metabolizing_VBG isozyme_NN cytochrome_NN P450_NN 2D6_NN -LRB-_-LRB- debrisoquin_NN hydroxylase_NN -RRB-_-RRB- is_VBZ reduced_VBN in_IN a_DT subset_NN of_IN the_DT caucasian_JJ population_NN -LRB-_-LRB- about_IN 7-10_CD %_NN of_IN caucasians_NNS are_VBP so_RB called_VBN poor_JJ metabolizers_NNS -RRB-_-RRB- ;_: ._. reliable_JJ estimates_NNS of_IN the_DT prevalence_NN of_IN reduced_VBN P450_NN 2D6_NN isozyme_NN activity_NN among_IN Asian_JJ ,_, African_JJ and_CC other_JJ populations_NNS are_VBP not_RB yet_RB available_JJ ._. Poor_NNP metabolizers_NNS have_VBP higher_JJR than_IN expected_VBN plasma_NN concentrations_NNS of_IN tricyclic_JJ antidepressants_NNS -LRB-_-LRB- TCAs_NNS -RRB-_-RRB- when_WRB given_VBN usual_JJ doses_NNS ._. 
Depending_VBG on_IN the_DT fraction_NN of_IN drug_NN metabolized_VBN by_IN P450_NN 2D6_NN ,_, the_DT increase_NN in_IN plasma_NN concentration_NN may_MD be_VB small_JJ ,_, or_CC quite_RB large_JJ -LRB-_-LRB- 8-fold_JJ increase_NN in_IN plasma_NN AUC_NN of_IN the_DT TCA_NNP -RRB-_-RRB- ._. In_IN addition_NN ,_, certain_JJ drugs_NNS inhibit_VBP the_DT activity_NN of_IN this_DT isozyme_NN and_CC make_VB normal_JJ metabolizers_NNS resemble_VBP poor_JJ metabolizers_NNS ._. An_DT individual_NN who_WP is_VBZ stable_JJ on_IN a_DT given_VBN dose_NN of_IN TCA_NNP may_MD become_VB abruptly_RB toxic_JJ when_WRB given_VBN one_CD of_IN these_DT inhibiting_VBG drugs_NNS as_IN concomitant_JJ therapy_NN ._. The_DT drugs_NNS that_WDT inhibit_VBP cytochrome_NN P450_NN 2D6_NN include_VBP some_DT that_WDT are_VBP not_RB metabolized_VBN by_IN the_DT enzyme_NN -LRB-_-LRB- quinidine_NN ._. cimetidine_NN -RRB-_-RRB- and_CC many_JJ that_WDT are_VBP substrates_NNS for_IN P450_NN 2D6_NN -LRB-_-LRB- many_JJ other_JJ antidepressants_NNS ,_, phenothiazines_NNS ,_, and_CC the_DT Type_NN 1C_NN antiarrhythmics_NNS propafenone_NN and_CC flecainide_NN -RRB-_-RRB- ._. While_IN all_PDT the_DT selective_JJ serotonin_NN reuptake_NN inhibitors_NNS -LRB-_-LRB- SSRIs_NNS -RRB-_-RRB- ,_, e.g._FW ,_, fluoxetine_NN ,_, sertraline_NN ,_, and_CC paroxetine_NN ,_, inhibit_VBP P450_NN 2D6_NN ,_, they_PRP may_MD vary_VB in_IN the_DT extent_NN of_IN inhibition_NN ._. The_DT extent_NN to_TO which_WDT SSRI-TCA_NNP interactions_NNS may_MD pose_VB clinical_JJ problems_NNS will_MD depend_VB on_IN the_DT degree_NN of_IN inhibition_NN and_CC the_DT pharmacokinetics_NNS of_IN the_DT SSRI_NNP involved_VBN ._. Nevertheless_RB ,_, caution_NN is_VBZ indicated_VBN in_IN the_DT coadministration_NN of_IN TCAs_NNS with_IN any_DT of_IN the_DT SSRIs_NNS and_CC also_RB in_IN switching_NN from_IN one_CD class_NN to_TO the_DT other_JJ ._. Of_IN particular_JJ importance_NN ,_, sufficient_JJ time_NN must_MD elapse_VB before_IN initiating_VBG TCA_NNP treatment_NN in_IN a_DT patient_NN being_VBG withdrawn_VBN from_IN fluoxetine_NN ,_, given_VBN the_DT long_JJ half-life_NN of_IN the_DT parent_NN and_CC active_JJ metabolite_NN -LRB-_-LRB- at_IN least_JJS 5_CD weeks_NNS may_MD be_VB necessary_JJ -RRB-_-RRB- ._. Concomitant_JJ use_NN of_IN tricyclic_JJ antidepressants_NNS with_IN drugs_NNS that_WDT can_MD inhibit_VB cytochrome_NN P450_NN 2D6_NN may_MD require_VB lower_JJR doses_NNS than_IN usually_RB prescribed_VBN for_IN either_CC the_DT tricyclic_JJ antidepressant_JJ or_CC the_DT other_JJ drug_NN ._. Furthermore_RB ,_, whenever_WRB one_CD of_IN these_DT other_JJ drugs_NNS is_VBZ withdrawn_VBN from_IN co-therapy_JJ ,_, an_DT increased_VBN dose_NN of_IN tricyclic_JJ antidepressant_JJ may_MD be_VB required_VBN ._. It_PRP is_VBZ desirable_JJ to_TO monitor_VB TCA_NNP plasma_NN levels_NNS whenever_WRB a_DT TCA_NNP is_VBZ going_VBG to_TO be_VB coadministered_VBN with_IN another_DT drug_NN known_VBN to_TO be_VB an_DT inhibitor_NN of_IN P450_NN 2D6_NN ._. Monoamine_NNP Oxidase_NNP Inhibitors_NNS :_: Guanethidine_NN or_CC similarly_RB acting_VBG compounds_NNS ._. thyroid_NN medication_NN ._. alcohol_NN ,_, barbiturates_NNS and_CC other_JJ CNS_NN depressants_NNS ._. and_CC disulfiram_NN When_WRB amitriptyline_NNP HCl_NN is_VBZ given_VBN with_IN anticholinergic_JJ agents_NNS or_CC sympathomimetic_JJ drugs_NNS ,_, including_VBG epinephrine_NN combined_VBN with_IN local_JJ anesthetics_NNS ,_, close_JJ supervision_NN and_CC careful_JJ adjustment_NN of_IN dosages_NNS are_VBP required_VBN ._. Hyperpyrexia_NNP has_VBZ been_VBN reported_VBN when_WRB amitriptyline_NNP HCl_NN is_VBZ administered_VBN with_IN anticholinergic_JJ agents_NNS or_CC with_IN neuroleptic_JJ drugs_NNS ,_, particularly_RB during_IN hot_JJ weather_NN ._. Paralytic_JJ ileus_NN may_MD occur_VB in_IN patients_NNS taking_VBG tricyclic_JJ antidepressants_NNS in_IN combination_NN with_IN anticholinergic-type_JJ drugs_NNS ._. Cimetidine_NNP is_VBZ reported_VBN to_TO reduce_VB hepatic_JJ metabolism_NN of_IN certain_JJ tricyclic_JJ antidepressants_NNS ,_, thereby_RB delaying_VBG elimination_NN and_CC increasing_VBG steady-state_JJ concentrations_NNS of_IN these_DT drugs_NNS ._. Clinically_RB significant_JJ effects_NNS have_VBP been_VBN reported_VBN with_IN the_DT tricyclic_JJ antidepressants_NNS when_WRB used_VBN concomitantly_RB with_IN cimetidine_NN ._. Increases_NNS in_IN plasma_NN levels_NNS of_IN tricyclic_JJ antidepressants_NNS ,_, and_CC in_IN the_DT frequency_NN and_CC severity_NN of_IN side_JJ effects_NNS ,_, particularly_RB anticholinergic_JJ ,_, have_VBP been_VBN reported_VBN when_WRB cimetidine_NN was_VBD added_VBN to_TO the_DT drug_NN regimen_NN ._. Discontinuation_NN of_IN cimetidine_NN in_IN well-controlled_JJ patients_NNS receiving_VBG tricyclic_JJ antidepressants_NNS and_CC cimetidine_NN may_MD decrease_VB the_DT plasma_NN levels_NNS and_CC efficacy_NN of_IN the_DT antidepressants_NNS ._. Caution_NN is_VBZ advised_VBN if_IN patients_NNS receive_VBP large_JJ doses_NNS of_IN ethchlorvynol_NN concurrently_RB ._. Transient_JJ delirium_NN has_VBZ been_VBN reported_VBN in_IN patients_NNS who_WP were_VBD treated_VBN with_IN one_CD gram_NN of_IN ethchlorvynol_NN and_CC 75_CD -_: 150_CD mg_NN of_IN amitriptyline_NNP HCl_NN ._. When_WRB administered_VBN concurrently_RB ,_, the_DT following_VBG drugs_NNS may_MD interact_VB with_IN amphotericin_NN B_NN :_: Antineoplastic_JJ agents_NNS :_: may_MD enhance_VB the_DT potential_NN for_IN renal_JJ toxicity_NN ,_, bronchospasm_NN and_CC hypotension_NN ._. Antineoplastic_JJ agents_NNS -LRB-_-LRB- e._FW g._FW ,_, nitrogen_NN mustard_NN ,_, etc._FW -RRB-_-RRB- should_MD be_VB given_VBN concomitantly_RB only_RB with_IN great_JJ caution_NN ._. Corticosteroids_NNS and_CC Corticotropin_NN -LRB-_-LRB- ACTH_NN -RRB-_-RRB- :_: may_MD potentiate_VB amphotericin_NN B_NN -_: induced_VBN hypokalemia_NN which_WDT may_MD predispose_VB the_DT patient_NN to_TO cardiac_JJ dysfunction_NN ._. Avoid_VB concomitant_JJ use_NN unless_IN necessary_JJ to_TO control_VB side_JJ effects_NNS of_IN amphotericin_NN B_NN ._. If_IN used_VBN concomitantly_RB ,_, closely_RB monitor_VB serum_NN electrolytes_NNS and_CC cardiac_JJ function_NN ._. Digitalis_NN glycosides_NNS :_: amphotericin_NN B-induced_JJ hypokalemia_NN may_MD potentiate_VB digitalis_NN toxicity_NN ._. Serum_NN potassium_NN levels_NNS and_CC cardiac_JJ function_NN should_MD be_VB closely_RB monitored_VBN and_CC any_DT deficit_NN promptly_RB corrected_VBN ._. Flucytosine_NNP :_: while_IN a_DT synergistic_JJ relationship_NN with_IN amphotericin_NN B_NN has_VBZ been_VBN reported_VBN ,_, concomitant_JJ use_NN may_MD increase_VB the_DT toxicity_NN of_IN flucytosine_NN by_IN possibly_RB increasing_VBG its_PRP$ cellular_JJ uptake_NN and/or_CC impairing_VBG its_PRP$ renal_JJ excretion_NN ._. Imidazoles_NNS -LRB-_-LRB- e._FW g._FW ,_, ketoconazole_NN ,_, miconazole_NN ,_, clotrimazole_NN ,_, fluconazole_NN ,_, etc._FW -RRB-_-RRB- :_: in_FW vitro_FW and_CC animal_JJ studies_NNS with_IN the_DT combination_NN of_IN amphotericin_NN B_NN and_CC imidazoles_NNS suggest_VBP that_IN imidazoles_NNS may_MD induce_VB fungal_JJ resistance_NN to_TO amphotericin_NN B._NNP Combination_NNP therapy_NN should_MD be_VB administered_VBN with_IN caution_NN ,_, especially_RB in_IN immunocompromised_JJ patients_NNS ._. Other_JJ nephrotoxic_JJ medications_NNS :_: agents_NNS such_JJ as_IN aminoglycosides_NNS ,_, cyclosporine_NN ,_, and_CC pentamidine_NN may_MD enhance_VB the_DT potential_NN for_IN drug-induced_JJ renal_JJ toxicity_NN ,_, and_CC should_MD be_VB used_VBN concomitantly_RB only_RB with_IN great_JJ caution_NN ._. Intensive_JJ monitoring_NN of_IN renal_JJ function_NN is_VBZ recommended_VBN in_IN patients_NNS requiring_VBG any_DT combination_NN of_IN nephrotoxic_JJ medications_NNS ._. Skeletal_JJ muscle_NN relaxants_NNS :_: amphotericin_NN B-induced_JJ hypokalemia_NN may_MD enhance_VB the_DT curariform_NN effect_NN of_IN skeletal_JJ muscle_NN relaxants_NNS -LRB-_-LRB- e.g._FW ,_, tubocurarine_NN -RRB-_-RRB- ._. Serum_NN potassium_NN levels_NNS should_MD be_VB monitored_VBN and_CC deficiencies_NNS corrected_VBN ._. Leukocyte_NN transfusions_NNS :_: acute_JJ pulmonary_JJ toxicity_NN has_VBZ been_VBN reported_VBN in_IN patients_NNS receiving_VBG intravenous_JJ amphotericin_NN B_NN and_CC leukocyte_NN transfusions_NNS ._. When_WRB administered_VBN concurrently_RB ,_, the_DT following_VBG drugs_NNS may_MD interact_VB with_IN ampicillin_NN ._. Allopurinol_NNP :_: Increased_VBN possibility_NN of_IN skin_NN rash_NN ,_, particularly_RB in_IN hyperuricemic_JJ patients_NNS may_MD occur_VB ._. Bacteriostatic_JJ Antibiotics_NNS :_: Chloramphenicol_NN ,_, erythromycins_NNS ,_, sulfonamides_NNS ,_, or_CC tetracyclines_NNS may_MD interfere_VB with_IN the_DT bactericidal_JJ effect_NN of_IN penicillins_NNS ._. This_DT has_VBZ been_VBN demonstrated_VBN in_IN view_NN ,_, however_RB ,_, the_DT clinical_JJ significance_NN of_IN this_DT interaction_NN is_VBZ not_RB well_RB documented_VBN ._. Oral_JJ Contraceptives_NNS :_: May_MD be_VB less_RBR effective_JJ and_CC increased_VBD breakthrough_NN bleeding_NN may_MD occur_VB ._. Probenecid_NNP :_: May_NNP decrease_VB renal_JJ tubular_JJ secretion_NN of_IN ampicillin_NN resulting_VBG in_IN increased_VBN blood_NN levels_NNS and/or_CC ampicillin_NN toxicity_NN ._. Drug/Laboratory_JJ Test_NN Interaction_NN After_IN treatment_NN with_IN ampicillin_NN ,_, a_DT false-positive_JJ reaction_NN for_IN glucose_NN in_IN the_DT urine_NN may_MD occur_VB with_IN copper_NN sulfate_NN tests_NNS -LRB-_-LRB- Benedicts_NNS solution_NN ,_, Fehlings_NNP solution_NN ,_, or_CC Clinitest_NNP tablets_NNS -RRB-_-RRB- but_CC not_RB with_IN enzyme_NN based_VBN tests_NNS such_JJ as_IN Clinistix_NNP and_CC Glucose_NNP Enzymatic_JJ Test_NN Strip_NNP USP_NNP ._. Amprenavir_NNP is_VBZ metabolized_VBN in_IN the_DT liver_NN by_IN the_DT cytochrome_NN P450_NN enzyme_NN system_NN ._. Amprenavir_NN inhibits_VBZ CYP3A4_NN ._. Caution_NN should_MD be_VB used_VBN when_WRB coadministering_VBG medications_NNS that_WDT are_VBP substrates_NNS ,_, inhibitors_NNS ,_, or_CC inducers_NNS of_IN CYP3A4_NN ,_, or_CC potentially_RB toxic_JJ medications_NNS that_WDT are_VBP metabolized_VBN by_IN CYP3A4_NN ._. Amprenavir_NNP does_VBZ not_RB inhibit_VB CYP2D6_NN ,_, CYP1A2_NN ,_, CYP2C9_NN ,_, CYP2C19_NN ,_, CYP2E1_NN ,_, or_CC uridine_NN glucuronosyltransferase_NN -LRB-_-LRB- UDPGT_NN -RRB-_-RRB- ._. HIV_NN Protease_NN Inhibitors_NNS :_: The_DT effect_NN of_IN amprenavir_NN on_IN total_JJ drug_NN concentrations_NNS of_IN other_JJ HIV_NN protease_NN inhibitors_NNS in_IN subjects_NNS receiving_VBG both_CC agents_NNS was_VBD evaluated_VBN using_VBG comparisons_NNS to_TO historical_JJ data_NNS ._. Indinavir_NNP steady-state_JJ Cmax_NNP ,_, A.C._NNP and_CC Cmin_NNP were_VBD decreased_VBN by_IN 22_CD %_NN ,_, 38_CD %_NN ,_, and_CC 27_CD %_NN ,_, respectively_RB ,_, by_IN concomitant_JJ amprenavir_NN ._. Similar_JJ decreases_NNS in_IN Cmax_NN and_CC AUC_NN were_VBD seen_VBN after_IN the_DT first_JJ dose_NN ._. Saquinavir_NNP steady-state_JJ Cmax_NNP ,_, A.C._NNP and_CC Cmin_NNP were_VBD increased_VBN 21_CD %_NN ,_, decreased_VBD 19_CD %_NN ,_, and_CC decreased_VBD 48_CD %_NN ,_, respectively_RB ,_, by_IN concomitant_JJ amprenavir_NN ._. Nelfinavir_NNP steady-state_JJ Cmax_NNP ,_, A.C._NNP and_CC Cmin_NNP were_VBD increased_VBN by_IN 12_CD %_NN ,_, 15_CD %_NN ,_, and_CC 14_CD %_NN ,_, respectively_RB ,_, by_IN concomitant_JJ amprenavir_NN ._. Methadone_NNP :_: Coadministration_NNP of_IN amprenavir_NN and_CC methadone_NN can_MD decrease_VB plasma_NN levels_NNS of_IN methadone_NN ._. Coadministration_NN of_IN amprenavir_NN and_CC methadone_NN as_IN compared_VBN to_TO a_DT non-matched_JJ historicalcontrol_NN group_NN resulted_VBD in_IN a_DT 30_CD %_NN ,_, 27_CD %_NN ,_, and_CC 25_CD %_NN decrease_NN in_IN serum_NN amprenavir_NN AUC_NN ,_, Cmax_NN ,_, andCmin_NN ,_, respectively_RB ._. Amprenavir_NNP is_VBZ an_DT inhibitor_NN of_IN cytochrome_NN P450_NN C.P.A._NN metabolism_NN and_CC therefore_RB should_MD not_RB be_VB administered_VBN concurrently_RB with_IN medications_NNS with_IN narrow_JJ therapeutic_JJ windows_NNS that_WDT are_VBP substrates_NNS of_IN CYP3A4_NN ._. There_EX are_VBP other_JJ agents_NNS that_WDT may_MD result_VB in_IN serious_JJ and/or_CC life-threatening_JJ drug_NN interactions_NNS ._. Laboratory_NN Tests_NNS :_: The_DT combination_NN of_IN Amprenavir_NNP and_CC low-dose_JJ ritonavir_NN has_VBZ been_VBN associated_VBN with_IN elevations_NNS of_IN cholesterol_NN and_CC triglycerides_NNS ,_, SGOT_NN -LRB-_-LRB- AST_NNP -RRB-_-RRB- ,_, and_CC SGPT_NN -LRB-_-LRB- ALT_NN -RRB-_-RRB- in_IN some_DT patients_NNS ._. Appropriate_JJ laboratory_NN testing_NN should_MD be_VB considered_VBN prior_RB to_TO initiating_VBG combination_NN therapy_NN with_IN Amprenavir_NN and_CC ritonavir_NN and_CC at_IN periodic_JJ intervals_NNS or_CC if_IN any_DT clinical_JJ signs_NNS or_CC symptoms_NNS of_IN hyperlipidemia_NN or_CC elevated_JJ liver_NN function_NN tests_NNS occur_VBP during_IN therapy_NN ._. For_IN comprehensive_JJ information_NN concerning_VBG laboratory_NN test_NN alterations_NNS associated_VBN with_IN ritonavir_NN ,_, physicians_NNS should_MD refer_VB to_TO the_DT complete_JJ prescribing_VBG information_NN for_IN NORVIR_NN -LRB-_-LRB- ritonavir_NN -RRB-_-RRB- ._. Taking_VBG amyl_NN nitrite_NN after_IN drinking_VBG alcohol_NN may_MD worsen_VB side_JJ effects_NNS and_CC may_MD cause_VB severe_JJ hypotension_NN and_CC cardiovascular_JJ collapse_NN ._. Limited_JJ PK_NN and/or_CC PD_NN studies_NNS investigating_VBG possible_JJ interactions_NNS between_IN anagrelide_NN and_CC other_JJ medicinal_JJ products_NNS have_VBP been_VBN conducted_VBN ._. In_FW vivo_FW interaction_NN studies_NNS in_IN humans_NNS have_VBP demonstrated_VBN that_IN digoxin_NN and_CC warfarin_NN do_VBP not_RB affect_VB the_DT PK_NN properties_NNS of_IN anagrelide_NN ,_, nor_CC does_VBZ anagrelide_NN affect_VB the_DT PK_NN properties_NNS of_IN digoxin_NN or_CC warfarin_NN ._. Although_IN additional_JJ drug_NN interaction_NN studies_NNS have_VBP not_RB been_VBN conducted_VBN ,_, the_DT most_RBS common_JJ medications_NNS used_VBN concomitantly_RB with_IN anagrelide_NN in_IN clinical_JJ trials_NNS were_VBD aspirin_NN ,_, acetaminophen_NN ,_, furosemide_NN ,_, iron_NN ,_, ranitidine_NN ,_, hydroxyurea_NN ,_, and_CC allopurinol_NN ._. There_EX is_VBZ no_DT clinical_JJ evidence_NN to_TO suggest_VB that_IN anagrelide_NN interacts_VBZ with_IN any_DT of_IN these_DT compounds_NNS ._. An_DT in_FW vivo_FW interaction_NN study_NN in_IN humans_NNS demonstrated_VBD that_IN a_DT single_JJ 1mg_JJ dose_NN of_IN anagrelide_NN administered_VBN concomitantly_RB with_IN a_DT single_JJ 900_CD mg_NN dose_NN of_IN aspirin_NN was_VBD generally_RB well_RB tolerated_VBN ._. There_EX was_VBD no_DT effect_NN on_IN bleeding_JJ time_NN ,_, PT_NN or_CC aPTT_NN ._. No_DT clinically_RB relevant_JJ pharmacokinetic_JJ interactions_NNS between_IN anagrelide_NN and_CC acetylsalicylic_JJ acid_NN were_VBD observed_VBN ._. In_IN that_DT same_JJ study_NN ,_, aspirin_NN alone_RB produced_VBD a_DT marked_JJ inhibition_NN in_IN platelet_NN aggregation_NN ex_FW vivo_FW ._. Anagrelide_NN alone_RB had_VBD no_DT effect_NN on_IN platelet_NN aggregation_NN ,_, but_CC did_VBD slightly_RB enhance_VB the_DT inhibition_NN of_IN platelet_NN aggregation_NN by_IN aspirin_NN ._. Anagrelide_NNP is_VBZ metabolized_VBN at_IN least_JJS in_IN part_NN by_IN CYP1A2_NN ._. It_PRP is_VBZ known_VBN that_IN CYP1A2_NN is_VBZ inhibited_VBN by_IN several_JJ medicinal_JJ products_NNS ,_, including_VBG fluvoxamine_NN ,_, and_CC such_JJ medicinal_JJ products_NNS could_MD theoretically_RB adversely_RB influence_VB the_DT clearance_NN of_IN anagrelide_NN ._. Anagrelide_NNP demonstrates_VBZ some_DT limited_JJ inhibitory_JJ activity_NN towards_IN CYP1A2_NN which_WDT may_MD present_VB a_DT theoretical_JJ potential_NN for_IN interaction_NN with_IN other_JJ coadministered_JJ medicinal_JJ products_NNS sharing_VBG that_IN clearance_NN mechanism_NN e.g._FW Anagrelide_FW demonstrates_VBZ some_DT limited_JJ inhibitory_JJ activity_NN towards_IN CYP1A2_NN which_WDT may_MD present_VB a_DT theoretical_JJ potential_NN for_IN interaction_NN with_IN other_JJ coadministered_JJ medicinal_JJ products_NNS sharing_VBG that_IN clearance_NN mechanism_NN e.g._FW theophylline_FW ._. Anagrelide_NNP is_VBZ an_DT inhibitor_NN of_IN cyclic_JJ AMP_NN PDE_NN III_CD ._. The_DT effects_NNS of_IN medicinal_JJ products_NNS with_IN similar_JJ properties_NNS such_JJ as_IN inotropes_NNS milrinone_NN ,_, enoximone_NN ,_, amrinone_NN ,_, olprinone_NN and_CC cilostazol_NN may_MD be_VB exacerbated_VBN by_IN anagrelide_NN ._. There_EX is_VBZ a_DT single_JJ case_NN report_NN ,_, which_WDT suggests_VBZ that_IN sucralfate_NN may_MD interfere_VB with_IN anagrelide_NN absorption_NN ._. Food_NNP has_VBZ no_DT clinically_RB significant_JJ effect_NN on_IN the_DT bioavailability_NN of_IN anagrelide_NN ._. No_DT drug-drug_NN interaction_NN studies_NNS in_IN human_JJ subjects_NNS have_VBP been_VBN conducted_VBN ._. Toxicologic_JJ and_CC toxicokinetic_JJ studies_NNS in_IN rats_NNS did_VBD not_RB demonstrate_VB any_DT alterations_NNS in_IN the_DT clearance_NN or_CC toxicologic_JJ profile_NN of_IN either_CC methotrexate_NN or_CC Kineret_NN when_WRB the_DT two_CD agents_NNS were_VBD administered_VBN together_RB ._. In_IN a_DT study_NN in_IN which_WDT patients_NNS with_IN active_JJ RA_NN were_VBD treated_VBN for_IN up_RB to_TO 24_CD weeks_NNS with_IN concurrent_JJ Kineret_NN and_CC etanercept_NN therapy_NN ,_, a_DT 7_CD %_NN rate_NN of_IN serious_JJ infections_NNS was_VBD observed_VBN ,_, which_WDT was_VBD higher_JJR than_IN that_DT observed_VBN with_IN etanercept_NN alone_RB -LRB-_-LRB- 0_CD %_NN -RRB-_-RRB- ._. Two_CD percent_NN of_IN patients_NNS treated_VBN concurrently_RB with_IN Kineret_NN and_CC etanercept_NN developed_VBD neutropenia_NN -LRB-_-LRB- ANC_NNP 1_CD x_CC 109/L_CD -RRB-_-RRB- ._. Anastrozole_NNP inhibited_VBD in_FW vitro_FW metabolic_JJ reactions_NNS catalyzed_VBN by_IN cytochromes_NNS P450_NN 1A2_NN ,_, 2C8/9_NN ,_, and_CC 3A4_NN but_CC only_RB at_IN relatively_RB high_JJ concentrations_NNS ._. Anastrozole_NNP did_VBD not_RB inhibit_VB P450_NN 2A6_NN or_CC the_DT polymorphic_JJ P450_NN 2D6_NN in_IN human_JJ liver_NN microsomes_NNS ._. Anastrozole_NNP did_VBD not_RB alter_VB the_DT pharmacokinetics_NNS of_IN antipyrine_NN ._. Although_IN there_EX have_VBP been_VBN no_DT formal_JJ interaction_NN studies_NNS other_JJ than_IN with_IN antipyrine_NN ,_, based_VBN on_IN these_DT in_FW vivo_FW and_CC in_FW vitro_FW studies_NNS ,_, it_PRP is_VBZ unlikely_JJ that_IN co-administration_NN of_IN a_DT 1_CD mg_NN dose_NN of_IN ARIMIDEX_NN with_IN other_JJ drugs_NNS will_MD result_VB in_IN clinically_RB significant_JJ drug_NN inhibition_NN of_IN cytochrome_NN P450-mediated_JJ metabolism_NN of_IN the_DT other_JJ drugs_NNS ._. An_DT interaction_NN study_NN with_IN warfarin_NN showed_VBD no_DT clinically_RB significant_JJ effect_NN of_IN anastrozole_NN on_IN warfarin_NN pharmacokinetics_NNS or_CC anticoagulant_JJ activity_NN ._. At_IN a_DT median_JJ follow-up_NN of_IN 33_CD months_NNS ,_, the_DT combination_NN of_IN ARIMIDEX_NNP and_CC tamoxifen_NN did_VBD not_RB demonstrate_VB any_DT efficacy_NN benefit_NN when_WRB compared_VBN with_IN tamoxifen_NN in_IN all_DT patients_NNS as_RB well_RB as_IN in_IN the_DT hormone_NN receptor-positive_JJ subpopulation_NN ._. This_DT treatment_NN arm_NN was_VBD discontinued_VBN from_IN the_DT trial_NN ._. Based_VBN on_IN clinical_JJ and_CC pharmacokinetic_JJ results_NNS from_IN the_DT ATAC_NN trial_NN ,_, tamoxifen_NN should_MD not_RB be_VB administered_VBN with_IN anastrozole_NN -LRB-_-LRB- see_VB CLINICAL_NNP PHARMACOLOGY_NNP Drug_NNP Interactions_NNS and_CC CLINICAL_JJ PHARMACOLOGY_NN -_: Clinical_JJ Studies_NNS -_: Adjuvant_JJ Treatment_NN of_IN Breast_NN Cancer_NN in_IN Postmenopausal_NNP Women_NNP subsections_NNS -RRB-_-RRB- ._. Co-administration_NN of_IN anastrozole_NN and_CC tamoxifen_NN resulted_VBD in_IN a_DT reduction_NN of_IN anastrozole_NN plasma_NN levels_NNS by_IN 27_CD %_NN compared_VBN with_IN those_DT achieved_VBN with_IN anastrozole_NN alone_RB ._. Estrogen-containing_JJ therapies_NNS should_MD not_RB be_VB used_VBN with_IN ARIMIDEX_NN as_IN they_PRP may_MD diminish_VB its_PRP$ pharmacologic_JJ action_NN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS No_DT clinically_RB significant_JJ changes_NNS in_IN the_DT results_NNS of_IN clinical_JJ laboratory_NN tests_NNS have_VBP been_VBN observed_VBN ._. No_DT clinically_RB relevant_JJ drug-drug_JJ interactions_NNS have_VBP been_VBN observed_VBN with_IN drugs_NNS likely_JJ to_TO be_VB co-administered_VBN with_IN anidulafungin_NN ._. Caution_NN should_MD be_VB observed_VBN when_WRB anileridine_NN is_VBZ coadministered_VBN with_IN other_JJ opioids_NNS ,_, sedatives_NNS ,_, phenothiazines_NNS ,_, or_CC anesthetics_NNS ,_, as_IN these_DT agents_NNS may_MD increase_VB respiratory_JJ and_CC circulatory_JJ depression_NN ._. Addition_NN or_CC deletion_NN of_IN any_DT drug_NN from_IN the_DT therapeutic_JJ regimen_NN of_IN patients_NNS receiving_VBG oral_JJ anticoagulants_NNS may_MD affect_VB patient_NN response_NN to_TO the_DT anticoagulant_NN ._. Frequent_JJ determination_NN of_IN prothrombin_NN time_NN and_CC close_JJ monitoring_NN of_IN the_DT patient_NN is_VBZ essential_JJ to_TO ascertain_VB when_WRB adjustment_NN of_IN dosage_NN of_IN anticoagulant_NN may_MD be_VB needed_VBN ._. Because_IN of_IN the_DT variability_NN of_IN individual_JJ patient_NN response_NN ,_, multiple_JJ interacting_VBG mechanisms_NNS with_IN some_DT drugs_NNS ,_, the_DT dependency_NN of_IN the_DT extent_NN of_IN the_DT interaction_NN on_IN the_DT dosage_NN and_CC duration_NN of_IN therapy_NN ,_, and_CC the_DT possible_JJ administration_NN of_IN several_JJ interacting_VBG drugs_NNS simultaneously_RB ,_, it_PRP is_VBZ difficult_JJ to_TO predict_VB the_DT direction_NN and_CC degree_NN of_IN the_DT ultimate_JJ effect_NN of_IN concomitant_JJ medications_NNS on_IN anticoagulant_JJ response_NN ._. For_IN example_NN ,_, since_IN cholestyramine_NN may_MD reduce_VB the_DT gastrointestinal_JJ absorption_NN of_IN both_CC the_DT oral_JJ anticoagulants_NNS and_CC vitamin_NN K_NN ,_, the_DT net_JJ effects_NNS are_VBP unpredictable_JJ ._. Therefore_RB ,_, the_DT potential_JJ exists_VBZ for_IN interaction_NN between_IN carbamazepine_NN and_CC any_DT agent_NN metabolized_VBN by_IN one_CD -LRB-_-LRB- or_CC more_JJR -RRB-_-RRB- of_IN these_DT enzymes_NNS ._. Agents_NNS that_WDT have_VBP been_VBN found_VBN ,_, or_CC are_VBP expected_VBN to_TO have_VB decreased_VBN plasma_NN levels_NNS in_IN the_DT presence_NN of_IN EQUETROTM_NNP due_JJ to_TO induction_NN of_IN CYP_NN enzymes_NNS are_VBP the_DT following_NN :_: Acetaminophen_NNP ,_, alprazolam_NN ,_, amitriptyline_NNP ,_, bupropion_NN ,_, buspirone_NN ,_, citalopram_NN ,_, clobazam_NN ,_, clonazepam_NN ,_, clozapine_NN ,_, cyclosporin_NN ,_, delavirdine_NN ,_, desipramine_NN ,_, diazepam_NN ,_, dicumarol_NN ,_, doxycycline_NN ,_, ethosuximide_NN ,_, felbamate_NN ,_, felodipine_NN ,_, glucocorticoids_NNS ,_, haloperidol_NN ,_, itraconazole_NN ,_, lamotrigine_NN ,_, levothyroxine_NN ,_, lorazepam_NN ,_, methadone_NN ,_, midazolam_NN ,_, mirtazapine_NN ,_, nortriptyline_NN ,_, olanzapine_NN ,_, oral_JJ contraceptives_NNS -LRB-_-LRB- 3_CD -RRB-_-RRB- ,_, oxcarbazepine_NN ,_, Phenytoin_NN -LRB-_-LRB- 4_CD -RRB-_-RRB- ,_, praziquantel_NN ,_, protease_NN inhibitors_NNS ,_, quetiapine_NN ,_, risperidone_NN ,_, theophylline_NN ,_, topiramate_NN ,_, tiagabine_NN ,_, tramadol_NN ,_, triazolam_NN ,_, valproate_NN ,_, warfarin_NN -LRB-_-LRB- 5_CD -RRB-_-RRB- ,_, ziprasidone_NN ,_, and_CC zonisamide_NN ._. Thus_RB ,_, if_IN a_DT patient_NN has_VBZ been_VBN titrated_VBN to_TO a_DT stable_JJ dosage_NN on_IN one_CD of_IN the_DT agents_NNS in_IN this_DT category_NN ,_, and_CC then_RB begins_VBZ a_DT course_NN of_IN treatment_NN with_IN EQUETROTM_NN ,_, it_PRP is_VBZ reasonable_JJ to_TO expect_VB that_IN a_DT dose_NN increase_NN for_IN the_DT concomitant_JJ agent_NN may_MD be_VB necessary_JJ ._. Agents_NNS with_IN Increased_VBN Levels_NNS in_IN the_DT Presence_NN of_IN Carbamazepine_NNP :_: EQUETROTM_NNP increases_VBZ the_DT plasma_NN levels_NNS of_IN the_DT following_VBG agents_NNS :_: Clomipramine_NNP HCl_NN ,_, Phenytoin_NNP -LRB-_-LRB- 6_CD -RRB-_-RRB- ,_, and_CC primidone_NN Thus_RB ,_, if_IN a_DT patient_NN has_VBZ been_VBN titrated_VBN to_TO a_DT stable_JJ dosage_NN on_IN one_CD of_IN the_DT agents_NNS in_IN this_DT category_NN ,_, and_CC then_RB begins_VBZ a_DT course_NN of_IN the_DT treatment_NN with_IN EQUETROTM_NN ,_, it_PRP is_VBZ reasonable_JJ to_TO expect_VB that_IN a_DT dose_NN decrease_NN for_IN the_DT concomitant_JJ agent_NN may_MD be_VB necessary_JJ ._. Pharmacological/Pharmacodynamic_JJ Interactions_NNS with_IN Carbamazepine_NNP Concomitant_JJ administration_NN of_IN carbamazepine_NN and_CC lithium_NN may_MD increase_VB the_DT risk_NN of_IN neurotoxic_JJ side_JJ effects_NNS ._. Given_VBN the_DT anticonvulsant_JJ properties_NNS of_IN carbamazepine_NN ,_, EQUETROTM_NN may_MD reduce_VB the_DT thyroid_NN function_NN as_IN has_VBZ been_VBN reported_VBN with_IN other_JJ anticonvulsants_NNS ._. Additionally_RB ,_, anti-malarial_JJ drugs_NNS ,_, such_JJ as_IN chloroquine_NN and_CC mefloquine_NN ,_, may_MD antagonize_VB the_DT activity_NN of_IN carbamazepine_NN ._. Thus_RB if_IN a_DT patient_NN has_VBZ been_VBN titrated_VBN to_TO a_DT stable_JJ dosage_NN on_IN one_CD of_IN the_DT agents_NNS in_IN this_DT category_NN ,_, and_CC then_RB begins_VBZ a_DT course_NN of_IN treatment_NN with_IN EQUETROTM_NN ,_, it_PRP is_VBZ reasonable_JJ to_TO expect_VB that_IN a_DT dose_NN adjustment_NN may_MD be_VB necessary_JJ ._. Because_IN of_IN its_PRP$ primary_JJ CNS_NN effect_NN ,_, caution_NN should_MD be_VB used_VBN when_WRB EQUETROTM_NNP is_VBZ taken_VBN with_IN other_JJ centrally_RB acting_VBG drugs_NNS and_CC alcohol_NN ._. Geocillin_NN -LRB-_-LRB- carbenicillin_NN indanyl_NN sodium_NN -RRB-_-RRB- blood_NN levels_NNS may_MD be_VB increased_VBN and_CC prolonged_VBN by_IN concurrent_JJ administration_NN of_IN probenecid_NN ._. Caution_NN should_MD be_VB exercised_VBN when_WRB the_DT following_VBG drugs_NNS are_VBP administered_VBN concomitantly_RB with_IN LODOSYN_NN -LRB-_-LRB- Carbidopa_NN -RRB-_-RRB- given_VBN with_IN levodopa_NN or_CC carbidopa-levodopa_NN combination_NN products_NNS ._. For_IN patients_NNS receiving_VBG monoamine_NN oxidase_NN inhibitors_NNS ,_, see_VBP CONTRAINDICATIONS_NNS ._. Dopamine_NN D2_NN receptor_NN antagonists_NNS -LRB-_-LRB- e.g._FW ,_, phenothiazines_NNS ,_, butyrophenones_NNS ,_, risperidone_NN -RRB-_-RRB- and_CC isoniazid_NN may_MD reduce_VB the_DT therapeutic_JJ effects_NNS of_IN levodopa_NN ._. In_IN addition_NN ,_, the_DT beneficial_JJ effects_NNS of_IN levodopa_NN in_IN Parkinsons_NNPS disease_NN have_VBP been_VBN reported_VBN to_TO be_VB reversed_VBN by_IN phenytoin_NN and_CC papaverine_NN ._. Patients_NNS taking_VBG these_DT drugs_NNS with_IN LODOSYN_NN and_CC levodopa_NN or_CC carbidopa-levodopa_NN combination_NN products_NNS should_MD be_VB carefully_RB observed_VBN for_IN loss_NN of_IN therapeutic_JJ response_NN ._. Iron_NNP salts_NNS may_MD reduce_VB the_DT bioavailability_NN of_IN carbidopa_NN and_CC levodopa_NN ._. The_DT clinical_JJ relevance_NN is_VBZ unclear_JJ ._. Although_IN metoclopramide_NN may_MD increase_VB the_DT bioavailability_NN of_IN levodopa_NN by_IN increasing_VBG gastric_JJ emptying_NN ,_, metoclopramide_NN may_MD also_RB adversely_RB affect_VB disease_NN control_NN by_IN its_PRP$ dopamine_NN receptor_NN antagonistic_JJ properties_NNS ._. Iodine_NN or_CC iodine_NN excess_NN may_MD decrease_VB the_DT effect_NN of_IN Carbimazole_NNP ,_, and_CC an_DT iodine_NN deficiency_NN can_MD increase_VB the_DT effect_NN of_IN Carbimazole_NN ._. Serum_NN concentration_NN of_IN digoxin_NN and_CC digitoxin_NN may_MD increase_VB when_WRB patients_NNS take_VBP antithyroid_JJ agents_NNS ._. A_DT decrease_NN of_IN the_DT dosage_NN may_MD be_VB necessary_JJ when_WRB patient_NN becomes_VBZ euthyroid_JJ ._. Antithyroid_JJ agents_NNS may_MD decrease_VB thyroidal_JJ uptake_NN of_IN sodium_NN iodide_NN I131_NN ,_, a_DT rebound_NN in_IN uptake_NN may_MD occur_VB up_RP to_TO 5_CD days_NNS after_IN sudden_JJ withdrawal_NN of_IN Carbimazole_NN ._. Patients_NNS response_NN to_TO oral_JJ anticoagulants_NNS may_MD be_VB affected_VBN by_IN his/her_NN thyroid_NN and_CC metabolic_JJ status_NN ._. An_DT evaluation_NN of_IN prothrombin_NN time_NN and_CC an_DT adjustment_NN of_IN anticoagulant_JJ dosage_NN are_VBP recommende_NN ._. Antihistamines_NNS may_MD enhance_VB the_DT effects_NNS of_IN tricyclic_JJ antidepressants_NNS ,_, barbiturates_NNS ,_, alcohol_NN ,_, and_CC other_JJ CNS_NN depressants_NNS ._. MAO_NN inhibitors_NNS prolong_VB and_CC intensify_VB the_DT anticholinergic_JJ effects_NNS of_IN antihistamines_NNS ._. Sympathomimetic_JJ amines_NNS may_MD reduce_VB the_DT antihypertensive_JJ effects_NNS of_IN reserpine_NN ,_, veratrum_NN alkaloids_NNS ,_, methyldopa_NN and_CC mecamylamine_NN ._. Effects_NNS of_IN sympathomimetics_NNS are_VBP increased_VBN with_IN MAO_NN inhibitors_NNS and_CC beta_NN adrenergic_JJ blockers_NNS ._. The_DT renal_JJ effects_NNS of_IN nephrotoxic_JJ compounds_NNS may_MD be_VB potentiated_VBN by_IN Carboplatin_NNP ._. HEMABATE_NN may_MD augment_VB the_DT activity_NN of_IN other_JJ oxytocic_JJ agents_NNS ._. Concomitant_JJ use_NN with_IN other_JJ oxytocic_JJ agents_NNS is_VBZ not_RB recommende_NN ._. Ocupress_NN should_MD be_VB used_VBN with_IN caution_NN in_IN patients_NNS who_WP are_VBP receiving_VBG a_DT beta-adrenergic_JJ blocking_VBG agent_NN orally_RB because_IN of_IN the_DT potential_NN for_IN additive_JJ effects_NNS on_IN systemic_JJ beta-blockade_NN ._. Close_JJ observation_NN of_IN the_DT patient_NN is_VBZ recommended_VBN when_WRB a_DT beta-blocker_NN is_VBZ administered_VBN to_TO patients_NNS receiving_VBG catecholamine-depleting_JJ drugs_NNS such_JJ as_IN reserpine_NN ,_, because_IN of_IN possible_JJ additive_JJ effects_NNS and_CC the_DT production_NN of_IN hypotension_NN and/or_CC marked_JJ bradycardia_NN ,_, which_WDT may_MD produce_VB vertigo_NN ,_, syncope_NN ,_, or_CC postural_JJ hypotension_NN ._. Inhibitors_NNS of_IN CYP2D6_NN ;_: ._. poor_JJ metabolizers_NNS of_IN debrisoquin_NN :_: Interactions_NNS of_IN carvedilol_NN with_IN strong_JJ inhibitors_NNS of_IN CYP2D6_NN -LRB-_-LRB- such_JJ as_IN quinidine_NN ,_, fluoxetine_NN ,_, paroxetine_NN ,_, and_CC propafenone_NN -RRB-_-RRB- have_VBP not_RB been_VBN studied_VBN ,_, but_CC these_DT drugs_NNS would_MD be_VB expected_VBN to_TO increase_VB blood_NN levels_NNS of_IN the_DT R_NN -LRB-_-LRB- +_CC -RRB-_-RRB- enantiomer_NN of_IN carvedilol_NN ._. Retrospective_JJ analysis_NN of_IN side_JJ effects_NNS in_IN clinical_JJ trials_NNS showed_VBD that_IN poor_JJ 2D6_NN metabolizers_NNS had_VBD a_DT higher_JJR rate_NN of_IN dizziness_NN during_IN up-titration_NN ,_, presumably_RB resulting_VBG from_IN vasodilating_VBG effects_NNS of_IN the_DT higher_JJR concentrations_NNS of_IN the_DT a-blocking_NN R_NN -LRB-_-LRB- +_CC -RRB-_-RRB- enantiomer_NN ._. Catecholamine-depleting_JJ Agents_NNS :_: Patients_NNS taking_VBG both_CC agents_NNS with_IN b-blocking_NN properties_NNS and_CC a_DT drug_NN that_WDT can_MD deplete_VB catecholamines_NNS -LRB-_-LRB- e.g._FW ,_, reserpine_NN and_CC monoamine_NN oxidase_NN inhibitors_NNS -RRB-_-RRB- should_MD be_VB observed_VBN closely_RB for_IN signs_NNS of_IN hypotension_NN and/or_CC severe_JJ bradycardia_NN ._. Clonidine_NNP :_: Concomitant_JJ administration_NN of_IN clonidine_NN with_IN agents_NNS with_IN b-blocking_NN properties_NNS may_MD potentiate_VB blood-pressure_NN -_: and_CC heart-rate-lowering_JJ effects_NNS ._. When_WRB concomitant_JJ treatment_NN with_IN agents_NNS with_IN b-blocking_NN properties_NNS and_CC clonidine_NN is_VBZ to_TO be_VB terminated_VBN ,_, the_DT b-blocking_JJ agent_NN should_MD be_VB discontinued_VBN first_RB ._. Clonidine_NN therapy_NN can_MD then_RB be_VB discontinued_VBN several_JJ days_NNS later_RB by_IN gradually_RB decreasing_VBG the_DT dosage_NN ._. Cyclosporine_NN :_: Modest_JJ increases_NNS in_IN mean_JJ trough_NN cyclosporine_NN concentrations_NNS were_VBD observed_VBN following_VBG initiation_NN of_IN carvedilol_NN treatment_NN in_IN 21_CD renal_JJ transplant_NN patients_NNS suffering_VBG from_IN chronic_JJ vascular_JJ rejection_NN ._. In_IN about_RB 30_CD %_NN of_IN patients_NNS ,_, the_DT dose_NN of_IN cyclosporine_NN had_VBD to_TO be_VB reduced_VBN in_IN order_NN to_TO maintain_VB cyclosporine_NN concentrations_NNS within_IN the_DT therapeutic_JJ range_NN ,_, while_IN in_IN the_DT remainder_NN no_DT adjustment_NN was_VBD needed_VBN ._. On_IN the_DT average_NN for_IN the_DT group_NN ,_, the_DT dose_NN of_IN cyclosporine_NN was_VBD reduced_VBN about_IN 20_CD %_NN in_IN these_DT patients_NNS ._. Due_JJ to_TO wide_JJ interindividual_JJ variability_NN in_IN the_DT dose_NN adjustment_NN required_VBN ,_, it_PRP is_VBZ recommended_VBN that_IN cyclosporine_NN concentrations_NNS be_VB monitored_VBN closely_RB after_IN initiation_NN of_IN carvedilol_NN therapy_NN and_CC that_IN the_DT dose_NN of_IN cyclosporine_NN be_VB adjusted_VBN as_IN appropriate_JJ ._. Digoxin_NNP :_: Digoxin_NN concentrations_NNS are_VBP increased_VBN by_IN about_RB 15_CD %_NN when_WRB digoxin_NN and_CC carvedilol_NN are_VBP administered_VBN concomitantly_RB ._. Both_DT digoxin_NN and_CC COREG_NNP slow_JJ AV_NN conduction_NN ._. Therefore_RB ,_, increased_VBD monitoring_NN of_IN digoxin_NN is_VBZ recommended_VBN when_WRB initiating_VBG ,_, adjusting_VBG ,_, or_CC discontinuing_VBG COREG_NNP ._. Inducers_NNS and_CC Inhibitors_NNS of_IN Hepatic_JJ Metabolism_NN :_: Rifampin_NNP reduced_VBD plasma_NN concentrations_NNS of_IN carvedilol_NN by_IN about_RB 70_CD %_NN ._. Cimetidine_NN increased_VBD AUC_NN by_IN about_IN 30_CD %_NN but_CC caused_VBD no_DT change_NN in_IN Cmax_NNP ._. Calcium_NN Channel_NNP Blockers_NNPS :_: Isolated_VBN cases_NNS of_IN conduction_NN disturbance_NN -LRB-_-LRB- rarely_RB with_IN hemodynamic_JJ compromise_NN -RRB-_-RRB- have_VBP been_VBN observed_VBN when_WRB COREG_NNP is_VBZ co-administered_VBN with_IN diltiazem_NN ._. As_IN with_IN other_JJ agents_NNS with_IN b-blocking_NN properties_NNS ,_, if_IN COREG_NNP is_VBZ to_TO be_VB administered_VBN orally_RB with_IN calcium_NN channel_NN blockers_NNS of_IN the_DT verapamil_NN or_CC diltiazem_NN type_NN ,_, it_PRP is_VBZ recommended_VBN that_IN ECG_NN and_CC blood_NN pressure_NN be_VB monitored_VBN ._. Insulin_NN or_CC Oral_JJ Hypoglycemics_NNS :_: Agents_NNS with_IN b-blocking_NN properties_NNS may_MD enhance_VB the_DT blood-sugar-reducing_JJ effect_NN of_IN insulin_NN and_CC oral_JJ hypoglycemics_NNS ._. Therefore_RB ,_, in_IN patients_NNS taking_VBG insulin_NN or_CC oral_JJ hypoglycemics_NNS ,_, regular_JJ monitoring_NN of_IN blood_NN glucose_NN is_VBZ recommended_VBN ._. Studies_NNS in_FW vitro_FW show_VBP that_IN caspofungin_NN acetate_NN is_VBZ not_RB an_DT inhibitor_NN of_IN any_DT enzyme_NN in_IN the_DT cytochrome_NN P450_NN -LRB-_-LRB- CYP_NN -RRB-_-RRB- system_NN ._. In_IN clinical_JJ studies_NNS ,_, caspofungin_NN did_VBD not_RB induce_VB the_DT CYP3A4_NN metabolism_NN of_IN other_JJ drugs_NNS ._. Caspofungin_NNP is_VBZ not_RB a_DT substrate_NN for_IN P-glycoprotein_NN and_CC is_VBZ a_DT poor_JJ substrate_NN for_IN cytochrome_NN P450_NN enzymes_NNS ._. Clinical_JJ studies_NNS in_IN healthy_JJ volunteers_NNS show_VBP that_IN the_DT pharmacokinetics_NNS of_IN CANCIDAS_NNP are_VBP not_RB altered_VBN by_IN itraconazole_NN ,_, amphotericin_NN B_NN ,_, mycophenolate_NN ,_, nelfinavir_NN ,_, or_CC tacrolimus_NN ._. CANCIDAS_NNP has_VBZ no_DT effect_NN on_IN the_DT pharmacokinetics_NNS of_IN itraconazole_NN ,_, amphotericin_NN B_NN ,_, or_CC the_DT active_JJ metabolite_NN of_IN mycophenolate_NN ._. CANCIDAS_NNP reduced_VBD the_DT blood_NN AUC0-12_NN of_IN tacrolimus_NN by_IN approximately_RB 20_CD %_NN ,_, peak_JJ blood_NN concentration_NN -LRB-_-LRB- Cmax_NN -RRB-_-RRB- by_IN 16_CD %_NN ,_, and_CC 12-hour_JJ blood_NN concentration_NN -LRB-_-LRB- C12hr_NN -RRB-_-RRB- by_IN 26_CD %_NN in_IN healthy_JJ subjects_NNS when_WRB tacrolimus_NN -LRB-_-LRB- 2_CD doses_NNS of_IN 0.1_CD mg/kg_NN 12_CD hours_NNS apart_RB -RRB-_-RRB- was_VBD administered_VBN on_IN the_DT 10th_JJ day_NN of_IN CANCIDAS_NNP 70_CD mg_NN daily_RB ,_, as_IN compared_VBN to_TO results_NNS from_IN a_DT control_NN period_NN in_IN which_WDT tacrolimus_NN was_VBD administered_VBN alone_RB ._. For_IN patients_NNS receiving_VBG both_CC therapies_NNS ,_, standard_JJ monitoring_NN of_IN tacrolimus_NN blood_NN concentrations_NNS and_CC appropriate_JJ tacrolimus_NN dosage_NN adjustments_NNS are_VBP recommended_VBN ._. In_IN two_CD clinical_JJ studies_NNS ,_, cyclosporine_NN -LRB-_-LRB- one_CD 4_CD mg/kg_NN dose_NN or_CC two_CD 3_CD mg/kg_NN doses_NNS -RRB-_-RRB- increased_VBD the_DT AUC_NN of_IN caspofungin_NN by_IN approximately_RB 35_CD %_NN ._. CANCIDAS_NNP did_VBD not_RB increase_VB the_DT plasma_NN levels_NNS of_IN cyclosporine_NN ._. There_EX were_VBD transient_JJ increases_NNS in_IN liver_NN ALT_NN and_CC AST_NNP when_WRB CANCIDAS_NNP and_CC cyclosporine_NN were_VBD co-administered_VBN ._. A_DT drug-drug_JJ interaction_NN study_NN with_IN rifampin_NN in_IN healthy_JJ volunteers_NNS has_VBZ shown_VBN a_DT 30_CD %_NN decrease_NN in_IN caspofungin_NN trough_NN concentrations_NNS ._. Patients_NNS on_IN rifampin_NN should_MD receive_VB 70_CD mg_NN of_IN CANCIDAS_NNP daily_RB ._. In_IN addition_NN ,_, results_VBZ from_IN regression_NN analyses_NNS of_IN patient_NN pharmacokinetic_JJ data_NNS suggest_VBP that_IN co-administration_NN of_IN other_JJ inducers_NNS of_IN drug_NN clearance_NN -LRB-_-LRB- efavirenz_NN ,_, nevirapine_NN ,_, phenytoin_NN ,_, dexamethasone_NN ,_, or_CC carbamazepine_NN -RRB-_-RRB- with_IN CANCIDAS_NNS may_MD result_VB in_IN clinically_RB meaningful_JJ reductions_NNS in_IN caspofungin_NN concentrations_NNS ._. It_PRP is_VBZ not_RB known_VBN which_WDT drug_NN clearance_NN mechanism_NN involved_VBN in_IN caspofungin_NN disposition_NN may_MD be_VB inducible_JJ ._. When_WRB CANCIDAS_NNP is_VBZ co-administered_VBN with_IN inducers_NNS of_IN drug_NN clearance_NN ,_, such_JJ as_IN efavirenz_NN ,_, nevirapine_NN ,_, phenytoin_NN ,_, dexamethasone_NN ,_, or_CC carbamazepine_NN ,_, use_NN of_IN a_DT daily_JJ dose_NN of_IN 70_CD mg_NN of_IN CANCIDAS_NNP should_MD be_VB considere_NN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS Positive_JJ direct_JJ Coombs_NNP tests_NNS have_VBP been_VBN reported_VBN during_IN treatment_NN with_IN the_DT cephalosporin_NN antibiotics_NNS ._. In_IN hematologic_JJ studies_NNS or_CC in_IN transfusion_NN cross-matching_NN procedures_NNS when_WRB anti-globulin_JJ tests_NNS are_VBP performed_VBN on_IN the_DT minor_JJ side_NN or_CC in_IN Coombs_NNP testing_NN of_IN newborns_NNS whose_WP$ mothers_NNS have_VBP received_VBN cephalosporin_NN antibiotics_NNS before_IN parturition_NN ,_, it_PRP should_MD be_VB recognized_VBN that_IN a_DT positive_JJ Coombs_NNP test_NN may_MD be_VB due_JJ to_TO the_DT drug_NN ._. Probenecid_NNP may_MD decrease_VB renal_JJ tubular_JJ secretion_NN of_IN cephalosporins_NNS when_WRB used_VBN concurrently_RB ,_, resulting_VBG in_IN increased_VBN and_CC more_RBR prolonged_JJ cephalosporin_NN blood_NN levels_NNS ._. Drug/Laboratory_JJ Test_NN Interactions_NNS A_DT false_JJ positive_JJ reaction_NN for_IN glucose_NN in_IN the_DT urine_NN may_MD occur_VB with_IN Benedicts_NNS solution_NN ,_, Fehlings_NNP solution_NN or_CC with_IN CLINITEST_NN tablets_NNS ,_, but_CC not_RB with_IN enzyme-based_JJ tests_NNS such_JJ as_IN CLINISTIX_NN ._. Positive_JJ direct_JJ and_CC indirect_JJ antiglobulin_NN -LRB-_-LRB- Coombs_NNS -RRB-_-RRB- tests_NNS have_VBP occurred_VBN ;_: ._. these_DT may_MD also_RB occur_VB in_IN neonates_NNS whose_WP$ mothers_NNS received_VBD cephalosporins_NNS before_IN delivery_NN ._. Antacids_NNS -LRB-_-LRB- aluminum_NN -_: or_CC magnesium-containing_JJ -RRB-_-RRB- :_: Concomitant_JJ administration_NN of_IN 300-mg_JJ cefdinir_NN capsules_NNS with_IN 30_CD mL_NN Maalox_NNP TC_NNP suspension_NN reduces_VBZ the_DT rate_NN -LRB-_-LRB- Cmax_NN -RRB-_-RRB- and_CC extent_NN -LRB-_-LRB- AUC_NN -RRB-_-RRB- of_IN absorption_NN by_IN approximately_RB 40_CD %_NN ._. Time_NNP to_TO reach_VB Cmax_NNP is_VBZ also_RB prolonged_VBN by_IN 1_CD hour_NN ._. There_EX are_VBP no_DT significant_JJ effects_NNS on_IN cefdinir_NN pharmacokinetics_NNS if_IN the_DT antacid_NN is_VBZ administered_VBN 2_CD hours_NNS before_IN or_CC 2_CD hours_NNS after_IN cefdinir_NN ._. If_IN antacids_NNS are_VBP required_VBN during_IN OMNICEF_NN therapy_NN ,_, OMNICEF_NN should_MD be_VB taken_VBN at_IN least_JJS 2_CD hours_NNS before_IN or_CC after_IN the_DT antacid_NN ._. Probenecid_NNP :_: As_IN with_IN other_JJ b-lactam_NN antibiotics_NNS ,_, probenecid_NN inhibits_VBZ the_DT renal_JJ excretion_NN of_IN cefdinir_NN ,_, resulting_VBG in_IN an_DT approximate_JJ doubling_NN in_IN A.C._NNP a_DT 54_CD %_NN increase_NN in_IN peak_JJ cefdinir_NN plasma_NN levels_NNS ,_, and_CC a_DT 50_CD %_NN prolongation_NN in_IN the_DT apparent_JJ elimination_NN half-life_NN ._. Iron_NNP Supplements_NNP and_CC Foods_NNP Fortified_VBD With_IN Iron_NNP Concomitant_JJ administration_NN of_IN cefdinir_NN with_IN a_DT therapeutic_JJ iron_NN supplement_NN containing_VBG 60_CD mg_NN of_IN elemental_JJ iron_NN -LRB-_-LRB- as_IN FeSO4_NN -RRB-_-RRB- or_CC vitamins_NNS supplemented_VBN with_IN 10_CD mg_NN of_IN elemental_JJ iron_NN reduced_VBD extent_NN of_IN absorption_NN by_IN 80_CD %_NN and_CC 31_CD %_NN ,_, respectively_RB ._. If_IN iron_NN supplements_NNS are_VBP required_VBN during_IN OMNICEF_NN therapy_NN ,_, OMNICEF_NN should_MD be_VB taken_VBN at_IN least_JJS 2_CD hours_NNS before_IN or_CC after_IN the_DT supplement_NN ._. The_DT effect_NN of_IN foods_NNS highly_RB fortified_VBD with_IN elemental_JJ iron_NN -LRB-_-LRB- primarily_RB iron-fortified_JJ breakfast_NN cereals_NNS -RRB-_-RRB- on_IN cefdinir_NN absorption_NN has_VBZ not_RB been_VBN studied_VBN ._. Concomitantly_RB administered_VBN iron-fortified_JJ infant_NN formula_NN -LRB-_-LRB- 2.2_CD mg_NN elemental_JJ iron/6_NN oz_NN -RRB-_-RRB- has_VBZ no_DT significant_JJ effect_NN on_IN cefdinir_NN pharmacokinetics_NNS ._. Therefore_RB ,_, OMNICEF_NN for_IN Oral_NNP Suspension_NNP can_MD be_VB administered_VBN with_IN iron-fortified_JJ infant_NN formula_NN ._. There_EX have_VBP been_VBN rare_JJ reports_NNS of_IN reddish_JJ stools_NNS in_IN patients_NNS who_WP have_VBP received_VBN cefdinir_NN in_IN Japan_NNP ._. The_DT reddish_JJ color_NN is_VBZ due_JJ to_TO the_DT formation_NN of_IN a_DT nonabsorbable_JJ complex_NN between_IN cefdinir_NN or_CC its_PRP$ breakdown_NN products_NNS and_CC iron_NN in_IN the_DT gastrointestinal_JJ tract_NN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS A_DT false-positive_JJ reaction_NN for_IN ketones_NNS in_IN the_DT urine_NN may_MD occur_VB with_IN tests_NNS using_VBG nitroprusside_NN ,_, but_CC not_RB with_IN those_DT using_VBG nitroferricyanide_NN ._. The_DT administration_NN of_IN cefdinir_NN may_MD result_VB in_IN a_DT false-positive_JJ reaction_NN for_IN glucose_NN in_IN urine_NN using_VBG Clinitest_NNP ,_, Benedict_NNP s_VBZ solution_NN ,_, or_CC Fehlings_NNP solution_NN ._. It_PRP is_VBZ recommended_VBN that_IN glucose_NN tests_NNS based_VBN on_IN enzymatic_JJ glucose_NN oxidase_NN reactions_NNS -LRB-_-LRB- such_JJ as_IN Clinistix_NNP or_CC Tes-Tape_NNP -RRB-_-RRB- be_VB used_VBN ._. Cephalosporins_NNS are_VBP known_VBN to_TO occasionally_RB induce_VB a_DT positive_JJ direct_JJ Coombs_NNS test_NN ._. Oral_JJ Contraceptives_NNS Multiple_JJ doses_NNS of_IN cefditoren_NN pivoxil_NN had_VBD no_DT effect_NN on_IN the_DT pharmacokinetics_NNS of_IN ethinyl_NN estradiol_NN ,_, the_DT estrogenic_JJ component_NN in_IN most_JJS oral_JJ contraceptives_NNS ._. Although_IN the_DT clinical_JJ significance_NN is_VBZ not_RB known_VBN ,_, it_PRP is_VBZ not_RB recommended_VBN that_IN cefditoren_NN pivoxil_NN be_VB taken_VBN concomitantly_RB with_IN antacids_NNS ._. H2-Receptor_NN Antagonists_NNS :_: Co-administration_NN of_IN a_DT single_JJ dose_NN of_IN intravenously_RB administered_VBN famotidine_NN -LRB-_-LRB- 20_CD mg_NN -RRB-_-RRB- reduced_VBD the_DT oral_JJ absorption_NN of_IN a_DT single_JJ 400_CD mg_NN dose_NN of_IN cefditoren_NN pivoxil_NN administered_VBN following_VBG a_DT meal_NN ,_, as_IN evidenced_VBN by_IN a_DT 27_CD %_NN decrease_NN in_IN mean_JJ Cmax_NN and_CC a_DT 22_CD %_NN decrease_NN in_IN mean_JJ AUC_NN ._. Although_IN the_DT clinical_JJ significance_NN is_VBZ not_RB known_VBN ,_, it_PRP is_VBZ not_RB recommended_VBN that_IN cefditoren_NN pivoxil_NN be_VB taken_VBN concomitantly_RB with_IN H2_NN receptor_NN antagonists_NNS ._. Probenecid_NNP :_: As_IN with_IN other_JJ b-lactam_NN antibiotics_NNS ,_, co-administration_NN of_IN probenecid_NN with_IN cefditoren_NN pivoxil_NN resulted_VBD in_IN an_DT increase_NN in_IN the_DT plasma_NN exposure_NN of_IN cefditoren_NNS ,_, with_IN a_DT 49_CD %_NN increase_NN in_IN mean_NN Cmax_NN ,_, a_DT 122_CD %_NN increase_NN in_IN mean_JJ AUC_NN ,_, and_CC a_DT 53_CD %_NN increase_NN in_IN half-life_NN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS Cephalosporins_NNS are_VBP known_VBN to_TO occasionally_RB induce_VB a_DT positive_JJ direct_JJ Coombs_NNS test_NN ._. A_DT false-positive_JJ reaction_NN for_IN glucose_NN in_IN the_DT urine_NN may_MD occur_VB with_IN copper_NN reduction_NN tests_NNS -LRB-_-LRB- Benedicts_NNS or_CC Fehlings_NNS solution_NN or_CC with_IN CLINITEST_NN tablets_NNS -RRB-_-RRB- ,_, but_CC not_RB with_IN enzyme-based_JJ tests_NNS for_IN glycosuria_NN -LRB-_-LRB- e.g._FW ,_, CLINISTIX_NN ,_, TES-TAPE_NN -RRB-_-RRB- ._. As_IN a_DT false-negative_JJ result_NN may_MD occur_VB in_IN the_DT ferricyanide_JJ test_NN ,_, it_PRP is_VBZ recommended_VBN that_IN either_CC the_DT glucose_NN oxidase_NN or_CC hexokinase_NN method_NN be_VB used_VBN to_TO determine_VB blood/plasma_NN glucose_NN levels_NNS in_IN patients_NNS receiving_VBG cefditoren_NN pivoxil_NN ._. Renal_JJ function_NN should_MD be_VB monitored_VBN carefully_RB if_IN high_JJ doses_NNS of_IN aminoglycosides_NNS are_VBP to_TO be_VB administered_VBN with_IN MAXIPIME_NN because_IN of_IN the_DT increased_VBN potential_NN of_IN nephrotoxicity_NN and_CC ototoxicity_NN of_IN aminoglycoside_NN antibiotics_NNS ._. Nephrotoxicity_NN has_VBZ been_VBN reported_VBN following_VBG concomitant_JJ administration_NN of_IN other_JJ cephalosporins_NNS with_IN potent_JJ diuretics_NNS such_JJ as_IN furosemide_NN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS The_DT administration_NN of_IN cefepime_NN may_MD result_VB in_IN a_DT false-positive_JJ reaction_NN for_IN glucose_NN in_IN the_DT urine_NN when_WRB using_VBG Clinitest_NNP tablets_NNS ._. It_PRP is_VBZ recommended_VBN that_IN glucose_NN tests_NNS based_VBN on_IN enzymatic_JJ glucose_NN oxidase_NN reactions_NNS -LRB-_-LRB- such_JJ as_IN Clinistix_NNP or_CC Tes-Tape_NNP -RRB-_-RRB- be_VB used_VBN ._. Carbamazepine_NNP :_: Elevated_JJ carbamazepine_NN levels_NNS have_VBP been_VBN reported_VBN in_IN postmarketing_VBG experience_NN when_WRB SUPRAX_NNP is_VBZ administered_VBN concomitantly_RB ._. Drug_NN monitoring_NN may_MD be_VB of_IN assistance_NN in_IN detecting_VBG alterations_NNS in_IN carbamazepine_NN plasma_NN concentrations_NNS ._. Warfarin_NNP and_CC Anticoagulants_NNPS :_: Increased_VBN prothrombin_NN time_NN ,_, with_IN or_CC without_IN clinical_JJ bleeding_NN ,_, has_VBZ been_VBN reported_VBN when_WRB cefixime_NN is_VBZ administered_VBN concomitantly_RB ._. Drug/Laboratory_JJ Test_NN Interactions_NNS A_DT false-positive_JJ reaction_NN for_IN ketones_NNS in_IN the_DT urine_NN may_MD occur_VB with_IN tests_NNS using_VBG nitroprusside_NN but_CC not_RB with_IN those_DT using_VBG nitroferricyanide_NN ._. The_DT administration_NN of_IN SUPRAX_NNP may_MD result_VB in_IN a_DT false-positive_JJ reaction_NN for_IN glucose_NN in_IN the_DT urine_NN using_VBG Clinitest_NNP **_SYM ,_, Benedict_NNP s_VBZ solution_NN ,_, or_CC Fehling_NN s_NNS solution_NN ._. It_PRP is_VBZ recommended_VBN that_IN glucose_NN tests_NNS based_VBN on_IN enzymatic_JJ glucose_NN oxidase_NN reactions_NNS -LRB-_-LRB- such_JJ as_IN Clinistix_NNP **_SYM or_CC Tes-Tape_JJ **_SYM -RRB-_-RRB- be_VB used_VBN ._. A_DT false-positive_JJ direct_JJ Coombs_NNS test_NN has_VBZ been_VBN reported_VBN during_IN treatment_NN with_IN other_JJ cephalosporin_NN antibiotics_NNS ._. therefore_RB ,_, it_PRP should_MD be_VB recognized_VBN that_IN a_DT positive_JJ Coombs_NNP test_NN may_MD be_VB due_JJ to_TO the_DT drug_NN ._. Increased_VBN nephrotoxicity_NN has_VBZ been_VBN reported_VBN following_VBG concomitant_JJ administration_NN of_IN cephalosporins_NNS and_CC aminoglycoside_NN antibiotics_NNS ._. Drug/Laboratory_JJ Test_NN Interactions_NNS Cephalosporins_NNS ,_, including_VBG cefotaxime_NN sodium_NN ,_, are_VBP known_VBN to_TO occasionally_RB induce_VB a_DT positive_JJ direct_JJ Coombs_NNS test_NN ._. Increases_NNS in_IN serum_NN creatinine_NN have_VBP occurred_VBN when_WRB CEFOTAN_NNP was_VBD given_VBN alone_RB ._. If_IN CEFOTAN_NNP and_CC an_DT aminoglycoside_NN are_VBP used_VBN concomitantly_RB ,_, renal_JJ function_NN should_MD be_VB carefully_RB monitored_VBN ,_, because_IN nephrotoxicity_NN may_MD be_VB potentiated_VBN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS :_: The_DT administration_NN of_IN CEFOTAN_NNP may_MD result_VB in_IN a_DT false_JJ positive_JJ reaction_NN for_IN glucose_NN in_IN the_DT urine_NN using_VBG Clinitest_NNP ,_, Benedicts_NNP solution_NN ,_, or_CC Fehlings_NNP solution_NN ._. It_PRP is_VBZ recommended_VBN that_IN glucose_NN tests_NNS based_VBN on_IN enzymatic_JJ glucose_NN oxidase_NN be_VB used_VBN ._. As_IN with_IN other_JJ cephalosporins_NNS ,_, high_JJ concentrations_NNS of_IN cefotetan_NN may_MD interfere_VB with_IN measurement_NN of_IN serum_NN and_CC urine_NN creatinine_NN levels_NNS by_IN Jaffe_NNP reaction_NN and_CC produce_VBP false_JJ increases_NNS in_IN the_DT levels_NNS of_IN creatinine_NN reported_VBD ._. Increased_VBN nephrotoxicity_NN has_VBZ been_VBN reported_VBN following_VBG concomitant_JJ administration_NN of_IN cephalosporins_NNS and_CC aminoglycoside_NN antibiotics_NNS ._. Drug/Laboratory_JJ Test_NN Interactions_NNS As_IN with_IN cephalothin_NN ,_, high_JJ concentrations_NNS of_IN cefoxitin_NN -LRB-_-LRB- 100_CD micrograms/mL_NNS -RRB-_-RRB- may_MD interfere_VB with_IN measurement_NN of_IN serum_NN and_CC urine_NN creatinine_NN levels_NNS by_IN the_DT Jaff_NNP reaction_NN ,_, and_CC produce_VBP false_JJ increases_NNS of_IN modest_JJ degree_NN in_IN the_DT levels_NNS of_IN creatinine_NN reported_VBD ._. Serum_NN samples_NNS from_IN patients_NNS treated_VBN with_IN cefoxitin_NN should_MD not_RB be_VB analyzed_VBN for_IN creatinine_NN if_IN withdrawn_VBN within_IN 2_CD hours_NNS of_IN drug_NN administration_NN ._. High_JJ concentrations_NNS of_IN cefoxitin_NN in_IN the_DT urine_NN may_MD interfere_VB with_IN measurement_NN of_IN urinary_JJ 17-hydroxy-corticosteroids_NNS by_IN the_DT Porter-Silber_NNP reaction_NN ,_, and_CC produce_VBP false_JJ increases_NNS of_IN modest_JJ degree_NN in_IN the_DT levels_NNS reported_VBD ._. A_DT false-positive_JJ reaction_NN for_IN glucose_NN in_IN the_DT urine_NN may_MD occur_VB ._. This_DT has_VBZ been_VBN observed_VBN with_IN CLINITEST_NN reagent_NN tablets_NNS ._. Registered_NNP trademark_NN of_IN Ames_NNP Company_NNP ,_, Division_NNP of_IN Miles_NNP Laboratories_NNPS ,_, Inc._NNP ._. Nephrotoxicity_NN has_VBZ been_VBN reported_VBN following_VBG concomitant_JJ administration_NN of_IN aminoglycoside_NN antibiotics_NNS and_CC cephalosporin_NN antibiotics_NNS ._. Concomitant_JJ administration_NN of_IN probenecid_NN doubled_VBD the_DT AUC_NN for_IN cefprozil_NN ._. The_DT bioavailability_NN of_IN the_DT capsule_NN formulation_NN of_IN cefprozil_NN was_VBD not_RB affected_VBN when_WRB administered_VBN 5_CD minutes_NNS following_VBG an_DT antacid_NN ._. Nephrotoxicity_NN has_VBZ been_VBN reported_VBN following_VBG concomitant_JJ administration_NN of_IN cephalosporins_NNS with_IN aminoglycoside_NN antibiotics_NNS or_CC potent_JJ diuretics_NNS such_JJ as_IN furosemide_NN ._. Renal_JJ function_NN should_MD be_VB carefully_RB monitored_VBN ,_, especially_RB if_IN higher_JJR dosages_NNS of_IN the_DT aminoglycosides_NNS are_VBP to_TO be_VB administered_VBN or_CC if_IN therapy_NN is_VBZ prolonged_VBN ,_, because_IN of_IN the_DT potential_JJ nephrotoxicity_NN and_CC ototoxicity_NN of_IN aminoglycosidic_JJ antibiotics_NNS ._. Nephrotoxicity_NN and_CC ototoxicity_NN were_VBD not_RB noted_VBN when_WRB ceftazidime_NN was_VBD given_VBN alone_RB in_IN clinical_JJ trials_NNS ._. Chloramphenicol_NN has_VBZ been_VBN shown_VBN to_TO be_VB antagonistic_JJ to_TO beta-lactam_JJ antibiotics_NNS ,_, including_VBG ceftazidime_NN ,_, based_VBN on_IN in_FW vitro_FW studies_NNS and_CC time_NN kill_VBP curves_NNS with_IN enteric_JJ gram-negative_JJ bacilli_NNS ._. Due_JJ to_TO the_DT possibility_NN of_IN antagonism_NN in_FW vivo_FW ,_, particularly_RB when_WRB bactericidal_JJ activity_NN is_VBZ desired_VBN ,_, this_DT drug_NN combination_NN should_MD be_VB avoided_VBN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS The_DT administration_NN of_IN ceftazidime_NN may_MD result_VB in_IN a_DT false-positive_JJ reaction_NN for_IN glucose_NN in_IN the_DT urine_NN when_WRB using_VBG CLINITEST_NN tablets_NNS ,_, Benedicts_NNP solution_NN ,_, or_CC Fehlings_NNP solution_NN ._. It_PRP is_VBZ recommended_VBN that_IN glucose_NN tests_NNS based_VBN on_IN enzymatic_JJ glucose_NN oxidase_NN reactions_NNS -LRB-_-LRB- such_JJ as_IN CLINISTIX_NN or_CC TES-TAPE_NN -RRB-_-RRB- be_VB used_VBN ._. Theophylline_NNP :_: Twelve_CD healthy_JJ male_JJ volunteers_NNS were_VBD administered_VBN one_CD 200-mg_JJ ceftibuten_NN capsule_NN twice_RB daily_RB for_IN 6_CD days_NNS ._. With_IN the_DT morning_NN dose_NN of_IN ceftibuten_NN on_IN day_NN 6_CD ,_, each_DT volunteer_NN received_VBD a_DT single_JJ intravenous_JJ infusion_NN of_IN theophylline_NN -LRB-_-LRB- 4_CD mg/kg_NN -RRB-_-RRB- ._. The_DT pharmacokinetics_NNS of_IN theophylline_NN were_VBD not_RB altered_VBN ._. The_DT effect_NN of_IN ceftibuten_NN on_IN the_DT pharmacokinetics_NNS of_IN theophylline_NN administered_VBN orally_RB has_VBZ not_RB been_VBN investigated_VBN ._. Antacids_NNS or_CC H_NN 2_CD -_: receptor_NN antagonists_NNS :_: The_DT effect_NN of_IN increased_VBN gastric_JJ pH_NN on_IN the_DT bioavailability_NN of_IN ceftibuten_NN was_VBD evaluated_VBN in_IN 18_CD healthy_JJ adult_JJ volunteers_NNS ._. Each_DT volunteer_NN was_VBD administered_VBN one_CD 400-mg_JJ ceftibuten_NN capsule_NN ._. A_DT single_JJ dose_NN of_IN liquid_JJ antacid_NN did_VBD not_RB affect_VB the_DT C_NN max_NN or_CC AUC_NN of_IN ceftibuten_NN ._. however_RB ,_, 150_CD mg_NN of_IN ranitidine_NN q12h_NN for_IN 3_CD days_NNS increased_VBD the_DT ceftibuten_NN C_NN max_NN by_IN 23_CD %_NN and_CC ceftibuten_NN AUC_NN by_IN 16_CD %_NN ._. The_DT clinical_JJ relevance_NN of_IN these_DT increases_NNS is_VBZ not_RB known_VBN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS :_: There_EX have_VBP been_VBN no_DT chemical_NN or_CC laboratory_NN test_NN interactions_NNS with_IN ceftibuten_NN noted_VBD to_TO date_NN ._. False-positive_JJ direct_JJ Coombs_NNP tests_NNS have_VBP been_VBN reported_VBN during_IN treatment_NN with_IN other_JJ cephalosporins_NNS ._. Therefore_RB ,_, it_PRP should_MD be_VB recognized_VBN that_IN a_DT positive_JJ Coombs_NNP test_NN could_MD be_VB due_JJ to_TO the_DT drug_NN ._. The_DT results_NNS of_IN assays_NNS using_VBG red_JJ cells_NNS from_IN healthy_JJ subjects_NNS to_TO determine_VB whether_IN ceftibuten_NN would_MD cause_VB direct_JJ Coombs_NNP reactions_NNS in_FW vitro_FW showed_VBD no_DT positive_JJ reaction_NN at_IN ceftibuten_NN concentrations_NNS as_IN high_JJ as_IN 40_CD g/mL_NN ._. Although_IN the_DT occurrence_NN has_VBZ not_RB been_VBN reported_VBN with_IN Cefizox_NN ,_, nephrotoxicity_NN has_VBZ been_VBN reported_VBN following_VBG concomitant_JJ administration_NN of_IN other_JJ cephalosporins_NNS and_CC aminoglycosides_NNS ._. Drug/Laboratory_JJ Test_NN Interactions_NNS :_: A_DT false-positive_JJ reaction_NN for_IN glucose_NN in_IN the_DT urine_NN may_MD occur_VB with_IN copper_NN reduction_NN tests_NNS -LRB-_-LRB- Benedict_NNP s_NNS or_CC Fehling_NN s_NNS solution_NN or_CC with_IN Clinitest_NNP tablets_NNS -RRB-_-RRB- but_CC not_RB with_IN enzyme-based_JJ tests_NNS for_IN glycosuria_NN ._. As_IN a_DT false-negative_JJ result_NN may_MD occur_VB in_IN the_DT ferricyanide_JJ test_NN ,_, it_PRP is_VBZ recommended_VBN that_IN either_CC the_DT glucose_NN oxidase_NN or_CC hexokinase_NN method_NN be_VB used_VBN to_TO determine_VB blood_NN plasma_NN glucose_NN levels_NNS in_IN patients_NNS receiving_VBG cefuroxime_NN ._. Cefuroxime_RB does_VBZ not_RB interfere_VB with_IN the_DT assay_NN of_IN serum_NN and_CC urine_NN creatinine_NN by_IN the_DT alkaline_NN picrate_NN method_NN ._. General_NNP :_: Significant_JJ interactions_NNS may_MD occur_VB when_WRB celecoxib_NN is_VBZ administered_VBN together_RB with_IN drugs_NNS that_WDT inhibit_VBP P450_NN 2C9_NN ._. Celecoxib_NNP metabolism_NN is_VBZ predominantly_RB mediated_VBN via_IN cytochrome_NN P450_NN 2C9_NN in_IN the_DT liver_NN ._. Co-administration_NN of_IN celecoxib_NN with_IN drugs_NNS that_WDT are_VBP known_VBN to_TO inhibit_VB 2C9_NN should_MD be_VB done_VBN with_IN caution_NN ._. In_FW vitro_FW studies_NNS indicate_VBP that_IN celecoxib_NN is_VBZ not_RB an_DT inhibitor_NN of_IN cytochrome_NN P450_NN 2C9_NN ,_, 2C19_NN or_CC 3A4_NN ._. In_FW vitro_FW studies_NNS also_RB indicate_VBP that_IN celecoxib_NN ,_, although_IN not_RB a_DT substrate_NN ,_, is_VBZ an_DT inhibitor_NN of_IN cytochrome_NN P450_NN 2D6_NN ._. Therefore_RB ,_, there_EX is_VBZ a_DT potential_NN for_IN an_DT in_FW vivo_FW drug_NN interaction_NN with_IN drugs_NNS that_WDT are_VBP metabolized_VBN by_IN P450_NN 2D6_NN ._. Clinical_JJ studies_NNS with_IN celecoxib_NNS have_VBP identified_VBN potentially_RB significant_JJ interactions_NNS with_IN fluconazole_NN and_CC lithium_NN ._. Experience_NN with_IN nonsteroidal_JJ anti-inflammatory_JJ drugs_NNS -LRB-_-LRB- NSAIDs_NNS -RRB-_-RRB- suggests_VBZ the_DT potential_NN for_IN interactions_NNS with_IN furosemide_NN and_CC ACE_NN inhibitors_NNS ._. The_DT effects_NNS celecoxib_VBP on_IN the_DT pharmacokinetics_NNS and/or_CC pharmacodynamics_NNS of_IN glyburide_NN ,_, ketoconazole_NN ,_, methotrexate_NN ,_, phenytoin_NN ,_, tolbutamide_NN ,_, and_CC warfarin_NN have_VBP been_VBN studied_VBN in_FW vivo_FW and_CC clinically_RB important_JJ interactions_NNS have_VBP not_RB been_VBN found_VBN ._. ACE_NN inhibitors_NNS :_: Reports_NNS suggest_VBP that_IN NSAIDs_NNS may_MD diminish_VB the_DT antihypertensive_JJ effect_NN of_IN Angiotensin_NN Converting_VBG Enzyme_NN -LRB-_-LRB- ACE_NN -RRB-_-RRB- inhibitors_NNS ._. This_DT interaction_NN should_MD be_VB given_VBN consideration_NN in_IN patients_NNS taking_VBG CELEBREX_NNP concomitantly_RB with_IN ACE-inhibitors_NNS ._. Furosemide_NNP :_: Clinical_JJ studies_NNS ,_, as_RB well_RB as_IN post_NN marketing_NN observations_NNS ,_, have_VBP shown_VBN that_IN NSAIDs_NNS can_MD reduce_VB the_DT natriuretic_JJ effect_NN of_IN furosemide_NN and_CC thiazides_NNS in_IN some_DT patients_NNS ._. This_DT response_NN has_VBZ been_VBN attributed_VBN to_TO inhibition_NN of_IN renal_JJ prostaglandin_NN synthesis_NN ._. Aspirin_NN :_: CELEBREX_NNP can_MD be_VB used_VBN with_IN low_JJ dose_NN aspirin_NN ._. However_RB ,_, concomitant_JJ administration_NN of_IN aspirin_NN with_IN CELEBREX_NNP may_MD result_VB in_IN an_DT increased_VBN rate_NN of_IN GI_NN ulceration_NN or_CC other_JJ complications_NNS ,_, compared_VBN to_TO use_VB of_IN CELEBREX_NNP alone_RB ._. Because_IN of_IN its_PRP$ lack_NN of_IN platelet_NN effects_NNS ,_, CELEBREX_NNP is_VBZ not_RB a_DT substitute_NN for_IN aspirin_NN for_IN cardiovascular_JJ prophylaxis_NN ._. Fluconazole_NNP :_: Concomitant_JJ administration_NN of_IN fluconazole_NN at_IN 200_CD mg_NN QD_NN resulted_VBD in_IN a_DT two-fold_JJ increase_NN in_IN celecoxib_NN plasma_NN concentration_NN ._. This_DT increase_NN is_VBZ due_JJ to_TO the_DT inhibition_NN of_IN celecoxib_NN metabolism_NN via_IN P450_NN 2C9_NN by_IN fluconazole_NN -LRB-_-LRB- see_VB CLINICAL_NNP PHARMACOLOGY_NNP -_: Pharmacokinetics_NNS :_: Metabolism_NN -RRB-_-RRB- ._. CELEBREX_NNP should_MD be_VB introduced_VBN at_IN the_DT lowest_JJS recommended_VBN dose_NN in_IN patients_NNS receiving_VBG fluconazole_NN ._. Lithium_NN :_: In_IN a_DT study_NN conducted_VBN in_IN healthy_JJ subjects_NNS ,_, mean_VB steady-state_JJ lithium_NN plasma_NN levels_NNS increased_VBD approximately_RB 17_CD %_NN in_IN subjects_NNS receiving_VBG lithium_NN 450_CD mg_NN BID_NNP with_IN CELEBREX_NNP 200_CD mg_NN BID_NNP as_IN compared_VBN to_TO subjects_NNS receiving_VBG lithium_NN alone_RB ._. Patients_NNS on_IN lithium_NN treatment_NN should_MD be_VB closely_RB monitored_VBN when_WRB CELEBREX_NNP is_VBZ introduced_VBN or_CC withdrawn_VBN ._. Methotrexate_NNP :_: In_IN an_DT interaction_NN study_NN of_IN rheumatoid_JJ arthritis_NN patients_NNS taking_VBG methotrexate_NN ,_, CELEBREX_NNP did_VBD not_RB have_VB a_DT significant_JJ effect_NN on_IN the_DT pharmacokinetics_NNS of_IN methotrexate_NN ._. Warfarin_NNP :_: The_DT effect_NN of_IN celecoxib_NN on_IN the_DT anti-coagulant_JJ effect_NN of_IN warfarin_NN was_VBD studied_VBN in_IN a_DT group_NN of_IN healthy_JJ subjects_NNS receiving_VBG daily_JJ doses_NNS of_IN 2-5_CD mg_NN of_IN warfarin_NN ._. In_IN these_DT subjects_NNS ,_, celecoxib_NN did_VBD not_RB alter_VB the_DT anticoagulant_JJ effect_NN of_IN warfarin_NN as_IN determined_VBN by_IN prothrombin_NN time_NN ._. However_RB ,_, caution_NN should_MD be_VB used_VBN when_WRB administering_VBG CELEBREX_NN with_IN warfarin_NN since_IN these_DT patients_NNS are_VBP at_IN increased_VBN risk_NN of_IN bleeding_VBG complications_NNS ._. Metformin_NNP :_: In_IN healthy_JJ subjects_NNS given_VBN single_JJ 500_CD mg_NN doses_NNS of_IN cephalexin_NN and_CC metformin_NN ,_, plasma_NN metformin_NN mean_VB cmax_NN and_CC AUC_NN increased_VBN by_IN an_DT average_NN of_IN 34_CD %_NN and_CC 24_CD %_NN ,_, respectively_RB ,_, and_CC metformin_NN mean_VBP renal_JJ clearance_NN decreased_VBN by_IN 14_CD %_NN ._. No_DT information_NN is_VBZ available_JJ about_IN the_DT interaction_NN of_IN cephalexin_NN and_CC metformin_NN following_VBG multiple_JJ doses_NNS of_IN either_CC drug_NN ._. Although_IN not_RB observed_VBN in_IN this_DT study_NN ,_, adverse_JJ effects_NNS could_MD potentially_RB arise_VB from_IN co-administration_NN of_IN cephalexin_NN and_CC metformin_NN by_IN inhibition_NN of_IN tubular_JJ secretion_NN via_IN organic_JJ cationic_JJ transporter_NN systems_NNS ._. Accordingly_RB ,_, careful_JJ patient_NN monitoring_NN and_CC dose_NN adjustment_NN of_IN metformin_NN is_VBZ recommended_VBN in_IN patients_NNS concomitantly_RB taking_VBG cephalexin_NN and_CC metformin_NN ._. Probenecid_NNP :_: As_IN with_IN other_JJ b-lactams_NNS ,_, the_DT renal_JJ excretion_NN of_IN cephalexin_NN is_VBZ inhibited_VBN by_IN probenecid_NN ._. Drug_NN /_: Laboratory_NNP Test_NNP Interactions_NNS As_IN a_DT result_NN of_IN administration_NN of_IN Keflex_NNP ,_, a_DT false-positive_JJ reaction_NN for_IN glucose_NN in_IN the_DT urine_NN may_MD occur_VB ._. This_DT has_VBZ been_VBN observed_VBN with_IN Benedict_NNP s_NNS and_CC Fehling_NN s_NNS solutions_NNS and_CC also_RB with_IN Clinitest_NNP tablets_NNS ._. Immunosuppressive_JJ Drugs_NNS ,_, Fibric_JJ Acid_NN Derivatives_NNS ,_, Niacin_NN -LRB-_-LRB- Nicotinic_JJ Acid_NN ,_, Erythromycin_NNP ,_, Azole_NNP Antifungals_NNPS :_: Skeletal_JJ Muscle_NN ._. ANTACID_NN -LRB-_-LRB- Magnesium-Aluminum_NNP Hydroxide_NNP -RRB-_-RRB- :_: Cerivastatin_NNP plasma_NN concentrations_NNS were_VBD not_RB affected_VBN by_IN co-administration_NN of_IN antacid_NN ._. CIMETlDINE_NNP :_: Cerivastatin_NNP plasma_NN concentrations_NNS were_VBD not_RB affected_VBN by_IN co-administration_NN of_IN cimetidine_NN ._. CHOLESTYRAMINE_NNP :_: The_DT influence_NN of_IN the_DT bile-acidsequestering_JJ agent_NN cholestyramine_NN on_IN the_DT pharmacokinetits_NNS of_IN cerivastatin_NN sodium_NN was_VBD evaluated_VBN in_IN 12_CD healthy_JJ males_NNS in_IN 2_CD separate_JJ randomized_JJ crossover_NN studies_NNS ._. In_IN the_DT first_JJ study_NN ,_, concomitant_JJ administration_NN of_IN 0.2_CD mg_NN cerivastatin_NN sodium_NN and_CC 12_CD g_NN cholestyramine_NN resulted_VBD in_IN decreases_NNS of_IN more_JJR than_IN 22_CD %_NN for_IN AUC_NN and_CC 40_CD %_NN for_IN Cmax_NNP when_WRB compared_VBN to_TO dosing_NN cerivastatin_NN sodium_NN alone_RB ._. However_RB ,_, in_IN the_DT second_JJ study_NN ,_, administration_NN of_IN 12_CD g_NN cholestyramine_NN 1_CD hour_NN before_IN the_DT evening_NN meal_NN and_CC 0.3_CD mg_NN cerivastatin_NN sodium_NN approximately_RB 4_CD hours_NNS after_IN the_DT same_JJ evening_NN meal_NN resulted_VBD in_IN a_DT decrease_NN in_IN the_DT cerivastatin_NN AUC_NN of_IN less_JJR than_IN 8_CD %_NN ,_, and_CC a_DT decrease_NN in_IN Cmax_NN of_IN about_IN 30_CD %_NN when_WRB compared_VBN to_TO dosing_NN cerivastatin_NN sodium_NN alone_RB ._. Therefore_RB ,_, it_PRP would_MD be_VB expected_VBN that_IN a_DT dosing_NN schedule_NN of_IN cerivastatin_NN sodium_NN given_VBN at_IN bedtime_NN and_CC cholestyramine_NN given_VBN before_IN the_DT evening_NN meal_NN would_MD not_RB result_VB in_IN a_DT significant_JJ decrease_NN in_IN the_DT clinical_JJ effect_NN of_IN cerivastatin_NN sodium_NN ._. DIGOXIN_NNP :_: Plasma_NN digoxin_NN levels_NNS and_CC digoxin_NN clearance_NN at_IN steady-state_JJ were_VBD not_RB affected_VBN by_IN co-administration_NN of_IN 0.2_CD mg_NN cerivastatin_NN sodium_NN ._. Cerivastatin_NNP plasma_NN concentrations_NNS were_VBD also_RB not_RB affected_VBN by_IN co-administration_NN of_IN digoxin_NN ._. WARFARIN_NNP :_: Co_NNP -_: administration_NN of_IN warfarin_NN and_CC cerivastatin_NN to_TO healthy_JJ volunteers_NNS did_VBD not_RB result_VB in_IN any_DT changes_NNS in_IN prothrombin_NN time_NN or_CC clotting_NN factor_NN VII_NN when_WRB compared_VBN to_TO co-administration_NN of_IN warfarin_NN and_CC placebo_NN ._. The_DT AUC_NN and_CC Cmax_NN of_IN both_CC the_DT -LRB-_-LRB- R_NN -RRB-_-RRB- and_CC -LRB-_-LRB- S_NN -RRB-_-RRB- isomers_NNS of_IN warfarin_NN were_VBD unaffected_JJ by_IN concurrent_JJ dosing_NN of_IN 0.3_CD mg_NN cerivastatin_NN sodium_NN ._. Co-administration_NN of_IN warfarin_NN and_CC cerivastatin_NN did_VBD not_RB alter_VB the_DT pharmacokinetics_NNS of_IN cerivastatin_NN sodium_NN ._. ERYTHROMYCIN_NNP :_: In_IN hypercholesterolemic_JJ patients_NNS ,_, steady-state_JJ cerivastatin_NN AUC_NN and_CC Cmax_NN increased_VBD approximately_RB 50_CD %_NN and_CC 24_CD %_NN respectively_RB after_IN 10_CD days_NNS with_IN co-administration_NN of_IN erythromycin_NN ,_, a_DT known_JJ inhibitor_NN of_IN cytochrome_NN P450_NN 3A4_NN ._. OTHER_JJ CONCOMITANT_JJ THERAPY_NN :_: Although_IN specific_JJ interaction_NN studies_NNS were_VBD not_RB performed_VBN ,_, in_IN clinical_JJ studies_NNS ,_, cerivastatin_NN sodium_NN was_VBD used_VBN concomitantly_RB with_IN angiotensin_NN -_: converting_VBG enzyme_NN -LRB-_-LRB- ACE_NN -RRB-_-RRB- inhibitors_NNS ,_, betablockers_NNS ,_, calcium-channel_JJ blockers_NNS ,_, diuretics_NNS ,_, and_CC nonsteroidal_JJ anti-inflammatory_JJ drugs_NNS -LRB-_-LRB- NSAIDs_NNS -RRB-_-RRB- without_IN evidence_NN of_IN clinically_RB significant_JJ adverse_JJ interactions_NNS ._. Pharmacokinetic_JJ interaction_NN studies_NNS with_IN cetirizine_NN in_IN adults_NNS were_VBD conducted_VBN with_IN pseudoephedrine_NN ,_, antipyrine_NN ,_, ketoconazole_NN ,_, erythromycin_NN and_CC azithromycin_NN ._. No_DT interactions_NNS were_VBD observed_VBN ._. 
In_IN a_DT multiple_JJ dose_NN study_NN of_IN theophylline_NN -LRB-_-LRB- 400_CD mg_NN once_RB daily_RB for_IN 3_CD days_NNS -RRB-_-RRB- and_CC cetirizine_NN -LRB-_-LRB- 20_CD mg_NN once_RB daily_RB for_IN 3_CD days_NNS -RRB-_-RRB- ,_, a_DT 16_CD %_NN decrease_NN in_IN the_DT clearance_NN of_IN cetirizine_NN was_VBD observed_VBN ._. The_DT disposition_NN of_IN theophylline_NN was_VBD not_RB altered_VBN by_IN concomitant_JJ cetirizine_NN administration_NN ._. Drug-Drug_NNP Interactions_NNS :_: No_DT clinically_RB significant_JJ drug_NN interactions_NNS have_VBP been_VBN found_VBN with_IN theophylline_NN at_IN a_DT low_JJ dose_NN ,_, azithromycin_NN ,_, pseudoephedrine_NN ,_, ketoconazole_NN ,_, or_CC erythromycin_NN ._. There_EX was_VBD a_DT small_JJ decrease_NN in_IN the_DT clearance_NN of_IN cetirizine_NN caused_VBN by_IN a_DT 400-mg_JJ dose_NN of_IN theophylline_NN ._. it_PRP is_VBZ possible_JJ that_IN larger_JJR theophylline_NN doses_NNS could_MD have_VB a_DT greater_JJR effect_NN ._. No_DT formal_JJ drug_NN interaction_NN studies_NNS have_VBP been_VBN performed_VBN with_IN Cetrotide_NN ._. A_DT drug_NN interaction_NN study_NN was_VBD performed_VBN in_IN which_WDT ERBITUX_NNP was_VBD administered_VBN in_IN combination_NN with_IN irinotecan_NN ._. There_EX was_VBD no_DT evidence_NN of_IN any_DT pharmacokinetic_JJ interactions_NNS between_IN ERBITUX_NNP and_CC irinotecan_NN ._. Cevimeline_NNP should_MD be_VB administered_VBN with_IN caution_NN to_TO patients_NNS taking_VBG beta_NN adrenergic_JJ antagonists_NNS ,_, because_IN of_IN the_DT possibility_NN of_IN conduction_NN disturbances_NNS ._. Drugs_NNS with_IN parasympathomimetic_JJ effects_NNS administered_VBN concurrently_RB with_IN cevimeline_NN can_MD be_VB expected_VBN to_TO have_VB additive_JJ effects_NNS ._. Cevimeline_NNP might_MD interfere_VB with_IN desirable_JJ antimuscarinic_JJ effects_NNS of_IN drugs_NNS used_VBN concomitantly_RB ._. Drugs_NNS which_WDT inhibit_VBP CYP2D6_NN and_CC CYP3A3/4_NN also_RB inhibit_VBP the_DT metabolism_NN of_IN cevimeline_NN ._. Cevimeline_NNP should_MD be_VB used_VBN with_IN caution_NN in_IN individuals_NNS known_VBN or_CC suspected_VBN to_TO be_VB deficient_JJ in_IN CYP2D6_NN activity_NN ,_, based_VBN on_IN previous_JJ experience_NN ,_, as_IN they_PRP may_MD be_VB at_IN a_DT higher_JJR risk_NN of_IN adverse_JJ events_NNS ._. In_IN an_DT in_FW vitro_FW study_NN ,_, cytochrome_NN P450_NN isozymes_NNS 1A2_NN ,_, 2A6_NN ,_, 2C9_NN ,_, 2C19_NN ,_, 2D6_NN ,_, 2E1_NN ,_, and_CC 3A4_NN were_VBD not_RB inhibited_VBN by_IN exposure_NN to_TO cevimeline_NN ._. There_EX are_VBP no_DT known_JJ drug/drug_NN interactions_NNS with_IN chlorambucil_NN ._. Although_IN clinical_JJ studies_NNS have_VBP not_RB established_VBN a_DT cause_NN and_CC effect_NN relationship_NN ,_, physicians_NNS should_MD be_VB aware_JJ that_IN variable_JJ effects_NNS an_DT blood_NN coagulation_NN have_VBP been_VBN reported_VBN very_RB rarely_RB in_IN patients_NNS receiving_VBG oral_JJ anticoagulants_NNS and_CC chlordiazepoxide_NN ._. The_DT concomitant_JJ use_NN of_IN alcohol_NN or_CC other_JJ central_JJ nervous_JJ system_NN depressants_NNS may_MD have_VB an_DT additive_JJ effect_NN ._. The_DT administration_NN of_IN local_JJ anesthetic_JJ solutions_NNS containing_VBG epinephrine_NN or_CC norepinephrine_NN to_TO patients_NNS receiving_VBG monoamine_NN oxidase_NN inhibitors_NNS ,_, tricyclic_JJ antidepressants_NNS or_CC phenothiazines_NNS may_MD produce_VB severe_JJ ,_, prolonged_JJ hypotension_NN or_CC hypertension_NN ._. Concurrent_JJ use_NN of_IN these_DT agents_NNS should_MD generally_RB be_VB avoided_VBN ._. In_IN situations_NNS when_WRB concurrent_JJ therapy_NN is_VBZ necessary_JJ ,_, careful_JJ patient_NN monitoring_NN is_VBZ essential_JJ ._. Concurrent_JJ administration_NN of_IN vasopressor_NN drugs_NNS -LRB-_-LRB- for_IN the_DT treatment_NN of_IN hypotension_NN related_JJ to_TO obstetric_JJ blocks_NNS -RRB-_-RRB- and_CC ergot-type_JJ oxytocic_JJ drugs_NNS may_MD cause_VB severe_JJ ,_, persistent_JJ hypertension_NN or_CC cerebrovascular_JJ accidents_NNS ._. The_DT para-aminobenzoic_JJ acid_NN metabolite_NN of_IN chloroprocaine_NN inhibits_VBZ the_DT action_NN of_IN sulfonamides_NNS ._. Therefore_RB ,_, chloroprocaine_NN should_MD not_RB be_VB used_VBN in_IN any_DT condition_NN in_IN which_WDT a_DT sulfonamide_NN drug_NN is_VBZ being_VBG employed_VBN ._. Antacids_NNS and_CC kaolin_NN :_: Antacids_NNS and_CC kaolin_NN can_MD reduce_VB absorption_NN of_IN chloroquine_NN ._. an_DT interval_NN of_IN at_IN least_JJS 4_CD hours_NNS between_IN intake_NN of_IN these_DT agents_NNS and_CC chloroquine_NN should_MD be_VB observed_VBN ._. Cimetidine_NNP :_: Cimetidine_NNP can_MD inhibit_VB the_DT metabolism_NN of_IN chloroquine_NN ,_, increasing_VBG its_PRP$ plasma_NN level_NN ._. Concomitant_JJ use_NN of_IN cimetidine_NN should_MD be_VB avoided_VBN ._. Ampicillin_NNP :_: In_IN a_DT study_NN of_IN healthy_JJ volunteers_NNS ,_, chloroquine_NN significantly_RB reduced_VBD the_DT bioavailability_NN of_IN ampicillin_NN ._. An_DT interval_NN of_IN at_IN least_JJS two_CD hours_NNS between_IN intake_NN of_IN this_DT agent_NN and_CC chloroquine_NN should_MD be_VB observed_VBN ._. Cyclosporin_NN :_: After_IN introduction_NN of_IN chloroquine_NN -LRB-_-LRB- oral_JJ form_NN -RRB-_-RRB- ,_, a_DT sudden_JJ increase_NN in_IN serum_NN cyclosporin_NN level_NN has_VBZ been_VBN reported_VBN ._. Therefore_RB ,_, close_JJ monitoring_NN of_IN serum_NN cyclosporin_NN level_NN is_VBZ recommended_VBN and_CC ,_, if_IN necessary_JJ ,_, chloroquine_NN should_MD be_VB discontinued_VBN ._. When_WRB given_VBN concurrently_RB the_DT following_VBG drugs_NNS may_MD interact_VB with_IN thiazide_JJ diuretics_NNS ._. -_: Alcohol_NN ,_, barbiturates_NNS ,_, or_CC narcotics_NNS :_: Potentiation_NN of_IN otthostatic_JJ hypotension_NN may_MD occu_VB ._. -_: Antidiabetic_JJ drugs_NNS :_: -LRB-_-LRB- Oral_JJ agents_NNS and_CC insulin_NN -RRB-_-RRB- Dosage_NN adjustment_NN of_IN the_DT antidiabetic_JJ drug_NN may_MD be_VB require_VB ._. -_: Other_JJ antihypertensive_JJ drugs_NNS :_: Additive_JJ effect_NN or_CC potentiatio_NN ._. -_: Cholestyramine_NN and_CC colestipol_NN resins_NNS :_: Cholestytamine_NN and_CC colestipol_NN resins_NNS have_VBP the_DT potential_NN of_IN binding_VBG thiazide_JJ diuretics_NNS and_CC reducing_VBG diuretic_JJ absorption_NN from_IN the_DT gastrointestinal_JJ trac_NN ._. -_: Corticosteroids_NNS ,_, ACTH_NN :_: Intensified_VBN electrolyte_NN depletion_NN ,_, particularly_RB hypokalemi_NN ._. -_: Pressor_NN amines_NNS -LRB-_-LRB- e.g._FW ,_, norepinephrine_NN -RRB-_-RRB- :_: Possible_JJ decreased_VBN response_NN to_TO pressor_NN amines_NNS but_CC not_RB sufficient_JJ to_TO preclude_VB their_PRP$ us_PRP ._. -_: Skeletal_JJ muscle_NN relaxants_NNS ,_, nondepolarizing_JJ -LRB-_-LRB- e.g._FW ,_, tubocurarine_NN -RRB-_-RRB- :_: Possible_JJ increased_VBN responsiveness_NN to_TO the_DT muscle_NN relaxan_NN ._. -_: Lithium_NN :_: Generally_RB should_MD not_RB be_VB given_VBN with_IN diuretics_NNS ._. Diuretic_JJ agents_NNS reduce_VB the_DT renal_JJ clearance_NN of_IN lithium_NN and_CC add_VB a_DT high_JJ risk_NN of_IN lithium_NN toxicity_NN ._. Refer_VB to_TO the_DT package_NN insert_NN for_IN lithium_NN preparations_NNS before_IN use_NN of_IN such_JJ preparations_NNS with_IN chlorothiazid_NN ._. -_: Non-steroidal_JJ Anti-inflammatory_JJ Drugs_NNS :_: In_IN some_DT patients_NNS ,_, the_DT administration_NN of_IN a_DT non-steroidal_JJ anti-inflammatory_JJ agent_NN can_MD reduce_VB the_DT diuretic_JJ ,_, natriuretic_JJ ,_, and_CC antihypertensive_JJ effects_NNS of_IN loop_NN ,_, potassium-sparing_NN and_CC thiazide_JJ diuretics_NNS ._. Therefore_RB ,_, when_WRB chlorothiazide_NN and_CC non-steroidal_JJ anti-inflammatory_JJ agents_NNS are_VBP used_VBN concomitantly_RB ,_, the_DT patient_NN should_MD be_VB observed_VBN closely_RB to_TO determine_VB if_IN the_DT desired_VBN effect_NN of_IN the_DT diuretic_JJ is_VBZ obtaine_NN ._. -_: Drug/Laboratory_NN Test_NN Interactions_NNS :_: Thiazides_NNS should_MD be_VB discontinued_VBN before_IN carrying_VBG out_RP tests_NNS for_IN parathyroid_JJ function_NN ._. Chlorotrianisene_NN may_MD interact_VB with_IN antidepressants_NNS ,_, aspirin_NN ,_, barbiturates_NNS ,_, bromocriptine_NN ,_, calcium_NN supplements_NNS ,_, corticosteroids_NNS ,_, corticotropin_NN ,_, cyclosporine_NN ,_, dantrolene_NN ,_, nicotine_NN ,_, somatropin_NN ,_, tamoxifen_NN ,_, and_CC warfarin_NN ._. May_NNP interact_VBP with_IN skin_NN products_NNS or_CC shampoos_NNS for_IN dandruff_NN or_CC psoriasis_NN ._. Substrate_NN of_IN CYP2D6_NN -LRB-_-LRB- minor_JJ -RRB-_-RRB- ,_, 3A4_NN -LRB-_-LRB- major_JJ -RRB-_-RRB- ;_: ._. Inhibits_VBZ CYP2D6_NN -LRB-_-LRB- weak_JJ -RRB-_-RRB- ._. Increased_VBN toxicity_NN -LRB-_-LRB- CNS_NN depression_NN -RRB-_-RRB- :_: CNS_NN depressants_NNS ,_, MAO_NN inhibitors_NNS ,_, tricyclic_JJ antidepressants_NNS ,_, phenothiazines_NNS ._. CYP3A4_NN inhibitors_NNS :_: May_NNP increase_VB the_DT levels/effects_NNS of_IN chlorpheniramine_NN ._. Example_NN inhibitors_NNS include_VBP azole_NN antifungals_NNS ,_, ciprofloxacin_NN ,_, clarithromycin_NN ,_, diclofenac_NN ,_, doxycycline_NN ,_, erythromycin_NN ,_, imatinib_NN ,_, isoniazid_NN ,_, nefazodone_NN ,_, nicardipine_NN ,_, propofol_NN ,_, protease_NN inhibitors_NNS ,_, quinidine_NN ,_, and_CC verapamil_NN ._. The_DT concurrent_JJ use_NN of_IN two_CD or_CC more_JJR drugs_NNS with_IN anticholinergic_JJ activity_NN --_: such_JJ as_IN an_DT antipsychotic_JJ drug_NN -LRB-_-LRB- eg_FW ,_, chlorpromazine_NN -RRB-_-RRB- ,_, an_DT antiparkinsonian_JJ drug_NN -LRB-_-LRB- eg_FW ,_, trihexyphenidyl_NN -RRB-_-RRB- ,_, and/or_CC a_DT tricyclic_JJ antidepressant_JJ -LRB-_-LRB- eg_FW ,_, amitriptyline_NNP -RRB-_-RRB- --_: commonly_RB results_VBZ in_IN excessive_JJ anticholinergic_JJ effects_NNS ,_, including_VBG dry_JJ mouth_NN and_CC associated_VBN dental_JJ complications_NNS ,_, blurred_VBD vision_NN ,_, and_CC ,_, in_IN patients_NNS exposed_VBN to_TO high_JJ temperature_NN and_CC humidity_NN ,_, hyperpyrexia_NN ._. Interactions_NNS may_MD also_RB occur_VB with_IN the_DT following_NN :_: anti-depressants/anti-anxiety_JJ drugs_NNS ,_, drugs_NNS used_VBN to_TO treat_VB an_DT overactive_JJ thyroid_NN ,_, beta-blockers_NNS -LRB-_-LRB- e.g._FW ,_, propranolol_NN -RRB-_-RRB- ,_, sparfloxacin_NN ,_, grepafloxacin_NN ,_, guanethidine_NN ,_, guanadrel_NN ,_, metrizamide_NN ,_, cabergoline_NN ,_, lithium_NN ,_, narcotic_JJ pain_NN medication_NN -LRB-_-LRB- e.g._FW ,_, codeine_NN -RRB-_-RRB- ,_, drugs_NNS used_VBN to_TO aid_VB sleep_NN ,_, drowsiness-causing_JJ antihistamines_NNS -LRB-_-LRB- e.g._FW ,_, diphenhydramine_NN -RRB-_-RRB- ,_, any_DT other_JJ drugs_NNS that_WDT may_MD make_VB you_PRP drowsy_JJ ._. The_DT hypoglycemic_JJ action_NN of_IN sulfonylurea_NN may_MD be_VB potentiated_VBN by_IN certain_JJ drugs_NNS including_VBG nonsteroidal_JJ anti-inflammatory_JJ agents_NNS and_CC other_JJ drugs_NNS that_WDT are_VBP highly_RB protein_NN bound_VBD ,_, salicylates_NNS ,_, sulfonamides_NNS ,_, chloramphenicol_NN ,_, probenecid_NN ,_, coumarins_NNS ,_, monoamine_NN oxidase_NN inhibitors_NNS ,_, and_CC beta_NN adrenergic_JJ blocking_VBG agents_NNS ._. When_WRB such_JJ drugs_NNS are_VBP administered_VBN to_TO a_DT patient_NN receiving_VBG DIABINESE_NNP ,_, the_DT patient_NN should_MD be_VB observed_VBN closely_RB for_IN hypoglycemia_NN ._. When_WRB such_JJ drugs_NNS are_VBP withdrawn_VBN from_IN a_DT patient_NN receiving_VBG DIABINESE_NNP ,_, the_DT patient_NN should_MD be_VB observed_VBN closely_RB for_IN loss_NN of_IN control_NN ._. Certain_JJ drugs_NNS tend_VBP to_TO produce_VB hyperglycemia_NN and_CC may_MD lead_VB to_TO loss_NN of_IN control_NN ._. These_DT drugs_NNS include_VBP the_DT thiazides_NNS and_CC other_JJ diuretics_NNS ,_, corticosteroids_NNS ,_, phenothiazines_NNS ,_, thyroid_NN products_NNS ,_, estrogens_NNS ,_, oral_JJ contraceptives_NNS ,_, phenytoin_NN ,_, nicotinic_JJ acid_NN ,_, sympathomimetics_NNS ,_, calcium_NN channel_NN blocking_VBG drugs_NNS ,_, and_CC isoniazid_NN ._. When_WRB such_JJ drugs_NNS are_VBP administered_VBN to_TO a_DT patient_NN receiving_VBG DIABINESE_NNP ,_, the_DT patient_NN should_MD be_VB closely_RB observed_VBN for_IN loss_NN of_IN control_NN ._. When_WRB such_JJ drugs_NNS are_VBP withdrawn_VBN from_IN a_DT patient_NN receiving_VBG DIABINESE_NNP ,_, the_DT patient_NN should_MD be_VB observed_VBN closely_RB for_IN hypoglycemia_NN ._. Since_IN animal_NN studies_NNS suggest_VBP that_IN the_DT action_NN of_IN barbiturates_NNS may_MD be_VB prolonged_VBN by_IN therapy_NN with_IN chlorpropamide_NN ,_, barbiturates_NNS should_MD be_VB employed_VBN with_IN caution_NN ._. In_IN some_DT patients_NNS ,_, a_DT disulfiram-like_JJ reaction_NN may_MD be_VB produced_VBN by_IN the_DT ingestion_NN of_IN alcohol_NN ._. A_DT potential_JJ interaction_NN between_IN oral_JJ miconazole_NN and_CC oral_JJ hypoglycemic_JJ agents_NNS leading_VBG to_TO severe_JJ hypoglycemia_NN has_VBZ been_VBN reported_VBN ._. Whether_IN this_DT interaction_NN also_RB occurs_VBZ with_IN the_DT intravenous_JJ ,_, topical_JJ ,_, or_CC vaginal_JJ preparations_NNS of_IN miconazole_NN is_VBZ not_RB known_VBN ._. Chlorprothixene_NN may_MD increase_VB the_DT plasma-level_NN of_IN concomitantly_RB given_VBN lithium_NN ._. In_IN order_NN to_TO avoid_VB lithium_NN intoxication_NN ,_, lithium_NN plasma_NN levels_NNS should_MD be_VB monitored_VBN closely_RB ._. If_IN chlorprothixene_NN is_VBZ given_VBN concomitantly_RB with_IN opioids_NNS ,_, the_DT opioid_JJ dose_NN should_MD be_VB reduced_VBN -LRB-_-LRB- by_IN approx_RB ._. 50_CD %_NN -RRB-_-RRB- ,_, because_IN chlorprothixene_NN amplifies_VBZ the_DT therapeutic_JJ actions_NNS and_CC side-effects_NNS of_IN opioids_NNS massively_RB ._. Avoid_VB the_DT concomitant_JJ use_NN of_IN chlorprothixene_NN and_CC tramadol_NN -LRB-_-LRB- Ultram_NN -RRB-_-RRB- ._. Massive_JJ seizures_NNS may_MD be_VB encountered_VBN with_IN this_DT combination_NN ._. Consider_VB additive_JJ sedative_JJ effects_NNS and_CC confusional_JJ states_NNS to_TO emerge_VB ,_, if_IN chlorprothixene_NN is_VBZ given_VBN with_IN benzodiazepines_NNS or_CC barbituates_NNS ._. Choose_VB particular_JJ low_JJ doses_NNS of_IN these_DT drugs_NNS ._. Exert_VB particular_JJ caution_NN in_IN combining_VBG chlorprothixene_NN with_IN other_JJ anticholinergic_JJ drugs_NNS -LRB-_-LRB- tricyclic_JJ antidepressants_NNS and_CC antiparkinsonian_JJ agents_NNS -RRB-_-RRB- :_: Particularly_RB the_DT elderly_JJ may_MD develop_VB delirium_NN ,_, high_JJ fever_NN ,_, severe_JJ obstipation_NN ,_, even_RB ileus_NN and_CC glaucoma_NN ._. Chlorthalidone_NNP may_MD add_VB to_TO or_CC potentiate_VB the_DT action_NN of_IN other_JJ antihypertensive_JJ drugs_NNS ._. Potentiation_NN occurs_VBZ with_IN ganglionic_JJ peripheral_JJ adrenergic_JJ blocking_NN drugs_NNS ._. Medication_NN such_JJ as_IN digitalis_NN may_MD also_RB influence_VB serum_NN electrolytes_NNS ._. Warning_NN signs_NNS ,_, irrespective_RB of_IN cause_NN ,_, are_VBP :_: dryness_NN of_IN mouth_NN ,_, thirst_NN ,_, weakness_NN ,_, lethargy_NN ,_, drowsiness_NN ,_, restlessness_NN ,_, muscle_NN pains_NNS or_CC cramps_NNS ,_, muscular_JJ fatigue_NN ,_, hypotension_NN ,_, oliguria_NN ,_, tachycardia_NN ,_, and_CC gastrointestinal_JJ disturbances_NNS such_JJ as_IN nausea_NN and_CC vomiting_NN ._. Insulin_NN requirements_NNS in_IN diabetic_JJ patients_NNS may_MD be_VB increased_VBN ,_, decreased_VBN ,_, or_CC unchanged_JJ ._. Higher_JJR dosage_NN of_IN oral_JJ hypoglycemic_JJ agents_NNS may_MD be_VB required_VBN ._. Latent_JJ diabetes_NN mellitus_NN may_MD become_VB manifest_JJ during_IN chlorthalidone_NN administration_NN ._. Chlorthalidone_NNP and_CC related_JJ drugs_NNS may_MD increase_VB the_DT responsiveness_NN to_TO tubocurarine_NN ._. Chlorthalidone_NNP and_CC related_JJ drugs_NNS may_MD decrease_VB arterial_JJ responsiveness_NN to_TO norepinephrine_NN ._. This_DT diminution_NN is_VBZ not_RB sufficient_JJ to_TO preclude_VB effectiveness_NN of_IN the_DT pressor_NN agent_NN for_IN therapeutic_JJ use_NN ._. The_DT concomitant_JJ use_NN of_IN alcohol_NN or_CC other_JJ central_JJ nervous_JJ system_NN depressants_NNS may_MD have_VB an_DT additive_JJ effect_NN ._. Interactions_NNS for_IN vitamin_NN D_NN analogues_NNS -LRB-_-LRB- Vitamin_NN D2_NN ,_, Vitamin_NN D3_NN ,_, Calcitriol_NN ,_, and_CC Calcidiol_NN -RRB-_-RRB- :_: Cholestyramine_NNP :_: Cholestyramine_NNP has_VBZ been_VBN reported_VBN to_TO reduce_VB intestinal_JJ absorption_NN of_IN fat_JJ soluble_JJ vitamins_NNS ._. as_IN such_JJ it_PRP may_MD impair_VB intestinal_JJ absorption_NN of_IN any_DT of_IN vitamin_NN D._NNP Phenytoin/Phenobarbital_NNP :_: The_DT coadministration_NN of_IN phenytoin_NN or_CC phenobarbital_NN will_MD not_RB affect_VB plasma_NN concentrations_NNS of_IN vitamin_NN D_NN ,_, but_CC may_MD reduce_VB endogenous_JJ plasma_NN levels_NNS of_IN calcitriol/ergocalcitriol_NN by_IN accelerating_VBG metabolism_NN ._. Since_IN blood_NN level_NN of_IN calcitriol/ergocalcitriol_NN will_MD be_VB reduced_VBN ,_, higher_JJR doses_NNS of_IN Rocaltrol_NNP may_MD be_VB necessary_JJ if_IN these_DT drugs_NNS are_VBP administered_VBN simultaneously_RB ._. Thiazides_NNP :_: Thiazides_NNS are_VBP known_VBN to_TO induce_VB hypercalcemia_NN by_IN the_DT reduction_NN of_IN calcium_NN excretion_NN in_IN urine_NN ._. Some_DT reports_NNS have_VBP shown_VBN that_IN the_DT concomitant_JJ administration_NN of_IN thiazides_NNS with_IN vitamin_NN D_NN causes_VBZ hypercalcemia_NN ._. Therefore_RB ,_, precaution_NN should_MD be_VB taken_VBN when_WRB coadministration_NN is_VBZ necessary_JJ ._. Digitalis_NNP :_: Vitamin_NN D_NN dosage_NN must_MD be_VB determined_VBN with_IN care_NN in_IN patients_NNS undergoing_VBG treatment_NN with_IN digitalis_NN ,_, as_IN hypercalcemia_NN in_IN such_JJ patients_NNS may_MD precipitate_VB cardiac_JJ arrhythmias_NNS ._. Ketoconazole_NN :_: Ketoconazole_NN may_MD inhibit_VB both_DT synthetic_JJ and_CC catabolic_JJ enzymes_NNS of_IN vitamin_NN D._NNP Reductions_NNPS in_IN serum_NN endogenous_JJ vitamin_NN D_NN concentrations_NNS have_VBP been_VBN observed_VBN following_VBG the_DT administration_NN of_IN 300_CD mg/day_NN to_TO 1200_CD mg/day_NN ketoconazole_NN for_IN a_DT week_NN to_TO healthy_JJ men_NNS ._. However_RB ,_, in_FW vivo_FW drug_NN interaction_NN studies_NNS of_IN ketoconazole_NN with_IN vitamin_NN D_NN have_VBP not_RB been_VBN investigated_VBN ._. Corticosteroids_NNS :_: A_DT relationship_NN of_IN functional_JJ antagonism_NN exists_VBZ between_IN vitamin_NN D_NN analogues_NNS ,_, which_WDT promote_VBP calcium_NN absorption_NN ,_, and_CC corticosteroids_NNS ,_, which_WDT inhibit_VBP calcium_NN absorption_NN ._. Phosphate-Binding_JJ Agents_NNS :_: Since_IN vitamin_NN D_NN also_RB has_VBZ an_DT effect_NN on_IN phosphate_NN transport_NN in_IN the_DT intestine_NN ,_, kidneys_NNS and_CC bones_NNS ,_, the_DT dosage_NN of_IN phosphate-binding_JJ agents_NNS must_MD be_VB adjusted_VBN in_IN accordance_NN with_IN the_DT serum_NN phosphate_NN concentration_NN ._. Vitamin_NN D_NN :_: The_DT coadministration_NN of_IN any_DT of_IN the_DT vitamin_NN D_NN analogues_NNS should_MD be_VB avoided_VBN as_IN this_DT could_MD create_VB possible_JJ additive_JJ effects_NNS and_CC hypercalcemia_NN ._. Calcium_NN Supplements_NNS :_: Uncontrolled_JJ intake_NN of_IN additional_JJ calcium-containing_JJ preparations_NNS should_MD be_VB avoided_VBN ._. Magnesium_NN :_: Magnesium-containing_JJ preparations_NNS -LRB-_-LRB- eg_FW ,_, antacids_NNS -RRB-_-RRB- may_MD cause_VB hypermagnesemia_NN and_CC should_MD therefore_RB not_RB be_VB taken_VBN during_IN therapy_NN with_IN vitamin_NN D_NN by_IN patients_NNS on_IN chronic_JJ renal_JJ dialysis_NN ._. Cholestyramine_NNP resin_NN may_MD delay_VB or_CC reduce_VB the_DT absorption_NN of_IN concomitant_JJ oral_JJ medication_NN such_JJ as_IN phenylbutazone_NN ,_, warfarin_NN ,_, thiazide_JJ diuretics_NNS -LRB-_-LRB- acidic_JJ -RRB-_-RRB- or_CC propranolol_NN -LRB-_-LRB- basic_JJ -RRB-_-RRB- ,_, as_RB well_RB as_IN tetracycline_NN penicillin_NN G_NN ,_, phenobarbital_NN ,_, thyroid_NN and_CC thyroxine_NN preparations_NNS ,_, estrogens_NNS and_CC progestins_NNS ,_, and_CC digitalis_NN ._. Interference_NN with_IN the_DT absorption_NN of_IN oral_JJ phosphate_NN supplements_NNS has_VBZ been_VBN observed_VBN with_IN another_DT positively-charged_JJ bile_NN acid_NN sequestrant_NN ._. Cholestyramine_NNP resin_NN may_MD interfere_VB with_IN the_DT pharmacokinetics_NNS of_IN drugs_NNS that_WDT undergo_VBP enterohepatic_JJ circulation_NN ,_, The_DT discontinuance_NN of_IN cholestyramine_NN resin_NN could_MD pose_VB a_DT hazard_NN to_TO health_NN if_IN a_DT potentially_RB toxic_JJ drug_NN such_JJ as_IN digitalis_NN has_VBZ been_VBN filtrated_VBN to_TO a_DT maintenance_NN level_NN while_IN the_DT patient_NN was_VBD taking_VBG cholestyramine_NN resin_NN ._. Because_IN cholestyramine_NN binds_VBZ bile_NN acids_NNS ,_, cholestyramine_NN resin_NN may_MD interfere_VB with_IN normal_JJ fat_JJ digestion_NN and_CC absorption_NN and_CC thus_RB may_MD prevent_VB absorption_NN of_IN fat_JJ soluble_JJ vitamins_NNS such_JJ as_IN A_DT ,_, D_NN ,_, E_NN ,_, and_CC K_NN ._. When_WRB cholestyramine_NN resin_NN is_VBZ given_VBN for_IN long_JJ periods_NNS of_IN time_NN ,_, concomitant_JJ supplementation_NN with_IN water-miscible_JJ -LRB-_-LRB- or_CC parenteral_JJ -RRB-_-RRB- forms_NNS of_IN fat-soluble_JJ vitamins_NNS should_MD be_VB considered_VBN ._. SINCE_IN CHOLESTYRAMINE_NNP RESIN_NNP MAY_NNP BIND_VBP OTHER_JJ DRUGS_NNS GIVEN_VBP CONCURRENTLY_RB ,_, IT_PRP IS_VBZ RECOMMENDED_NNP THAT_WDT PATIENTS_NNS TAKE_VBP OTHER_JJ DRUGS_NNS AT_IN LEAST_NN 1_CD HOUR_NN BEFORE_IN OR_NN 4_CD TO_TO 6_CD HOURS_NNS AFTER_IN CHOLESTYRAMINE_NNP RESIN_NNP -LRB-_-LRB- OR_NN AT_IN AS_JJ GREAT_JJ AN_DT INTERVAL_NNP AS_NNP POSSIBLE_NN -RRB-_-RRB- TO_TO AVOID_VB IMPEDING_NNP THEIR_NNP ABSORPTION_NNP ._. Based_VBN on_IN in_FW vitro_FW studies_NNS in_IN human_JJ liver_NN microsomes_NNS ,_, des-ciclesonide_NN appears_VBZ to_TO have_VB no_DT inhibitory_JJ or_CC induction_NN potential_NN on_IN the_DT metabolism_NN of_IN other_JJ drugs_NNS metabolized_VBN by_IN CYP_NN 450_CD enzymes_NNS ._. The_DT inhibitory_JJ potential_NN of_IN ciclesonide_NN on_IN CYP450_NN isoenzymes_NNS has_VBZ not_RB been_VBN studied_VBN ._. In_FW vitro_FW studies_NNS demonstrated_VBD that_IN the_DT plasma_NN protein_NN binding_NN of_IN des-ciclesonide_NN was_VBD not_RB affected_VBN by_IN warfarin_NN or_CC salicylic_JJ acid_NN ,_, indicating_VBG no_DT potential_NN for_IN protein_NN binding-based_JJ drug_NN interactions_NNS ._. In_IN a_DT drug_NN interaction_NN study_NN ,_, co-administration_NN of_IN orally_RB inhaled_VBN ciclesonide_NN and_CC oral_JJ erythromycin_NN ,_, an_DT inhibitor_NN of_IN cytochrome_NN P450_NN 3A4_NN ,_, had_VBD no_DT effect_NN on_IN the_DT pharmacokinetics_NNS of_IN either_CC des-ciclesonide_NN or_CC erythromycin_NN ._. In_IN another_DT drug_NN interaction_NN study_NN ,_, co-administration_NN of_IN orally_RB inhaled_VBN ciclesonide_NN and_CC oral_JJ ketoconazole_NN ,_, a_DT potent_JJ inhibitor_NN of_IN cytochrome_NN P450_NN 3A4_NN ,_, increased_VBD the_DT exposure_NN -LRB-_-LRB- AUC_NN -RRB-_-RRB- of_IN des-ciclesonide_NN by_IN approximately_RB 3.6-fold_RB at_IN steady_JJ state_NN ,_, while_IN levels_NNS of_IN ciclesonide_NN remained_VBD unchanged_JJ ._. Therefore_RB ,_, ketoconazole_NN should_MD be_VB administered_VBN with_IN caution_NN with_IN intranasal_JJ ciclesonide_NN ._. Probenecid_NNP :_: Probenecid_NNP is_VBZ known_VBN to_TO interact_VB with_IN the_DT metabolism_NN or_CC renal_JJ tubular_JJ excretion_NN of_IN many_JJ drugs_NNS -LRB-_-LRB- e.g._FW ,_, acetaminophen_NN ,_, acyclovir_NN ,_, angiotensin-converting_JJ enzyme_NN inhibitors_NNS ,_, aminosalicylic_JJ acid_NN ,_, barbiturates_NNS ,_, benzodiazepines_NNS ,_, bumetanide_NN ,_, clofibrate_NN ,_, methotrexate_NN ,_, famotidine_NN ,_, furosemide_NN ,_, nonsteroidal_JJ anti-inflammatory_JJ agents_NNS ,_, theophylline_NN ,_, and_CC zidovudine_NN -RRB-_-RRB- ._. Concomitant_JJ medications_NNS should_MD be_VB carefully_RB assessed_VBN ._. Zidovudine_NN should_MD either_RB be_VB temporarily_RB discontinued_VBN or_CC decreased_VBN by_IN 50_CD %_NN when_WRB coadministered_VBN with_IN probenecid_NN on_IN the_DT day_NN of_IN VISTIDE_NNP infusion_NN ._. Nephrotoxic_JJ agents_NNS :_: Concomitant_JJ administration_NN of_IN VISTIDE_NNP and_CC agents_NNS with_IN nephrotoxic_JJ potential_JJ -LSB-_-LRB- e.g._FW ,_, intravenous_JJ aminoglycosides_NNS -LRB-_-LRB- e.g._FW ,_, tobramycin_NN ,_, gentamicin_NN ,_, and_CC amikacin_NN -RRB-_-RRB- ,_, amphotericin_NN B_NN ,_, foscarnet_NN ,_, intravenous_JJ pentamidine_NN ,_, vancomycin_NN ,_, and_CC non-steroidal_JJ anti-inflammatory_JJ agents_NNS -RSB-_-RRB- is_VBZ contraindicated_VBN ._. Such_JJ agents_NNS must_MD be_VB discontinued_VBN at_IN least_JJS seven_CD days_NNS prior_RB to_TO starting_VBG therapy_NN with_IN VISTIDE_NN ._. Since_IN PLETAL_NN is_VBZ extensively_RB metabolized_VBN by_IN cytochrome_NN P-450_NN isoenzymes_NNS ,_, caution_NN should_MD be_VB exercised_VBN when_WRB PLETAL_NNP is_VBZ coadministered_VBN with_IN inhibitors_NNS of_IN C.P.A._NNP such_JJ as_IN ketoconazole_NN and_CC erythromycin_NN or_CC inhibitors_NNS of_IN CYP2C19_NN such_JJ as_IN omeprazole_NN ._. Pharmacokinetic_JJ studies_NNS have_VBP demonstrated_VBN that_IN omeprazole_NN and_CC erythromycin_NN significantly_RB increased_VBD the_DT systemic_JJ exposure_NN of_IN cilostazol_NN and/or_CC its_PRP$ major_JJ metabolites_NNS ._. Population_NNP pharmacokinetic_JJ studies_NNS showed_VBD higher_JJR concentrations_NNS of_IN cilostazol_NN among_IN patients_NNS concurrently_RB treated_VBN with_IN diltiazem_NN ,_, an_DT inhibitor_NN of_IN C.P.A._NNP Pletal_NNP does_VBZ not_RB ,_, however_RB ,_, appear_VBP to_TO cause_VB increased_VBN blood_NN levels_NNS of_IN drugs_NNS metabolized_VBN by_IN CYP3A4_NN ,_, as_IN it_PRP had_VBD no_DT effect_NN on_IN lovastatin_NN ,_, a_DT drug_NN with_IN metabolism_NN very_RB sensitive_JJ to_TO C.P.A._NNP inhibition_NN ._. Tagamet_NNP ,_, apparently_RB through_IN an_DT effect_NN on_IN certain_JJ microsomal_JJ enzyme_NN systems_NNS ,_, has_VBZ been_VBN reported_VBN to_TO reduce_VB the_DT hepatic_JJ metabolism_NN of_IN warfarin-type_JJ anticoagulants_NNS ,_, phenytoin_NN ,_, propranolol_NN ,_, nifedipine_NN ,_, chlordiazepoxide_NN ,_, diazepam_NN ,_, certain_JJ tricyclic_JJ antidepressants_NNS ,_, lidocaine_NN ,_, theophylline_NN and_CC metronidazole_NN ,_, thereby_RB delaying_VBG elimination_NN and_CC increasing_VBG blood_NN levels_NNS of_IN these_DT drugs_NNS ._. Clinically_RB significant_JJ effects_NNS have_VBP been_VBN reported_VBN with_IN the_DT warfarin_NN anticoagulants_NNS ._. therefore_RB ,_, close_JJ monitoring_NN of_IN prothrombin_NN time_NN is_VBZ recommended_VBN ,_, and_CC adjustment_NN of_IN the_DT anticoagulant_JJ dose_NN may_MD be_VB necessary_JJ when_WRB Tagamet_NNP is_VBZ administered_VBN concomitantly_RB ._. Interaction_NN with_IN phenytoin_NN ,_, lidocaine_NN and_CC theophylline_NN has_VBZ also_RB been_VBN reported_VBN to_TO produce_VB adverse_JJ clinical_JJ effects_NNS ._. However_RB ,_, a_DT crossover_NN study_NN in_IN healthy_JJ subjects_NNS receiving_VBG either_CC Tagamet_NNP 300_CD mg_NN q.i.d._NN or_CC 800_CD mg_NN h.s._NN concomitantly_RB with_IN a_DT 300_CD mg_NN b.i.d._NN dosage_NN of_IN theophylline_NN -LRB-_-LRB- Theo-Dur_NNP ,_, Key_NNP Pharmaceuticals_NNP ,_, Inc._NNP -RRB-_-RRB- demonstrated_VBD less_JJR alteration_NN in_IN steady-state_JJ theophylline_NN peak_NN serum_NN levels_NNS with_IN the_DT 800_CD mg_NN h.s._NN regimen_NN ,_, particularly_RB in_IN subjects_NNS aged_JJ 54_CD years_NNS and_CC older_JJR ._. Data_NNS beyond_IN 10_CD days_NNS are_VBP not_RB available_JJ ._. -LRB-_-LRB- Note_NN :_: All_DT patients_NNS receiving_VBG theophylline_NN should_MD be_VB monitored_VBN appropriately_RB ,_, regardless_RB of_IN concomitant_JJ drug_NN therapy_NN ._. Dosage_NN of_IN the_DT drugs_NNS mentioned_VBN above_IN and_CC other_JJ similarly_RB metabolized_VBN drugs_NNS ,_, particularly_RB those_DT of_IN low_JJ therapeutic_JJ ratio_NN or_CC in_IN patients_NNS with_IN renal_JJ and/or_CC hepatic_JJ impairment_NN ,_, may_MD require_VB adjustment_NN when_WRB starting_VBG or_CC stopping_VBG concomitantly_RB administered_VBN Tagamet_NNP to_TO maintain_VB optimum_JJ therapeutic_JJ blood_NN levels_NNS ._. Alteration_NN of_IN pH_NN may_MD affect_VB absorption_NN of_IN certain_JJ drugs_NNS -LRB-_-LRB- e.g._FW ,_, ketoconazole_NN -RRB-_-RRB- ._. If_IN these_DT products_NNS are_VBP needed_VBN ,_, they_PRP should_MD be_VB given_VBN at_IN least_JJS 2_CD hours_NNS before_IN cimetidine_NN administration_NN ._. Additional_JJ clinical_JJ experience_NN may_MD reveal_VB other_JJ drugs_NNS affected_VBN by_IN the_DT concomitant_JJ administration_NN of_IN Tagamet_NNP ._. and/or_CC Drug/Laboratory_JJ Test_NN Interactions_NNS See_VB CLINICAL_NNP PHARMACOLOGY_NNP ,_, Pharmacokinetics_NNP and_CC Drug_NNP Interactions_NNS ._. Effect_NN of_IN Sensipar_NN on_IN other_JJ drugs_NNS :_: Drugs_NNS metabolized_VBN by_IN cytochrome_NN P450_NN 2D6_NN -LRB-_-LRB- CYP2D6_NN -RRB-_-RRB- :_: Sensipar_NN is_VBZ a_DT strong_JJ in_FW vitro_FW inhibitor_NN of_IN CYP2D6_NN ._. Therefore_RB ,_, dose_NN adjustments_NNS of_IN concomitant_JJ medications_NNS that_WDT are_VBP predominantly_RB metabolized_VBN by_IN CYP2D6_NN and_CC have_VBP a_DT narrow_JJ therapeutic_JJ index_NN -LRB-_-LRB- e.g._FW ,_, flecainide_NN ,_, vinblastine_NN ,_, thioridazine_NN and_CC most_RBS tricyclic_JJ antidepressants_NNS -RRB-_-RRB- may_MD be_VB required_VBN ._. Amitriptyline_NNP :_: Concurrent_JJ administration_NN of_IN 25_CD mg_NN or_CC 100_CD mg_NN cinacalcet_NN with_IN 50_CD mg_NN amitriptyline_NNP increased_VBD amitriptyline_NNP exposure_NN and_CC nortriptyline_NN -LRB-_-LRB- active_JJ metabolite_NN -RRB-_-RRB- exposure_NN by_IN approximately_RB 20_CD %_NN in_IN CYP2D6_NN extensive_JJ metabolizers_NNS ._. Effect_NN of_IN other_JJ drugs_NNS on_IN Sensipar_NNP :_: Sensipar_NNP is_VBZ metabolized_VBN by_IN multiple_JJ cytochrome_NN P450_NN enzymes_NNS ,_, primarily_RB CYP3A4_NN ,_, CYP2D6_NN ,_, and_CC CYP1A2_NN ._. Ketoconazole_NN :_: Sensipar_NN is_VBZ metabolized_VBN in_IN part_NN by_IN CYP3A4_NN ._. Co-administration_NN of_IN ketoconazole_NN ,_, a_DT strong_JJ inhibitor_NN of_IN CYP3A4_NN ,_, increased_VBD cinacalcet_NN exposure_NN following_VBG a_DT single_JJ 90_CD mg_NN dose_NN of_IN Sensipar_NN by_IN 2.3_CD fold_NN ._. Dose_NN adjustment_NN of_IN Sensipar_NN may_MD be_VB required_VBN and_CC PTH_NN and_CC serum_NN calcium_NN concentrations_NNS should_MD be_VB closely_RB monitored_VBN if_IN a_DT patient_NN initiates_VBZ or_CC discontinues_VBZ therapy_NN with_IN a_DT strong_JJ CYP3A4_NN inhibitor_NN -LRB-_-LRB- e.g._FW ,_, ketoconazole_NN ,_, erythromycin_NN ,_, itraconazole_NN ._. see_VB DOSAGE_NNP AND_CC ADMINISTRATION_NNP -RRB-_-RRB- ._. Elevated_JJ plasma_NN levels_NNS of_IN theophylline_NN have_VBP been_VBN reported_VBN with_IN concomitant_JJ use_NN of_IN some_DT quinolones_NNS ._. There_EX have_VBP been_VBN reports_NNS of_IN theophylline-related_JJ side-effects_NNS in_IN patients_NNS on_IN concomitant_JJ theophylline-quinolone_JJ therapy_NN ._. Therefore_RB ,_, monitoring_NN of_IN theophylline_NN plasma_NN levels_NNS should_MD be_VB considered_VBN and_CC dosage_NN of_IN theophylline_NN adjusted_VBN as_IN required_VBN ._. Quinolones_NNS have_VBP also_RB been_VBN shown_VBN to_TO interfere_VB with_IN the_DT metabolism_NN of_IN caffeine_NN ._. This_DT may_MD lead_VB to_TO reduced_VBN clearance_NN of_IN caffeine_NN and_CC a_DT prolongation_NN of_IN its_PRP$ plasma_NN half-life_NN ._. Although_IN this_DT interaction_NN has_VBZ not_RB been_VBN reported_VBN with_IN cinoxacin_NN ,_, caution_NN should_MD be_VB exercised_VBN when_WRB cinoxacin_NN is_VBZ given_VBN concomitantly_RB with_IN caffeine-containing_JJ products_NNS ._. Antacids_NNS or_CC sucralfate_NN substantially_RB interfere_VBP with_IN the_DT absorption_NN of_IN some_DT quinolones_NNS ,_, resulting_VBG in_IN low_JJ urine_NN levels_NNS ._. Also_RB ,_, concomitant_JJ administration_NN of_IN quinolones_NNS with_IN products_NNS containing_VBG iron_NN ,_, multivitamins_NNS containing_VBG zinc_NN ,_, or_CC Videx_NNP -LRB-_-LRB- didanosine_NN -RRB-_-RRB- chewable/buffered_VBD tablets_NNS or_CC the_DT pediatric_JJ powder_NN for_IN oral_JJ solution_NN may_MD result_VB in_IN low_JJ urine_NN levels_NNS ._. Quinolones_NNP ,_, including_VBG cinoxacin_NN ,_, may_MD enhance_VB the_DT effects_NNS of_IN oral_JJ anticoagulants_NNS ,_, such_JJ as_IN warfarin_NN or_CC its_PRP$ derivatives_NNS ._. When_WRB these_DT products_NNS are_VBP administered_VBN concomitantly_RB ,_, prothrombin_NN time_NN or_CC other_JJ suitable_JJ coagulation_NN tests_NNS should_MD be_VB closely_RB monitored_VBN ._. Seizures_NNS have_VBP been_VBN reported_VBN in_IN patients_NNS taking_VBG another_DT quinolone_NN class_NN antimicrobial_JJ and_CC the_DT nonsteroidal_JJ anti-inflammatory_JJ drug_NN fenbufen_NN concurrently_RB ._. Animal_NN studies_NNS also_RB suggest_VBP an_DT increased_VBN potential_NN for_IN seizures_NNS when_WRB these_DT 2_CD drugs_NNS are_VBP given_VBN concomitantly_RB ._. Fenbufen_NNP is_VBZ not_RB approved_VBN in_IN the_DT United_NNP States_NNPS at_IN this_DT time_NN ._. Physicians_NNP are_VBP provided_VBN this_DT information_NN to_TO increase_VB awareness_NN of_IN the_DT potential_NN for_IN serious_JJ interactions_NNS when_WRB cinoxacin_NN and_CC certain_JJ nonsteroidal_JJ anti-inflammatory_JJ agents_NNS are_VBP administered_VBN concomitantly_RB ._. Elevated_JJ cyclosporine_NN serum_NN levels_NNS have_VBP been_VBN reported_VBN with_IN the_DT concomitant_JJ use_NN of_IN quinolones_NNS and_CC cyclosporine_NN ._. Some_DT quinolones_NNS ,_, including_VBG ciprofloxacin_NN ,_, have_VBP also_RB been_VBN shown_VBN to_TO interfere_VB with_IN the_DT metabolism_NN of_IN caffeine_NN ._. This_DT may_MD lead_VB to_TO reduced_VBN clearance_NN of_IN caffeine_NN and_CC a_DT prolongation_NN of_IN its_PRP$ serum_NN half-life_NN ._. Some_DT quinolones_NNS ,_, including_VBG ciprofloxacin_NN ,_, have_VBP been_VBN associated_VBN with_IN transient_JJ elevations_NNS in_IN serum_NN creatinine_NN in_IN patients_NNS receiving_VBG cyclosporine_NN concomitantly_RB ._. Glyburide_NNP :_: The_DT concomitant_JJ administration_NN of_IN ciprofloxacin_NN with_IN the_DT sulfonylurea_NN glyburide_NN has_VBZ ,_, on_IN rare_JJ occasions_NNS ,_, resulted_VBD in_IN severe_JJ hypoglycemia_NN ._. Histamine_NN H2-receptor_NN antagonists_NNS :_: Histamine_NN H2-receptor_NN antagonists_NNS appear_VBP to_TO have_VB no_DT significant_JJ effect_NN on_IN the_DT bioavailability_NN of_IN ciprofloxacin_NN ._. Methotrexate_NNP Renal_JJ tubular_JJ transport_NN of_IN methotrexate_NN may_MD be_VB inhibited_VBN by_IN concomitant_JJ administration_NN of_IN ciprofloxacin_NN ,_, potentially_RB leading_VBG to_TO increased_VBN plasma_NN levels_NNS of_IN methotrexate_NN ._. This_DT might_MD increase_VB the_DT risk_NN of_IN methotrexate_NN toxic_JJ reactions_NNS ._. Therefore_RB ,_, patients_NNS under_IN methotrexate_NN therapy_NN should_MD be_VB carefully_RB monitored_VBN when_WRB concomitant_JJ ciprofloxacin_NN therapy_NN is_VBZ indicated_VBN ._. Multivalent_JJ Cation-Containing_NNP Products_NNPS :_: Concurrent_JJ administration_NN of_IN a_DT quinolone_NN ,_, including_VBG ciprofloxacin_NN ,_, with_IN multivalent_JJ cation-containing_JJ products_NNS such_JJ as_IN magnesium_NN or_CC aluminum_NN antacids_NNS ,_, sucralfate_NN ,_, VIDEX_NNP chewable/buffered_VBD tablets_NNS or_CC pediatric_JJ powder_NN ,_, or_CC products_NNS containing_VBG calcium_NN ,_, iron_NN ,_, or_CC zinc_NN may_MD substantially_RB decrease_VB the_DT absorption_NN of_IN ciprofloxacin_NN ,_, resulting_VBG in_IN serum_NN and_CC urine_NN levels_NNS considerably_RB lower_JJR than_IN desired_VBN ._. Proquin_NNP XR_NNP should_MD be_VB administered_VBN at_IN least_JJS 4_CD hours_NNS before_IN or_CC 2_CD hours_NNS after_IN these_DT products_NNS ._. This_DT time_NN window_NN is_VBZ different_JJ than_IN for_IN other_JJ oral_JJ formulations_NNS of_IN ciprofloxacin_NN ,_, which_WDT are_VBP usually_RB administered_VBN 2_CD hours_NNS before_IN or_CC 6_CD hours_NNS after_IN antacids_NNS ._. Non-steroidal_JJ anti-inflammatory_JJ drugs_NNS -LRB-_-LRB- but_CC not_RB aspirin_NN -RRB-_-RRB- :_: These_DT drugs_NNS in_IN combination_NN with_IN very_RB high_JJ doses_NNS of_IN quinolones_NNS have_VBP been_VBN shown_VBN to_TO provoke_VB convulsions_NNS in_IN pre-clinical_JJ studies_NNS ._. Omeprazole_NNP :_: The_DT rate_NN and_CC extent_NN of_IN absorption_NN of_IN ciprofloxacin_NN was_VBD bioequivalent_JJ when_WRB Proquin_NNP XR_NNP was_VBD given_VBN alone_RB or_CC when_WRB Proquin_NNP XR_NNP was_VBD given_VBN 2_CD hours_NNS after_IN omeprazole_NN at_IN the_DT dose_NN that_WDT maximally_RB suppresses_VBZ gastric_JJ acid_NN secretion_NN ._. Omeprazole_NNP should_MD be_VB taken_VBN as_IN directed_VBN and_CC Proquin_NNP XR_NN should_MD be_VB taken_VBN with_IN a_DT main_JJ meal_NN of_IN the_DT day_NN ,_, preferably_RB the_DT evening_NN meal_NN ._. Phenytoin_NNP :_: Altered_JJ serum_NN levels_NNS of_IN phenytoin_NN -LRB-_-LRB- increased_VBN and_CC decreased_VBN -RRB-_-RRB- have_VBP been_VBN reported_VBN in_IN patients_NNS receiving_VBG concomitant_JJ ciprofloxacin_NN ._. Probenecid_NNP :_: Probenecid_NNP interferes_VBZ with_IN renal_JJ tubular_JJ secretion_NN of_IN ciprofloxacin_NN and_CC produces_VBZ an_DT increase_NN in_IN the_DT level_NN of_IN ciprofloxacin_NN in_IN serum_NN ._. Theophylline_NNP :_: As_IN with_IN some_DT other_JJ quinolones_NNS ,_, concurrent_JJ administration_NN of_IN ciprofloxacin_NN with_IN theophylline_NN may_MD lead_VB to_TO elevated_JJ serum_NN concentrations_NNS of_IN theophylline_NN and_CC prolongation_NN of_IN its_PRP$ elimination_NN half-life_NN ._. This_DT may_MD result_VB in_IN increased_VBN risk_NN of_IN theophylline-related_JJ adverse_JJ reactions_NNS ._. If_IN concomitant_JJ use_NN can_MD not_RB be_VB avoided_VBN ,_, serum_NN levels_NNS of_IN theophylline_NN should_MD be_VB monitored_VBN and_CC dosage_NN adjustments_NNS made_VBN as_IN appropriate_JJ ._. Warfarin_NNP :_: Quinolones_NNS have_VBP been_VBN reported_VBN to_TO enhance_VB the_DT effects_NNS of_IN the_DT oral_JJ anticoagulant_JJ warfarin_NN or_CC its_PRP$ derivatives_NNS ._. When_WRB these_DT products_NNS are_VBP administered_VBN concomitantly_RB ,_, prothrombin_NN time_NN or_CC other_JJ suitable_JJ coagulation_NN tests_NNS should_MD be_VB monitored_VBN ._. Cisapride_NNP is_VBZ metabolized_VBN mainly_RB via_IN the_DT cytochrome_NN P450_NN 3A4_NN enzyme_NN ._. In_IN some_DT cases_NNS where_WRB serious_JJ ventricular_JJ arrhythmias_NNS ,_, QT_NN prolongation_NN ,_, and_CC torsades_NNS de_IN pointes_NNS have_VBP occurred_VBN when_WRB cisapride_NN was_VBD taken_VBN in_IN conjunction_NN with_IN one_CD of_IN the_DT cytochrome_NN P450_NN 3A4_NN inhibitors_NNS ,_, elevated_JJ blood_NN cisapride_NN levels_NNS were_VBD noted_VBN at_IN the_DT time_NN of_IN the_DT QT_NNP prolongation_NN ._. Antibiotics_NNS :_: In_FW vitro_FW and/or_CC in_FW vivo_FW data_NNS show_VBP that_IN clarithromycin_NN ,_, erythromycin_NN ,_, and_CC troleandomycin_NN markedly_RB inhibit_VBP the_DT metabolism_NN of_IN cisapride_NN ,_, which_WDT can_MD result_VB in_IN an_DT increase_NN in_IN plasma_NN cisapride_NN levels_NNS and_CC prolongation_NN of_IN the_DT QT_NNP interval_NN on_IN the_DT ECG_NN ._. Anticholinergics_NNP :_: Concurrent_JJ administration_NN of_IN certain_JJ anticholinergic_JJ compounds_NNS ,_, such_JJ as_IN belladonna_NN alkaloids_NNS and_CC dicyclomine_NN ,_, would_MD be_VB expected_VBN to_TO compromise_VB the_DT beneficial_JJ effects_NNS of_IN cisapride_NN ._. Anticoagulants_NNS -LRB-_-LRB- Oral_JJ -RRB-_-RRB- :_: In_IN patients_NNS receiving_VBG oral_JJ anticoagulants_NNS ,_, the_DT coagulation_NN times_NNS were_VBD increased_VBN in_IN some_DT cases_NNS ._. It_PRP is_VBZ advisable_JJ to_TO check_VB coagulation_NN time_NN within_IN the_DT first_JJ few_JJ days_NNS after_IN the_DT start_NN and_CC discontinuation_NN of_IN cisapride_NN therapy_NN ,_, with_IN an_DT appropriate_JJ adjustment_NN of_IN the_DT anticoagulant_JJ dose_NN ,_, if_IN necessary_JJ ._. Antidepressants_NNS :_: In_FW vitro_FW data_NNS indicate_VBP that_IN nefazodone_NN inhibits_VBZ the_DT metabolism_NN of_IN cisapride_NN ,_, which_WDT can_MD result_VB in_IN an_DT increase_NN in_IN plasma_NN cisapride_NN levels_NNS and_CC prolongation_NN of_IN the_DT QT_NNP interval_NN on_IN the_DT ECG_NN ._. Antifungals_NNS :_: In_FW vitro_FW and/or_CC in_FW vivo_FW data_NNS indicate_VBP that_IN fluconazole_NN ,_, itraconazole_NN ,_, and_CC oral_JJ ketoconazole_NN markedly_RB inhibit_VBP the_DT metabolism_NN of_IN cisapride_NN ,_, which_WDT can_MD result_VB in_IN an_DT increase_NN in_IN plasma_NN cisapride_NN levels_NNS and_CC prolongation_NN of_IN the_DT QT_NNP interval_NN on_IN the_DT ECG_NN ._. Human_JJ pharmacokinetic_JJ data_NNS indicate_VBP that_IN oral_JJ ketoconazole_NN markedly_RB inhibits_VBZ the_DT metabolism_NN of_IN cisapride_NN ,_, resulting_VBG in_IN a_DT mean_NN eight-fold_JJ increase_NN in_IN AUC_NN of_IN cisapride_NN ._. A_DT study_NN in_IN 14_CD normal_JJ male_NN and_CC female_JJ volunteers_NNS suggests_VBZ that_IN coadministration_NN of_IN cisapride_NN and_CC ketoconazole_NN can_MD result_VB in_IN prolongation_NN of_IN the_DT QT_NNP interval_NN on_IN the_DT ECG_NN ._. H2_NN Receptor_NN Antagonists_NNS :_: Cimetidine_NN coadministration_NN leads_VBZ to_TO an_DT increased_VBN peak_NN plasma_NN concentration_NN and_CC AUC_NN of_IN cisapride_NN ,_, there_EX is_VBZ no_DT effect_NN on_IN cisapride_NN absorption_NN when_WRB it_PRP is_VBZ coadministered_VBN with_IN ranitidine_NN ._. The_DT gastrointestinal_JJ absorption_NN of_IN cimetidine_NN and_CC ranitidine_NN is_VBZ accelerated_VBN when_WRB they_PRP are_VBP coadministered_VBN with_IN cisapride_NN ._. Protease_NN Inhibitors_NNS :_: In_FW vitro_FW data_NNS indicate_VBP that_IN indinavir_NN and_CC ritonavir_NN markedly_RB inhibit_VBP the_DT metabolism_NN of_IN cisapride_NN which_WDT can_MD result_VB in_IN an_DT increase_NN in_IN plasma_NN cisapride_NN levels_NNS and_CC prolongation_NN of_IN the_DT QT_NNP interval_NN on_IN the_DT ECG_NN ._. Other_JJ :_: Coadministration_NN of_IN grapefruit_NN juice_NN with_IN cisapride_NN increases_VBZ the_DT bioavailability_NN of_IN cisapride_NN and_CC concomitant_JJ use_NN should_MD be_VB avoided_VBN ._. Cisapride_NNP should_MD not_RB be_VB used_VBN concomitantly_RB with_IN other_JJ drugs_NNS known_VBN to_TO prolong_VB the_DT QT_NNP interval_NN :_: certain_JJ antiarrhythmics_NNS ,_, including_VBG those_DT of_IN Class_NNP IA_NNP -LRB-_-LRB- such_JJ as_IN quinidine_NN and_CC procainamide_NN -RRB-_-RRB- and_CC Class_NN III_CD -LRB-_-LRB- such_JJ as_IN sotalol_NN -RRB-_-RRB- ._. tricyclic_JJ antidepressants_NNS -LRB-_-LRB- such_JJ as_IN amitriptyline_NNP -RRB-_-RRB- ._. certain_JJ tetracyclic_JJ antidepressants_NNS -LRB-_-LRB- such_JJ as_IN maprotiline_NN -RRB-_-RRB- ._. certain_JJ antipsychotic_JJ medications_NNS -LRB-_-LRB- such_JJ as_IN sertindole_NN -RRB-_-RRB- ._. astemizole_NN ,_, bepridil_NN ,_, sparfloxacin_NN ,_, and_CC terodiline_NN ._. The_DT preceding_VBG lists_NNS of_IN drugs_NNS are_VBP not_RB comprehensive_JJ ._. The_DT acceleration_NN of_IN gastric_JJ emptying_NN by_IN cisapride_NN could_MD affect_VB the_DT rate_NN of_IN absorption_NN of_IN other_JJ drugs_NNS ._. Patients_NNS receiving_VBG narrow_JJ therapeutic_JJ ratio_NN drugs_NNS or_CC other_JJ drugs_NNS that_WDT require_VBP careful_JJ titration_NN should_MD be_VB followed_VBN closely_RB ;_: ._. if_IN plasma_NN levels_NNS are_VBP being_VBG monitored_VBN ,_, they_PRP should_MD be_VB reassessed_VBN ._. Administration_NN of_IN 0.1-mg_JJ /_: kg_NN -LRB-_-LRB- 2_CD x_CC ED95_NN -RRB-_-RRB- NIMBEX_NN at_IN 10_CD %_NN or_CC 95_CD %_NN recovery_NN following_VBG an_DT intubating_VBG dose_NN of_IN succinylcholine_NN -LRB-_-LRB- 1_CD mg/kg_NN -RRB-_-RRB- produced_VBD 95_CD %_NN neuromuscular_JJ block_NN ._. The_DT time_NN to_TO onset_NN of_IN maximum_NN block_NN following_VBG NIMBEX_NNP is_VBZ approximately_RB 2_CD minutes_NNS faster_RBR with_IN prior_JJ administration_NN of_IN succinylcholine_NN ._. Prior_RB administration_NN of_IN succinylcholine_NN had_VBD no_DT effect_NN on_IN the_DT duration_NN of_IN neuromuscular_JJ block_NN following_VBG initial_JJ or_CC maintenance_NN bolus_NN doses_NNS of_IN NIMBEX_NNP ._. Infusion_NN requirements_NNS of_IN NIMBEX_NNP in_IN patients_NNS administered_VBN succinylcholine_NN prior_RB to_TO infusions_NNS of_IN NIMBEX_NNP were_VBD comparable_JJ to_TO or_CC slightly_RB greater_JJR than_IN when_WRB succinylcholine_NN was_VBD not_RB administered_VBN ._. The_DT use_NN of_IN NIMBEX_NN before_IN succinylcholine_NN to_TO attenuate_VB some_DT of_IN the_DT side_JJ effects_NNS of_IN succinylcholine_NN has_VBZ not_RB been_VBN studied_VBN ._. Although_IN not_RB studied_VBN systematically_RB in_IN clinical_JJ trials_NNS ,_, no_DT drug_NN interactions_NNS were_VBD observed_VBN when_WRB vecuronium_NN ,_, pancuronium_NN ,_, or_CC atracurium_NN were_VBD administered_VBN following_VBG varying_VBG degrees_NNS of_IN recovery_NN from_IN single_JJ doses_NNS or_CC infusions_NNS of_IN NIMBEX_NNP ._. Isoflurane_NN or_CC enflurane_NN administered_VBN with_IN nitrous_JJ oxide/oxygen_NN to_TO achieve_VB 1.25_CD MAC_NNP -LSB-_-LRB- Minimum_NNP Alveolar_JJ Concentration_NN -RSB-_-RRB- may_MD prolong_VB the_DT clinically_RB effective_JJ duration_NN of_IN action_NN of_IN initial_JJ and_CC maintenance_NN doses_NNS of_IN NIMBEX_NNP and_CC decrease_VB the_DT required_VBN infusion_NN rate_NN of_IN NIMBEX_NNP ._. The_DT magnitude_NN of_IN these_DT effects_NNS may_MD depend_VB on_IN the_DT duration_NN of_IN administration_NN of_IN the_DT volatile_JJ agents_NNS ._. Fifteen_CD to_TO 30_CD minutes_NNS of_IN exposure_NN to_TO 1.25_CD MAC_NNP isoflurane_NN or_CC enflurane_NN had_VBD minimal_JJ effects_NNS on_IN the_DT duration_NN of_IN action_NN of_IN initial_JJ doses_NNS of_IN NIMBEX_NNP and_CC therefore_RB ,_, no_DT adjustment_NN to_TO the_DT initial_JJ dose_NN should_MD be_VB necessary_JJ when_WRB NIMBEX_NNP is_VBZ administered_VBN shortly_RB after_IN initiation_NN of_IN volatile_JJ agents_NNS ._. In_IN long_JJ surgical_JJ procedures_NNS during_IN enflurane_NN or_CC isoflurane_NN anesthesia_NN ,_, less_JJR frequent_JJ maintenance_NN dosing_NN ,_, lower_JJR maintenance_NN doses_NNS ,_, or_CC reduced_VBN infusion_NN rates_NNS of_IN NIMBEX_NNP may_MD be_VB necessary_JJ ._. The_DT average_JJ infusion_NN rate_NN requirement_NN may_MD be_VB decreased_VBN by_IN as_RB much_JJ as_IN 30_CD %_NN to_TO 40_CD %_NN ._. In_IN clinical_JJ studies_NNS propofol_NN had_VBD no_DT effect_NN on_IN the_DT duration_NN of_IN action_NN or_CC dosing_NN requirements_NNS for_IN NIMBEX_NNP ._. Other_JJ drugs_NNS which_WDT may_MD enhance_VB the_DT neuromuscular_JJ blocking_VBG action_NN of_IN nondepolarizing_JJ agents_NNS such_JJ as_IN NIMBEX_NNP include_VBP certain_JJ antibiotics_NNS -LRB-_-LRB- e._FW g._FW ,_, aminoglycosides_NNS ,_, tetracyclines_NNS ,_, bacitracin_NN ,_, polymyxins_NNS ,_, lincomycin_NN ,_, clindamycin_NN ,_, colistin_NN ,_, and_CC sodium_NN colistemethate_NN -RRB-_-RRB- ,_, magnesium_NN salts_NNS ,_, lithium_NN ,_, local_JJ anesthetics_NNS ,_, procainamide_NN ,_, and_CC quinidine_NN ._. Resistance_NN to_TO the_DT neuromuscular_JJ blocking_VBG action_NN of_IN nondepolarizing_JJ neuromuscular_JJ blocking_VBG agents_NNS has_VBZ been_VBN demonstrated_VBN in_IN patients_NNS chronically_RB administered_VBN phenytoin_NN or_CC carbamazepine_NN ._. While_IN the_DT effects_NNS of_IN chronic_JJ phenytoin_NN or_CC carbamazepine_NN therapy_NN on_IN the_DT action_NN of_IN NIMBEX_NNP are_VBP unknown_JJ ,_, slightly_RB shorter_JJR durations_NNS of_IN neuromuscular_JJ block_NN may_MD be_VB anticipated_VBN and_CC infusion_NN rate_NN requirements_NNS may_MD be_VB higher_JJR ._. Drug/Laboratory_JJ Test_NN Interactions_NNS None_NN known_VBN ._. Plasma_NN levels_NNS of_IN anticonvulsant_JJ agents_NNS may_MD become_VB subtherapeutic_JJ during_IN cisplatin_NN therapy_NN ._. Central_NNP nervous_JJ system_NN depressant_NN -LRB-_-LRB- CNS_NN -RRB-_-RRB- drugs_NNS including_VBG alcohol_NN ,_, antidepressants_NNS ,_, antihistamines_NNS ,_, antipsychotics_NNS ,_, blood_NN pressure_NN medications_NNS -LRB-_-LRB- reserpine_NN ,_, methyldopa_NN ,_, beta-blockers_NNS -RRB-_-RRB- ,_, motion_NN sickness_NN medications_NNS ,_, muscle_NN relaxants_NNS ,_, narcotics_NNS ,_, sedatives_NNS ,_, sleeping_VBG pills_NNS and_CC tranquilizer_NN ._. There_EX are_VBP no_RB known_VBN drug_NN interactions_NNS with_IN LEUSTATIN_NNP Injection_NN ._. Caution_NN should_MD be_VB exercised_VBN if_IN LEUSTATIN_NNP Injection_NN is_VBZ administered_VBN before_RB ,_, after_IN ,_, or_CC in_IN conjunction_NN with_IN other_JJ drugs_NNS known_VBN to_TO cause_VB immunosuppression_NN or_CC myelosuppression_NN ._. The_DT concurrent_JJ administration_NN of_IN allopurinol_NN and_CC ampicillin_NN increases_NNS substantially_RB the_DT incidence_NN of_IN rashes_NNS in_IN patients_NNS receiving_VBG both_CC drugs_NNS as_IN compared_VBN to_TO patients_NNS receiving_VBG ampicillin_NN alone_RB ._. It_PRP is_VBZ not_RB known_VBN whether_IN this_DT potentiation_NN of_IN ampicillin_NN rashes_NNS is_VBZ due_JJ to_TO allopurinol_NN or_CC the_DT hyperuricemia_NN present_JJ in_IN these_DT patients_NNS ._. In_IN controlled_JJ clinical_JJ trials_NNS of_IN AUGMENTIN_NNP XR_NNP ,_, 22_CD patients_NNS received_VBD concomitant_JJ allopurinol_NN and_CC AUGMENTIN_NNP XR_NNP ._. No_DT rashes_NNS were_VBD reported_VBN in_IN these_DT patients_NNS ._. However_RB ,_, this_DT sample_NN size_NN is_VBZ too_RB small_JJ to_TO allow_VB for_IN any_DT conclusions_NNS to_TO be_VB drawn_VBN regarding_VBG the_DT risk_NN of_IN rashes_NNS with_IN concomitant_JJ AUGMENTIN_NNP XR_NN and_CC allopurinol_NN use_NN ._. In_IN common_JJ with_IN other_JJ broad-spectrum_JJ antibiotics_NNS ,_, AUGMENTIN_NNP XR_NNP may_MD reduce_VB the_DT efficacy_NN of_IN oral_JJ contraceptive_NN ._. Additive_JJ CNS_NN depression_NN may_MD occur_VB when_WRB antihistamines_NNS are_VBP administered_VBN concomitantly_RB with_IN other_JJ CNS_NN depressants_NNS including_VBG barbiturates_NNS ,_, tranquilizers_NNS ,_, and_CC alcohol_NN ._. Patients_NNS receiving_VBG antihistamines_NNS should_MD be_VB advised_VBN against_IN the_DT concurrent_JJ use_NN of_IN other_JJ CNS_NNS depressant_NN drugs_NNS ._. Monoamine_NN oxidase_NN -LRB-_-LRB- MAO_NN -RRB-_-RRB- inhibitors_NNS prolong_VB and_CC intensify_VB the_DT anticholinergic_JJ effects_NNS of_IN antihistamines_NNS ._. Amantadine_NNP ,_, tricyclic_JJ antidepressants_NNS ,_, and_CC MAOIs_NNS may_MD increase_VB anticholinergic_JJ effect_NN of_IN clidinium_NN ._. Clidinium_NNP may_MD decrease_VB the_DT effect_NN of_IN phenothiazines_NNS ,_, levodopa_NN ,_, and_CC ketoconazole_NN ._. Clindamycin_NNP has_VBZ been_VBN shown_VBN to_TO have_VB neuromuscular_JJ blocking_VBG properties_NNS that_WDT may_MD enhance_VB the_DT action_NN of_IN other_JJ neuromuscular_JJ blocking_VBG agents_NNS ._. Therefore_RB ,_, it_PRP should_MD be_VB used_VBN with_IN caution_NN in_IN patients_NNS receiving_VBG such_JJ agents_NNS ._. Antagonism_NN has_VBZ been_VBN demonstrated_VBN between_IN clindamycin_NN and_CC erythromycin_NN in_FW vitro_FW ._. Because_IN of_IN possible_JJ clinical_JJ significance_NN ,_, these_DT two_CD drugs_NNS should_MD not_RB be_VB administered_VBN concurrently_RB ._. Alcohol_NN -LRB-_-LRB- increases_NNS bioavailability_NN by_IN 50_CD %_NN -RRB-_-RRB- ,_, cimetidine_NN ,_, and_CC valproates_NNS ._. No_DT separate_JJ information_NN available_JJ ._. Although_IN no_DT clinical_JJ drug-drug_JJ interaction_NN studies_NNS have_VBP been_VBN conducted_VBN to_TO date_NN ,_, on_IN the_DT basis_NN of_IN the_DT in_FW vitro_FW studies_NNS ,_, cytochrome_NN p450_NN inhibitors_NNS and_CC inducers_NNS are_VBP unlikely_JJ to_TO affect_VB the_DT metabolism_NN of_IN clofarabine_NN ._. The_DT effect_NN of_IN clofarabine_NN on_IN the_DT metabolism_NN of_IN cytochrome_NN p450_NN substrates_NNS has_VBZ not_RB been_VBN studied_VBN ._. Drug/Laboratory_NNP Tests_NNP Interactions_NNS There_EX are_VBP no_DT known_JJ clinically_RB significant_JJ interactions_NNS of_IN CLOLAR_NN with_IN other_JJ medications_NNS or_CC laboratory_NN tests_NNS ._. No_DT formal_JJ drug/laboratory_JJ test_NN interaction_NN studies_NNS have_VBP been_VBN conducted_VBN with_IN CLOLAR_NN ._. Preliminary_JJ data_NNS which_WDT suggest_VBP that_IN dapsone_NN may_MD inhibit_VB the_DT anti-inflammatory_JJ activity_NN of_IN Lamprene_NNP have_VBP not_RB been_VBN confirmed_VBN ._. If_IN leprosy-associated_JJ inflammatory_JJ reactions_NNS develop_VBP in_IN patients_NNS being_VBG treated_VBN with_IN dapsone_NN and_CC clofazimine_NN ,_, it_PRP is_VBZ still_RB advisable_JJ to_TO continue_VB treatment_NN with_IN both_CC drugs_NNS ._. Caution_NN should_MD be_VB exercised_VBN when_WRB anticoagulants_NNS are_VBP given_VBN in_IN conjunction_NN with_IN Atromid-S_NN ._. Usually_RB ,_, the_DT dosage_NN of_IN the_DT anticoagulant_NN should_MD be_VB reduced_VBN by_IN one-half_NN -LRB-_-LRB- depending_VBG on_IN the_DT individual_JJ case_NN -RRB-_-RRB- to_TO maintain_VB the_DT prothrombin_NN time_NN at_IN the_DT desired_VBN level_NN to_TO prevent_VB bleeding_JJ complications_NNS ._. Frequent_JJ prothrombin_NN determinations_NNS are_VBP advisable_JJ until_IN it_PRP has_VBZ been_VBN determined_VBN definitely_RB that_IN the_DT prothrombin_NN level_NN has_VBZ been_VBN stabilized_VBN ._. Atromid-S_NN may_MD displace_VB acidic_JJ drugs_NNS such_JJ as_IN phenytoin_NN or_CC tolbutamide_NN from_IN their_PRP$ binding_NN sites_NNS ._. Caution_NN should_MD be_VB exercised_VBN when_WRB treating_VBG patients_NNS with_IN either_DT of_IN these_DT drugs_NNS or_CC other_JJ highly_RB protein-bound_JJ drugs_NNS and_CC Atromid-S_NN ._. The_DT hypoglycemic_JJ effect_NN of_IN tolbutamide_NN has_VBZ been_VBN reported_VBN to_TO increase_VB when_WRB Atromid-S_NN is_VBZ given_VBN concurrently_RB ._. Fulminant_JJ rhabdomyolysis_NN has_VBZ been_VBN seen_VBN as_IN early_JJ as_IN three_CD weeks_NNS after_IN initiation_NN of_IN combined_JJ therapy_NN with_IN another_DT fibrate_NN and_CC lovastatin_NN but_CC may_MD be_VB seen_VBN after_IN several_JJ months_NNS ._. For_IN these_DT reasons_NNS ,_, it_PRP is_VBZ felt_VBN that_IN ,_, in_IN most_JJS subjects_NNS who_WP have_VBP had_VBD an_DT unsatisfactory_JJ lipid_NN response_NN to_TO either_CC drug_NN alone_RB ,_, the_DT possible_JJ benefits_NNS of_IN combined_JJ therapy_NN with_IN lovastatin_NN and_CC a_DT fibrate_NN do_VBP not_RB outweigh_VB the_DT risks_NNS of_IN severe_JJ myopathy_NN ,_, rhabdomyolysis_NN ,_, and_CC acute_JJ renal_JJ failure_NN ._. While_IN it_PRP is_VBZ not_RB known_VBN whether_IN this_DT interaction_NN occurs_VBZ with_IN fibrates_NNS other_JJ than_IN gemfibrozil_NN ,_, myopathy_NN and_CC rhabdomyolysis_NN have_VBP occasionally_RB been_VBN associated_VBN with_IN the_DT use_NN of_IN fibrates_NNS alone_RB ,_, including_VBG clofibrate_NN ._. Therefore_RB ,_, the_DT combined_VBN use_NN of_IN lovastatin_NN with_IN fibrates_NNS should_MD generally_RB be_VB avoided_VBN ._. Drug_NN interactions_NNS with_IN clomiphene_NN citrate_NN tablets_NNS USP_NNP have_VBP not_RB been_VBN documented_VBN ._. The_DT risks_NNS of_IN using_VBG Anafranil_NNP in_IN combination_NN with_IN other_JJ drugs_NNS have_VBP not_RB been_VBN systematically_RB evaluated_VBN ._. Given_VBN the_DT primary_JJ CNS_NN effects_NNS of_IN Anafranil_NNP ,_, caution_NN is_VBZ advised_VBN in_IN using_VBG it_PRP concomitantly_RB with_IN other_JJ CNS-active_JJ drugs_NNS ._. Anafranil_NNP should_MD not_RB be_VB used_VBN with_IN MAO_NN inhibitors_NNS ._. Close_JJ supervision_NN and_CC careful_JJ adjustment_NN of_IN dosage_NN are_VBP required_VBN when_WRB Anafranil_NNP is_VBZ administered_VBN with_IN anticholinergic_JJ or_CC sympathomimetic_JJ drugs_NNS ._. Several_JJ tricyclic_JJ antidepressants_NNS have_VBP been_VBN reported_VBN to_TO block_VB the_DT pharmacologic_JJ effects_NNS of_IN guanethidine_NN ,_, clonidine_NN ,_, or_CC similar_JJ agents_NNS ,_, and_CC such_PDT an_DT effect_NN may_MD be_VB anticipated_VBN with_IN CMI_NN because_IN of_IN its_PRP$ structural_JJ similarity_NN to_TO other_JJ tricyclic_JJ antidepressants_NNS ._. The_DT plasma_NN concentration_NN of_IN CMI_NNP has_VBZ been_VBN reported_VBN to_TO be_VB increased_VBN by_IN the_DT concomitant_JJ administration_NN of_IN haloperidol_NN ._. plasma_NN levels_NNS of_IN several_JJ closely_RB related_JJ tricyclic_JJ antidepressants_NNS have_VBP been_VBN reported_VBN to_TO be_VB increased_VBN by_IN the_DT concomitant_JJ administration_NN of_IN methylphenidate_NN or_CC hepatic_JJ enzyme_NN inhibitors_NNS -LRB-_-LRB- e.g._FW ,_, cimetidine_NN ,_, fluoxetine_NN -RRB-_-RRB- and_CC decreased_VBN by_IN the_DT concomitant_JJ administration_NN of_IN hepatic_JJ enzyme_NN inducers_NNS -LRB-_-LRB- e.g._FW ,_, barbiturates_NNS ,_, phenytoin_NN -RRB-_-RRB- ,_, and_CC such_PDT an_DT effect_NN may_MD be_VB anticipated_VBN with_IN CMI_NNP as_RB well_RB ._. Administration_NN of_IN CMI_NNP has_VBZ been_VBN reported_VBN to_TO increase_VB the_DT plasma_NN levels_NNS of_IN phenobarbital_NN ,_, if_IN given_VBN concomitantly_RB ._. Drugs_NNS Metabolized_VBN by_IN P450_NN 2D6_NN :_: The_DT biochemical_JJ activity_NN of_IN the_DT drug_NN metabolizing_VBG isozyme_NN cytochrome_NN P450_NN 2D6_NN -LRB-_-LRB- debrisoquin_NN hydroxylase_NN -RRB-_-RRB- is_VBZ reduced_VBN in_IN a_DT subset_NN of_IN the_DT aucasian_JJ population_NN -LRB-_-LRB- about_IN 7_CD %_NN -10_CD %_NN of_IN Caucasians_NNPS are_VBP so-called_JJ poor_JJ metabolizers_NNS -RRB-_-RRB- ;_: ._. reliable_JJ estimates_NNS of_IN the_DT prevalence_NN of_IN reduced_VBN P450_NN 2D6_NN isozyme_NN activity_NN among_IN Asian_JJ ,_, African_JJ and_CC other_JJ populations_NNS are_VBP not_RB yet_RB available_JJ ._. Poor_NNP metabolizers_NNS have_VBP higher_JJR than_IN expected_VBN lasma_NN concentrations_NNS of_IN tricyclic_JJ antidepressants_NNS -LRB-_-LRB- TCAs_NNS -RRB-_-RRB- when_WRB given_VBN usual_JJ doses_NNS ._. Depending_VBG on_IN the_DT fraction_NN of_IN drug_NN metabolized_VBN by_IN P450_NN 2D6_NN ,_, the_DT increase_NN in_IN plasma_NN concentration_NN may_MD be_VB small_JJ ,_, or_CC quite_RB large_JJ -LRB-_-LRB- 8_CD fold_JJ increase_NN in_IN plasma_NN AUC_NN of_IN the_DT TCA_NNP -RRB-_-RRB- ._. In_IN addition_NN ,_, certain_JJ drugs_NNS inhibit_VBP the_DT activity_NN of_IN this_DT isozyme_NN and_CC make_VB normal_JJ metabolizers_NNS resemble_VBP poor_JJ metabolizers_NNS ._. An_DT individual_NN who_WP is_VBZ stable_JJ on_IN a_DT given_VBN dose_NN of_IN TCAmay_NN become_VBP abruptly_RB toxic_JJ when_WRB given_VBN one_CD of_IN these_DT inhibiting_VBG drugs_NNS as_IN concomitant_JJ therapy_NN ._. The_DT drugs_NNS that_WDT inhibit_VBP cytochrome_NN P450_NN 2D6_NN include_VBP some_DT that_WDT are_VBP not_RB metabolized_VBN by_IN the_DT enzyme_NN -LRB-_-LRB- quinidine_NN ._. cimetidine_NN -RRB-_-RRB- and_CC many_JJ that_WDT are_VBP substrates_NNS for_IN P450_NN 2D6_NN -LRB-_-LRB- many_JJ other_JJ antidepressants_NNS ,_, phenothiazines_NNS ,_, and_CC the_DT Type_NN 1C_NN antiarrhythmics_NNS propafenone_NN and_CC flecainide_NN -RRB-_-RRB- ._. While_IN all_PDT the_DT selective_JJ serotonin_NN reuptake_NN inhibitors_NNS -LRB-_-LRB- SSRIs_NNS -RRB-_-RRB- ,_, e.g._FW ,_, fluoxetine_NN ,_, sertraline_NN ,_, paroxetine_NN ,_, and_CC fluvoxamine_NN ,_, inhibit_VBP P450_NN 2D6_NN ,_, they_PRP may_MD vary_VB in_IN the_DT extent_NN of_IN inhibition_NN ._. Fluvoxamine_NNP has_VBZ also_RB been_VBN shown_VBN to_TO inhibit_VB P450_NN 1A2_NN ,_, an_DT isoform_NN also_RB involved_VBN in_IN TCAmetabolism_NN ._. The_DT extent_NN to_TO which_WDT SSRI-TCAinteractions_NNS may_MD pose_VB clinical_JJ problems_NNS will_MD depend_VB on_IN the_DT degree_NN of_IN inhibition_NN and_CC the_DT pharmacokinetics_NNS of_IN the_DT SSRI_NNP involved_VBN ._. Nevertheless_RB ,_, caution_NN is_VBZ indicated_VBN in_IN the_DT co-administration_NN of_IN TCAs_NNS with_IN any_DT of_IN the_DT SSRIs_NNS and_CC also_RB in_IN switching_NN from_IN one_CD class_NN to_TO the_DT other_JJ ._. Of_IN particular_JJ importance_NN ,_, sufficient_JJ time_NN must_MD elapse_VB before_IN initiating_VBG TCAtreatment_NN in_IN a_DT patient_NN being_VBG withdrawn_VBN from_IN fluoxetine_NN ,_, given_VBN the_DT long_JJ half-life_NN of_IN the_DT parent_NN and_CC active_JJ metabolite_NN -LRB-_-LRB- at_IN least_JJS 5_CD weeks_NNS may_MD be_VB necessary_JJ -RRB-_-RRB- ._. Concomitant_JJ use_NN of_IN agents_NNS in_IN the_DT tricyclic_JJ antidepressant_JJ class_NN -LRB-_-LRB- which_WDT includes_VBZ Anafranil_NNP -RRB-_-RRB- with_IN drugs_NNS that_WDT can_MD inhibit_VB cytochrome_NN P450_NN 2D6_NN may_MD require_VB lower_JJR doses_NNS than_IN usually_RB prescribed_VBN for_IN either_CC the_DT tricyclic_JJ antidepressant_JJ agent_NN or_CC the_DT other_JJ drug_NN ._. Furthermore_RB ,_, whenever_WRB one_CD of_IN these_DT drugs_NNS is_VBZ withdrawn_VBN from_IN co-therapy_JJ ,_, an_DT increased_VBN dose_NN of_IN tricyclic_JJ antidepressant_JJ agent_NN may_MD be_VB required_VBN ._. It_PRP is_VBZ desirable_JJ to_TO monitor_VB TCAplasma_NN levels_NNS whenever_WRB an_DT agent_NN of_IN the_DT tricyclic_JJ antidepressant_JJ class_NN including_VBG Anafranil_NNP is_VBZ going_VBG to_TO be_VB co-administered_VBN with_IN another_DT drug_NN known_VBN to_TO be_VB an_DT inhibitor_NN of_IN P450_NN 2D6_NN -LRB-_-LRB- and/or_CC P450_NN 1A2_NN -RRB-_-RRB- ._. Because_IN Anafranil_NNP is_VBZ highly_RB bound_VBN to_TO serum_NN protein_NN ,_, the_DT administration_NN of_IN Anafranil_NNP to_TO patients_NNS taking_VBG other_JJ drugs_NNS that_WDT are_VBP highly_RB bound_VBN to_TO protein_NN -LRB-_-LRB- e.g._FW ,_, warfarin_NN ,_, digoxin_NN -RRB-_-RRB- may_MD cause_VB an_DT increase_NN in_IN plasma_NN concentrations_NNS of_IN these_DT drugs_NNS ,_, potentially_RB resulting_VBG in_IN adverse_JJ effects_NNS ._. Conversely_RB ,_, adverse_JJ effects_NNS may_MD result_VB from_IN displacement_NN of_IN protein-bound_JJ Anafranil_NNP by_IN other_JJ highly_RB bound_VBN drugs_NNS ._. Effect_NN of_IN Clonazepam_NNP on_IN the_DT Pharmacokinetics_NNS of_IN Other_JJ Drugs_NNS :_: Clonazepam_NN does_VBZ not_RB appear_VB to_TO alter_VB the_DT pharmacokinetics_NNS of_IN phenytoin_NN ,_, carbamazepine_NN ,_, or_CC phenobarbital_NN ._. The_DT effect_NN of_IN clonazepam_NN on_IN the_DT metabolism_NN of_IN other_JJ drugs_NNS has_VBZ not_RB been_VBN investigated_VBN ._. Effect_NN of_IN Other_JJ Drugs_NNS on_IN the_DT Pharmacokinetics_NNS of_IN Clonazepam_NNP :_: Literature_NNP reports_NNS suggest_VBP that_IN ranitidine_NN ,_, an_DT agent_NN that_WDT decreases_VBZ stomach_NN acidity_NN ,_, does_VBZ not_RB greatly_RB alter_VB clonazepam_NN pharmacokinetics_NNS ._. In_IN a_DT study_NN in_IN which_WDT the_DT 2_CD mg_NN clonazepam_NN orally_RB disintegrating_VBG tablet_NN was_VBD administered_VBN with_IN and_CC without_IN propantheline_NN -LRB-_-LRB- an_DT anticholinergic_JJ agent_NN with_IN multiple_JJ effects_NNS on_IN the_DT GI_NN tract_NN -RRB-_-RRB- to_TO healthy_JJ volunteers_NNS ,_, the_DT AUC_NN of_IN clonazepam_NN was_VBD 10_CD %_NN lower_JJR and_CC the_DT Cmax_NN of_IN clonazepam_NN was_VBD 20_CD %_NN lower_JJR when_WRB the_DT orally_RB disintegrating_VBG tablet_NN was_VBD given_VBN with_IN propantheline_NN compared_VBN to_TO when_WRB it_PRP was_VBD given_VBN alone_RB ._. Fluoxetine_NN does_VBZ not_RB affect_VB the_DT pharmacokinetics_NNS of_IN clonazepam_NN ._. Cytochrome_NN P-450_NN inducers_NNS ,_, such_JJ as_IN phenytoin_NN ,_, carbamazepine_NN and_CC phenobarbital_NN ,_, induce_VBP clonazepam_NN metabolism_NN ,_, causing_VBG an_DT approximately_RB 30_CD %_NN decrease_NN in_IN plasma_NN clonazepam_NN levels_NNS ._. Although_IN clinical_JJ studies_NNS have_VBP not_RB been_VBN performed_VBN ,_, based_VBN on_IN the_DT involvement_NN of_IN the_DT cytochrome_NN P-450_NN 3A_NN family_NN in_IN clonazepam_NN metabolism_NN ,_, inhibitors_NNS of_IN this_DT enzyme_NN system_NN ,_, notably_RB oral_JJ antifungal_JJ agents_NNS ,_, should_MD be_VB used_VBN cautiously_RB in_IN patients_NNS receiving_VBG clonazepam_NN ._. Pharmacodynamic_JJ Interactions_NNS :_: The_DT CNS-depressant_JJ action_NN of_IN the_DT benzodiazepine_NN class_NN of_IN drugs_NNS may_MD be_VB potentiated_VBN by_IN alcohol_NN ,_, narcotics_NNS ,_, barbiturates_NNS ,_, nonbarbiturate_JJ hypnotics_NNS ,_, antianxiety_JJ agents_NNS ,_, the_DT phenothiazines_NNS ,_, thioxanthene_NN and_CC butyrophenone_NN classes_NNS of_IN antipsychotic_JJ agents_NNS ,_, monoamine_NN oxidase_NN inhibitors_NNS and_CC the_DT tricyclic_JJ antidepressants_NNS ,_, and_CC by_IN other_JJ anticonvulsant_JJ drugs_NNS ._. Tablet_NNP If_IN a_DT patient_NN receiving_VBG clonidine_NN hydrochloride_NN is_VBZ also_RB taking_VBG tricyclic_JJ antidepressants_NNS ,_, the_DT effect_NN of_IN clonidine_NN may_MD be_VB reduced_VBN ,_, thus_RB necessitating_VBG an_DT increase_NN in_IN dosage_NN ._. Clonidine_NN hydrochloride_NN may_MD enhance_VB the_DT CNS-depressive_JJ effects_NNS of_IN alcohol_NN ,_, barbiturates_NNS or_CC other_JJ sedatives_NNS ._. Amitriptyline_NNP in_IN combination_NN with_IN clonidine_NN enhances_VBZ the_DT manifestation_NN of_IN corneal_NN lesions_NNS in_IN rats_NNS Epidural_JJ Injection_NN Clonidine_NN may_MD potentiate_VB the_DT CNS-depressive_JJ effect_NN of_IN alcohol_NN ,_, barbiturates_NNS or_CC other_JJ sedating_VBG drugs_NNS ._. Narcotic_JJ analgesics_NNS may_MD potentiate_VB the_DT hypotensive_JJ effects_NNS of_IN clonidine_NN ._. Tricyclic_JJ antidepressants_NNS may_MD antagonize_VB the_DT hypotensive_JJ effects_NNS of_IN clonidine_NN ._. The_DT effects_NNS of_IN tricyclic_JJ antidepressants_NNS on_IN clonidines_NNS analgesic_JJ actions_NNS are_VBP not_RB known_VBN ._. Beta_NN blockers_NNS may_MD exacerbate_VB the_DT hypertensive_JJ response_NN seen_VBN with_IN clonidine_NN withdrawl_NN ._. Also_RB ,_, due_JJ to_TO the_DT potential_NN for_IN additive_JJ effects_NNS such_JJ as_IN bradycardia_NN and_CC AV_NN block_NN ,_, caution_NN is_VBZ warranted_VBN in_IN patients_NNS receiving_VBG clonidine_NN with_IN agents_NNS known_VBN to_TO affect_VB sinus_NN node_NN function_NN or_CC AV_NN nodal_JJ conduction_NN -LRB-_-LRB- e.g._FW ,_, digitalis_NN ,_, calcium_NN channel_NN blockers_NNS ,_, and_CC beta-blockers_NNS ._. There_EX is_VBZ one_CD reported_VBD case_NN of_IN a_DT patient_NN with_IN acute_JJ delirium_NN associated_VBN with_IN the_DT simultaneous_JJ use_NN of_IN fluphenazine_NN and_CC oral_JJ clonidine_NN ._. Symptoms_NNS resolved_VBN when_WRB clonidine_NN was_VBD withdrawn_VBN and_CC recurred_VBN when_WRB the_DT patient_NN was_VBD rechallenged_VBN with_IN clonidine_NN ._. Epidural_JJ clonidine_NN may_MD prolong_VB the_DT duration_NN of_IN pharmacologic_JJ effects_NNS of_IN epidural_JJ local_JJ anesthetics_NNS ,_, including_VBG both_DT sensory_JJ and_CC motor_NN blockade_NN ._. Aspirin_NN ,_, warfarin_NN ,_, heparin_NN ,_, NSAID_NN ._. 
If_IN TRANXENE_NN is_VBZ to_TO be_VB combined_VBN with_IN other_JJ drugs_NNS acting_VBG on_IN the_DT central_JJ nervous_JJ system_NN ,_, careful_JJ consideration_NN should_MD be_VB given_VBN to_TO the_DT pharmacology_NN of_IN the_DT agents_NNS to_TO be_VB employed_VBN ._. Animal_NN experience_NN indicates_VBZ that_IN clorazepate_NN dipotassium_NN prolongs_VBZ the_DT sleeping_VBG time_NN after_IN hexobarbital_JJ or_CC after_IN ethyl_NN alcohol_NN ,_, increases_VBZ the_DT inhibitory_JJ effects_NNS of_IN chlorpromazine_NN ,_, but_CC does_VBZ not_RB exhibit_VB monoamine_NN oxidase_NN inhibition_NN ._. Clinical_JJ studies_NNS have_VBP shown_VBN increased_VBN sedation_NN with_IN concurrent_JJ hypnotic_JJ medications_NNS ._. The_DT actions_NNS of_IN the_DT benzodiazepines_NNS may_MD be_VB potentiated_VBN by_IN barbiturates_NNS ,_, narcotics_NNS ,_, phenothiazines_NNS ,_, monoamine_NN oxidase_NN inhibitors_NNS or_CC other_JJ antidepressants_NNS ._. If_IN TRANXENE_NN tablets_NNS are_VBP used_VBN to_TO treat_VB anxiety_NN associated_VBN with_IN somatic_JJ disease_NN states_NNS ,_, careful_JJ attention_NN must_MD be_VB paid_VBN to_TO possible_JJ drug_NN interaction_NN with_IN concomitant_JJ medication_NN ._. In_IN bioavailability_NN studies_NNS with_IN normal_JJ subjects_NNS ,_, the_DT concurrent_JJ administration_NN of_IN antacids_NNS at_IN therapeutic_JJ levels_NNS did_VBD not_RB significantly_RB influence_VB the_DT bioavailability_NN of_IN TRANXENE_NNP tablets_NNS ._. The_DT risks_NNS of_IN using_VBG Clozapine_NNP in_IN combination_NN with_IN other_JJ drugs_NNS have_VBP not_RB been_VBN systematically_RB evaluated_VBN ._. Pharmacodynamic-related_JJ Interactions_NNS :_: The_DT mechanism_NN of_IN Clozapine_NN induced_VBD agranulocytosis_NN is_VBZ unknown_JJ ._. nonetheless_RB ,_, the_DT possibility_NN that_IN causative_JJ factors_NNS may_MD interact_VB synergistically_RB to_TO increase_VB the_DT risk_NN and/or_CC severity_NN of_IN bone_NN marrow_NN suppression_NN warrants_NNS consideration_NN ._. Therefore_RB ,_, Clozapine_NNP should_MD not_RB be_VB used_VBN with_IN other_JJ agents_NNS having_VBG a_DT well-known_JJ potential_NN to_TO suppress_VB bone_NN marrow_NN function_NN ._. Given_VBN the_DT primary_JJ CNS_NN effects_NNS of_IN Clozapine_NNP ,_, caution_NN is_VBZ advised_VBN in_IN using_VBG it_PRP concomitantly_RB with_IN other_JJ CNS-active_JJ drugs_NNS or_CC alcohol_NN ._. Orthostatic_JJ hypotension_NN in_IN patients_NNS taking_VBG clozapine_NN can_MD ,_, in_IN rare_JJ cases_NNS -LRB-_-LRB- approximately_RB 1_CD case_NN per_IN 3,000_CD patients_NNS -RRB-_-RRB- ,_, be_VB accompanied_VBN by_IN profound_JJ collapse_NN and_CC respiratory_JJ and/or_CC cardiac_JJ arrest_NN ._. Some_DT of_IN the_DT cases_NNS of_IN collapse/respiratory_JJ arrest/cardiac_JJ arrest_NN during_IN initial_JJ treatment_NN occurred_VBD in_IN patients_NNS who_WP were_VBD being_VBG administered_VBN benzodiazepines_NNS ._. similar_JJ events_NNS have_VBP been_VBN reported_VBN in_IN patients_NNS taking_VBG other_JJ psychotropic_JJ drugs_NNS or_CC even_RB Clozapine_NNP by_IN itself_PRP ._. Although_IN it_PRP has_VBZ not_RB been_VBN established_VBN that_IN there_EX is_VBZ an_DT interaction_NN between_IN Clozapine_NNP and_CC benzodiazepines_NNS or_CC other_JJ psychotropics_NNS ,_, caution_NN is_VBZ advised_VBN when_WRB clozapine_NN is_VBZ initiated_VBN in_IN patients_NNS taking_VBG a_DT benzodiazepine_NN or_CC any_DT other_JJ psychotropic_JJ drug_NN ._. Clozapine_NNP may_MD potentiate_VB the_DT hypotensive_JJ effects_NNS of_IN antihypertensive_JJ drugs_NNS and_CC the_DT anticholinergic_JJ effects_NNS of_IN atropine-type_JJ drugs_NNS ._. The_DT administration_NN of_IN epinephrine_NN should_MD be_VB avoided_VBN in_IN the_DT treatment_NN of_IN drug_NN induced_VBD hypotension_NN because_IN of_IN a_DT possible_JJ reverse_JJ epinephrine_NN effect_NN ._. Pharmacokinetic-related_JJ Interactions_NNS :_: Clozapine_NNP is_VBZ a_DT substrate_NN for_IN many_JJ CYP_NN 450_CD isozymes_NNS ,_, in_IN particular_JJ 1A2_NN ,_, 2D6_NN ,_, and_CC 3A4_NN ._. The_DT risk_NN of_IN metabolic_JJ interactions_NNS caused_VBN by_IN an_DT effect_NN on_IN an_DT individual_JJ isoform_NN is_VBZ therefore_RB minimized_VBN ._. Nevertheless_RB ,_, caution_NN should_MD be_VB used_VBN in_IN patients_NNS receiving_VBG concomitant_JJ treatment_NN with_IN other_JJ drugs_NNS that_WDT are_VBP either_DT inhibitors_NNS or_CC inducers_NNS of_IN these_DT enzymes_NNS ._. Concomitant_JJ administration_NN of_IN drugs_NNS known_VBN to_TO induce_VB cytochrome_NN P450_NN enzymes_NNS may_MD decrease_VB the_DT plasma_NN levels_NNS of_IN clozapine_NN ._. Phenytoin_NNP ,_, nicotine_NN ,_, and_CC rifampin_NN may_MD decrease_VB Clozapine_NNP plasma_NN levels_NNS ,_, resulting_VBG in_IN a_DT decrease_NN in_IN effectiveness_NN of_IN a_DT previously_RB effective_JJ Clozapine_NNP dose_NN ._. Concomitant_JJ administration_NN of_IN drugs_NNS known_VBN to_TO inhibit_VB the_DT activity_NN of_IN cytochrome_NN P450_NN isozymes_NNS may_MD increase_VB the_DT plasma_NN levels_NNS of_IN clozapine_NN ._. Cimetidine_NNP ,_, caffeine_NN ,_, and_CC erythromycin_NN may_MD increase_VB plasma_NN levels_NNS of_IN Clozapine_NNP ,_, potentially_RB resulting_VBG in_IN adverse_JJ effects_NNS ._. Although_IN concomitant_JJ use_NN of_IN Clozapine_NNP and_CC carbamazepine_NN is_VBZ not_RB recommended_VBN ,_, it_PRP should_MD be_VB noted_VBN that_IN discontinuation_NN of_IN concomitant_JJ carbamazepine_NN administration_NN may_MD result_VB in_IN an_DT increase_NN in_IN Clozapine_NNP plasma_NN levels_NNS ._. In_IN a_DT study_NN of_IN schizophrenic_JJ patients_NNS who_WP received_VBD clozapine_NN under_IN steady_JJ state_NN conditions_NNS ,_, fluvoxamine_NN or_CC paroxetine_NN was_VBD added_VBN in_IN 16_CD and_CC 14_CD patients_NNS ,_, respectively_RB ._. After_IN 14_CD days_NNS of_IN co-administration_NN ,_, mean_VB trough_NN concentrations_NNS of_IN clozapine_NN and_CC its_PRP$ metabolites_NNS ,_, N-desmethylclozapine_NN and_CC clozapine_NN N-oxide_NN ,_, were_VBD elevated_JJ with_IN fluvoxamine_NN by_IN about_IN three-fold_JJ compared_VBN to_TO baseline_NN concentrations_NNS ._. Paroxetine_NNP produced_VBD only_RB minor_JJ changes_NNS in_IN the_DT levels_NNS of_IN clozapine_NN and_CC its_PRP$ metabolites_NNS ._. However_RB ,_, other_JJ published_VBN reports_NNS describe_VBP modest_JJ elevations_NNS -LRB-_-LRB- less_JJR than_IN two-fold_JJ -RRB-_-RRB- of_IN clozapine_NN and_CC metabolite_NN concentrations_NNS when_WRB clozapine_NN was_VBD taken_VBN with_IN paroxetine_NN ,_, fluoxetine_NN ,_, and_CC sertraline_NN ._. Therefore_RB ,_, such_JJ combined_JJ treatment_NN should_MD be_VB approached_VBN with_IN caution_NN and_CC patients_NNS should_MD be_VB monitored_VBN closely_RB when_WRB Clozapine_NNP is_VBZ combined_VBN with_IN these_DT drugs_NNS ,_, particularly_RB with_IN fluvoxamine_NN ._. A_DT reduced_VBN Clozapine_NNP dose_NN should_MD be_VB considered_VBN ._. A_DT subset_NN -LRB-_-LRB- 3_CD %_NN -10_CD %_NN -RRB-_-RRB- of_IN the_DT population_NN has_VBZ reduced_VBN activity_NN of_IN certain_JJ drug_NN metabolizing_VBG enzymes_NNS such_JJ as_IN the_DT cytochrome_NN P450_NN isozyme_NN P450_NN 2D6_NN ._. Such_JJ individuals_NNS are_VBP referred_VBN to_TO as_IN poor_JJ metabolizers_NNS of_IN drugs_NNS such_JJ as_IN debrisoquin_NN ,_, dextromethorphan_NN ,_, the_DT tricyclic_JJ antidepressants_NNS ,_, and_CC clozapine_NN ._. These_DT individuals_NNS may_MD develop_VB higher_JJR than_IN expected_VBN plasma_NN concentrations_NNS of_IN clozapine_NN when_WRB given_VBN usual_JJ doses_NNS ._. In_IN addition_NN ,_, certain_JJ drugs_NNS that_WDT are_VBP metabolized_VBN by_IN this_DT isozyme_NN ,_, including_VBG many_JJ antidepressants_NNS -LRB-_-LRB- clozapine_NN ,_, selective_JJ serotonin_NN reuptake_NN inhibitors_NNS ,_, and_CC others_NNS -RRB-_-RRB- ,_, may_MD inhibit_VB the_DT activity_NN of_IN this_DT isozyme_NN ,_, and_CC thus_RB may_MD make_VB normal_JJ metabolizers_NNS resemble_VBP poor_JJ metabolizers_NNS with_IN regard_NN to_TO concomitant_JJ therapy_NN with_IN other_JJ drugs_NNS metabolized_VBN by_IN this_DT enzyme_NN system_NN ,_, leading_VBG to_TO drug_NN interaction_NN ._. Concomitant_JJ use_NN of_IN clozapine_NN with_IN other_JJ drugs_NNS metabolized_VBN by_IN cytochrome_NN P450_NN 2D6_NN may_MD require_VB lower_JJR doses_NNS than_IN usually_RB prescribed_VBN for_IN either_CC clozapine_NN or_CC the_DT other_JJ drug_NN ._. Therefore_RB ,_, co-administration_NN of_IN clozapine_NN with_IN other_JJ drugs_NNS that_WDT are_VBP metabolized_VBN by_IN this_DT isozyme_NN ,_, including_VBG antidepressants_NNS ,_, phenothiazines_NNS ,_, carbamazepine_NN ,_, and_CC Type_NN 1C_NN antiarrhythmics_NNS -LRB-_-LRB- e.g._FW ,_, propafenone_NN ,_, flecainide_NN and_CC encainide_NN -RRB-_-RRB- ,_, or_CC that_IN inhibit_VBP this_DT enzyme_NN -LRB-_-LRB- e.g._FW ,_, quinidine_NN -RRB-_-RRB- ,_, should_MD be_VB approached_VBN with_IN caution_NN ._. The_DT risk_NN of_IN a_DT potential_JJ interaction_NN between_IN NovoSeven_NNP and_CC coagulation_NN factor_NN concentrates_VBZ has_VBZ not_RB been_VBN adequately_RB evaluated_VBN in_IN preclinical_JJ or_CC clinical_JJ studies_NNS ._. Simultaneous_JJ use_NN of_IN activated_VBN prothrombin_NN complex_NN concentrates_VBZ or_CC prothrombin_NN complex_NN concentrates_VBZ should_MD be_VB avoided_VBN ._. Although_IN the_DT specific_JJ drug_NN interaction_NN was_VBD not_RB studied_VBN in_IN a_DT clinical_JJ trial_NN ,_, there_EX have_VBP been_VBN more_JJR than_IN 50_CD episodes_NNS of_IN concomitant_JJ use_NN of_IN antifibrinolytic_JJ therapies_NNS -LRB-_-LRB- i.e._FW ,_, tranexamic_JJ acid_NN ,_, aminocaproic_JJ acid_NN -RRB-_-RRB- and_CC NovoSeven_NNP ._. NovoSeven_NNP should_MD not_RB be_VB mixed_VBN with_IN infusion_NN solutions_NNS until_IN clinical_JJ data_NNS are_VBP available_JJ to_TO direct_VB this_DT use_NN ._. Codeine_NNP in_IN combination_NN with_IN other_JJ narcotic_JJ analgesics_NNS ,_, general_JJ anesthetics_NNS ,_, phenothiazines_NNS ,_, tranquilizers_NNS ,_, sedative-hypnotics_NNS ,_, or_CC other_JJ CNS_NN depressants_NNS -LRB-_-LRB- including_VBG alcohol_NN -RRB-_-RRB- has_VBZ additive_JJ depressant_NN effects_NNS ._. When_WRB s.c._NN combination_NN therapy_NN is_VBZ contemplated_VBN ,_, the_DT dosage_NN of_IN one_CD or_CC both_DT agents_NNS should_MD be_VB reduced_VBN ._. Colchicine_NNP is_VBZ inhibited_VBN by_IN acidifying_VBG agents_NNS ._. The_DT action_NN of_IN colchicine_NN is_VBZ potentiated_VBN by_IN alkalinizing_VBG agents_NNS ._. Colchicine_NNP may_MD increase_VB sensitivity_NN to_TO the_DT CNS_NN depressants_NNS ._. Response_NN to_TO sympathomimetic_JJ agents_NNS may_MD be_VB enhanced_VBN by_IN colchicine_NN ._. WelChol_NNP has_VBZ been_VBN studied_VBN in_IN several_JJ human_JJ drug_NN interaction_NN studies_NNS in_IN which_WDT it_PRP was_VBD administered_VBN with_IN a_DT meal_NN and_CC the_DT test_NN drug_NN ._. WelChol_NNP was_VBD found_VBN to_TO have_VB no_DT significant_JJ effect_NN on_IN the_DT bioavailability_NN of_IN digoxin_NN ,_, lovastatin_NN ,_, metoprolol_NN ,_, quinidine_NN ,_, valproic_JJ acid_NN ,_, and_CC warfarin_NN ._. WelChol_NNP decreased_VBD the_DT Cmax_NN and_CC AUC_NN of_IN sustained-release_JJ verapamil_NN -LRB-_-LRB- Calan_JJ SR_NN -RRB-_-RRB- by_IN approximately_RB 31_CD %_NN and_CC 11_CD %_NN ,_, respectively_RB ._. Since_IN there_EX is_VBZ a_DT high_JJ degree_NN of_IN variability_NN in_IN the_DT bioavailability_NN of_IN verapamil_NN ,_, the_DT clinical_JJ significance_NN of_IN this_DT finding_NN is_VBZ unclear_JJ ._. INCREASED_VBN PHENYTOIN_NNP LEVELS_NNP SHOULD_MD BE_VB TREATED_VBN WITH_IN APPROPRIATE_JJ DOSAGE_NN ADJUSTMENT_NN ._. It_PRP may_MD be_VB necessary_JJ to_TO adjust_VB the_DT dosage_NN of_IN oral_JJ anticoagulants_NNS upon_IN beginning_VBG or_CC stopping_VBG disulfiram_NN ._. since_IN disulfiram_NN may_MD prolong_VB prothrombin_NN time_NN ._. Patients_NNS taking_VBG isoniazid_NN when_WRB disulfiram_NN is_VBZ given_VBN should_MD be_VB observed_VBN for_IN the_DT appearance_NN of_IN unsteady_JJ gait_NN or_CC marked_JJ changes_NNS in_IN mental_JJ status_NN ._. the_DT disulfiram_NN should_MD be_VB discontinued_VBN if_IN such_JJ signs_NNS appear_VBP ._. In_IN rats_NNS ,_, simultaneous_JJ ingestion_NN of_IN disulfiram_NN and_CC nitrite_NN in_IN the_DT diet_NN for_IN 78_CD weeks_NNS has_VBZ been_VBN reported_VBN to_TO cause_VB tumors_NNS ,_, and_CC it_PRP has_VBZ been_VBN suggested_VBN that_IN disulfiram_NN may_MD react_VB with_IN nitrites_NNS in_IN the_DT rat_NN stomach_NN to_TO form_VB a_DT nitrosamine_NN ,_, which_WDT is_VBZ tumorigenic_JJ ._. Disulfiram_NNP alone_RB in_IN the_DT rat_NN s_VBZ diet_NN did_VBD not_RB lead_VB to_TO such_JJ tumors_NNS ._. The_DT relevance_NN of_IN this_DT finding_NN to_TO humans_NNS is_VBZ not_RB known_VBN at_IN this_DT time_NN ._. Animal_NN studies_NNS indicate_VBP that_IN dobutamine_NN may_MD be_VB ineffective_JJ if_IN the_DT patient_NN has_VBZ recently_RB received_VBN a_DT b-blocking_NN drug_NN ._. In_IN such_PDT a_DT case_NN ,_, the_DT peripheral_JJ vascular_JJ resistance_NN may_MD increase_VB ._. Preliminary_JJ studies_NNS indicate_VBP that_IN the_DT concomitant_JJ use_NN of_IN dobutamine_NN and_CC nitroprusside_JJ results_NNS in_IN a_DT higher_JJR cardiac_JJ output_NN and_CC ,_, usually_RB ,_, a_DT lower_JJR pulmonary_JJ wedge_NN pressure_NN than_IN when_WRB either_CC drug_NN is_VBZ used_VBN alone_RB ._. There_EX was_VBD no_DT evidence_NN of_IN drug_NN interactions_NNS in_IN clinical_JJ studies_NNS in_IN which_WDT dobutamine_NN was_VBD administered_VBN concurrently_RB with_IN other_JJ drugs_NNS ,_, including_VBG digitalis_NN preparations_NNS ,_, furosemide_NN ,_, spironolactone_NN ,_, lidocaine_NN ,_, glyceryl_NN trinitrate_NN ,_, isosorbide_NN dinitrate_NN ,_, morphine_NN ,_, atropine_NN ,_, heparin_NN ,_, protamine_NN ,_, potassium_NN chloride_NN ,_, folic_JJ acid_NN ,_, and_CC acetaminophen_NN ._. There_EX have_VBP been_VBN no_DT formal_JJ clinical_JJ studies_NNS to_TO evaluate_VB the_DT drug_NN interactions_NNS of_IN TAXOTERE_NN with_IN other_JJ medications_NNS ._. In_FW vitro_FW studies_NNS have_VBP shown_VBN that_IN the_DT metabolism_NN of_IN docetaxel_NN may_MD be_VB modified_VBN by_IN the_DT concomitant_JJ administration_NN of_IN compounds_NNS that_WDT induce_VBP ,_, inhibit_VBP ,_, or_CC are_VBP metabolized_VBN by_IN cytochrome_NN P450_NN 3A4_NN ,_, such_JJ as_IN cyclosporine_NN ,_, terfenadine_NN ,_, ketoconazole_NN ,_, erythromycin_NN ,_, and_CC troleandomycin_NN ._. Caution_NN should_MD be_VB exercised_VBN with_IN these_DT drugs_NNS when_WRB treating_VBG patients_NNS receiving_VBG TAXOTERE_NN as_IN there_EX is_VBZ a_DT potential_NN for_IN a_DT significant_JJ interaction_NN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS None_NN known_VBN ._. Drug-Drug_NNP Interactions_NNS Cimetidine_NNP :_: Concomitant_JJ use_NN of_IN cimetidine_NN is_VBZ contraindicated_VBN ._. Cimetidine_NN at_IN 400_CD mg_NN BID_NNP -LRB-_-LRB- the_DT usual_JJ prescription_NN dose_NN -RRB-_-RRB- co-administered_JJ with_IN TIKOSYN_NN -LRB-_-LRB- 500_CD mcg_NN BID_NNP -RRB-_-RRB- for_IN 7_CD days_NNS has_VBZ been_VBN shown_VBN to_TO increase_VB dofetilide_NN plasma_NN levels_NNS by_IN 58_CD %_NN ._. Cimetidine_NN at_IN doses_NNS of_IN 100_CD mg_NN BID_NNP -LRB-_-LRB- OTC_NNP dose_NN -RRB-_-RRB- resulted_VBD in_IN a_DT 13_CD %_NN increase_NN in_IN dofetilide_NN plasma_NN levels_NNS -LRB-_-LRB- 500_CD mcg_NN single_JJ dose_NN -RRB-_-RRB- ._. No_DT studies_NNS have_VBP been_VBN conducted_VBN at_IN intermediate_JJ doses_NNS of_IN cimetidine_NN ._. If_IN a_DT patient_NN requires_VBZ TIKOSYN_NNP and_CC anti-ulcer_JJ therapy_NN ,_, it_PRP is_VBZ suggested_VBN that_IN omeprazole_NN ,_, ranitidine_NN ,_, or_CC antacids_NNS -LRB-_-LRB- aluminum_NN and_CC magnesium_NN hydroxides_NNS -RRB-_-RRB- be_VB used_VBN as_IN alternatives_NNS to_TO cimetidine_NN ,_, as_IN these_DT agents_NNS have_VBP no_DT effect_NN on_IN the_DT pharmacokinetic_JJ profile_NN of_IN TIKOSYN_NNP ._. Verapamil_NNP :_: Concomitant_JJ use_NN of_IN verapamil_NN is_VBZ contraindicated_VBN ._. Co-administration_NN of_IN TIKOSYN_NN with_IN verapamil_NN resulted_VBD in_IN increases_NNS in_IN dofetilide_NN peak_NN plasma_NN levels_NNS of_IN 42_CD %_NN ,_, although_IN overall_JJ exposure_NN to_TO dofetilide_NN was_VBD not_RB significantly_RB increased_VBN ._. In_IN an_DT analysis_NN of_IN the_DT supraventricular_JJ arrhythmia_NN and_CC DIAMOND_NN patient_NN populations_NNS ,_, the_DT concomitant_JJ administration_NN of_IN verapamil_NN with_IN dofetilide_NN was_VBD associated_VBN with_IN a_DT higher_JJR occurrence_NN of_IN torsade_FW de_FW pointes_FW ._. Ketoconazole_NN :_: Concomitant_JJ use_NN of_IN ketoconazole_NN is_VBZ contraindicated_VBN ._. Ketoconazole_NN at_IN 400_CD mg_NN daily_JJ -LRB-_-LRB- the_DT maximum_NN approved_VBD prescription_NN dose_NN -RRB-_-RRB- co-administered_JJ with_IN TIKOSYN_NN -LRB-_-LRB- 500_CD mcg_NN BID_NNP -RRB-_-RRB- for_IN 7_CD days_NNS has_VBZ been_VBN shown_VBN to_TO increase_VB dofetilide_NN Cmax_NN by_IN 53_CD %_NN in_IN males_NNS and_CC 97_CD %_NN in_IN females_NNS ,_, and_CC AUC_NN by_IN 41_CD %_NN in_IN males_NNS and_CC 69_CD %_NN in_IN females_NNS ._. Trimethoprim_NNP Alone_RB or_CC in_IN Combination_NN with_IN Sulfamethoxazole_NNP :_: Concomitant_JJ use_NN of_IN trimethoprim_NN alone_RB or_CC in_IN combination_NN with_IN sulfamethoxazole_NN is_VBZ contraindicated_VBN ._. Hydrochlorothiazide_NN -LRB-_-LRB- HCTZ_NN -RRB-_-RRB- Alone_RB or_CC in_IN Combination_NN with_IN Triamterene_NN :_: Concomitant_JJ use_NN of_IN HCTZ_NN alone_RB or_CC in_IN combination_NN with_IN triamterene_NN is_VBZ contraindicated_VBN ._. HCTZ_NN 50_CD mg_NN QD_NN or_CC HCTZ/triamterene_NN 50/100_CD mg_NN QD_NN was_VBD co-administered_VBN with_IN TIKOSYN_NN -LRB-_-LRB- 500_CD mcg_NN BID_NNP -RRB-_-RRB- for_IN 5_CD days_NNS -LRB-_-LRB- following_VBG 2_CD days_NNS of_IN diuretic_JJ use_NN at_IN half_NN dose_NN -RRB-_-RRB- ._. In_IN patients_NNS receiving_VBG HCTZ_NN alone_RB ,_, dofetilide_NN AUC_NN increased_VBN by_IN 27_CD %_NN and_CC Cmax_NN by_IN 21_CD %_NN ._. However_RB ,_, the_DT pharmacodynamic_JJ effect_NN increased_VBN by_IN 197_CD %_NN -LRB-_-LRB- QTc_NN increase_NN over_IN time_NN -RRB-_-RRB- and_CC by_IN 95_CD %_NN -LRB-_-LRB- maximum_NN QTc_NN increase_NN -RRB-_-RRB- ._. However_RB ,_, the_DT pharmacodynamic_JJ effect_NN increased_VBN by_IN 190_CD %_NN -LRB-_-LRB- QTc_NN increase_NN over_IN time_NN -RRB-_-RRB- and_CC by_IN 84_CD %_NN -LRB-_-LRB- Maximum_NNP QTc_NNP increase_NN -RRB-_-RRB- ._. The_DT pharmacodynamic_JJ effects_NNS can_MD be_VB explained_VBN by_IN a_DT combination_NN of_IN the_DT increase_NN in_IN dofetilide_NN exposure_NN and_CC the_DT reductions_NNS in_IN serum_NN potassium_NN ._. In_IN the_DT DIAMOND_NN trials_NNS ,_, 1252_CD patients_NNS were_VBD treated_VBN with_IN TIKOSYN_NN and_CC diuretics_NNS concomitantly_RB of_IN whom_WP 493_CD died_VBD compared_VBN to_TO 508_CD deaths_NNS among_IN the_DT 1248_CD patients_NNS receiving_VBG placebo_NN and_CC diuretics_NNS ._. Of_IN the_DT 229_CD patients_NNS who_WP had_VBD potassium_NN depleting_VBG diuretics_NNS added_VBD to_TO their_PRP$ concomitant_JJ medications_NNS in_IN the_DT DIAMOND_NN trials_NNS ,_, the_DT patients_NNS on_IN TIKOSYN_NNP had_VBD a_DT non-significantly_JJ reduced_VBN relative_JJ risk_NN for_IN death_NN of_IN 0.68_CD -LRB-_-LRB- 95_CD %_NN CI_NN 0.376_CD ,_, 1.230_CD -RRB-_-RRB- ._. Potential_JJ Drug_NN Interactions_NNS Dofetilide_NNP is_VBZ eliminated_VBN in_IN the_DT kidney_NN by_IN cationic_JJ secretion_NN ._. Inhibitors_NNS of_IN renal_JJ cationic_JJ secretion_NN are_VBP contraindicated_VBN with_IN TIKOSYN_NN ._. In_IN addition_NN ,_, drugs_NNS that_WDT are_VBP actively_RB secreted_VBN via_IN this_DT route_NN -LRB-_-LRB- e.g._FW ,_, triamterene_NN ,_, metformin_NN and_CC amiloride_NN -RRB-_-RRB- should_MD be_VB co-administered_VBN with_IN care_NN as_IN they_PRP might_MD increase_VB dofetilide_NN levels_NNS ._. Dofetilide_NNP is_VBZ metabolized_VBN to_TO a_DT small_JJ extent_NN by_IN the_DT CYP3A4_NN isoenzyme_NN of_IN the_DT cytochrome_NN P450_NN system_NN ._. Inhibitors_NNS of_IN the_DT CYP3A4_NN isoenzyme_NN could_MD increase_VB systemic_JJ dofetilide_NN exposure_NN ._. Inhibitors_NNS of_IN this_DT isoenzyme_NN -LRB-_-LRB- e.g._FW ,_, macrolide_NN antibiotics_NNS ,_, azole_JJ antifungal_JJ agents_NNS ,_, protease_NN inhibitors_NNS ,_, serotonin_NN reuptake_NN inhibitors_NNS ,_, amiodarone_NN ,_, cannabinoids_NNS ,_, diltiazem_NN ,_, grapefruit_NN juice_NN ,_, nefazadone_NN ,_, norfloxacin_NN ,_, quinine_NN ,_, zafirlukast_NN -RRB-_-RRB- should_MD be_VB cautiously_RB coadministered_VBN with_IN TIKOSYN_NN as_IN they_PRP can_MD potentially_RB increase_VB dofetilide_NN levels_NNS ._. Dofetilide_NNP is_VBZ not_RB an_DT inhibitor_NN of_IN CYP3A4_NN nor_CC of_IN other_JJ cytochrome_NN P450_NN isoenzymes_NNS -LRB-_-LRB- e.g._FW ,_, CYP2C9_NN ,_, CYP2D6_NN -RRB-_-RRB- and_CC is_VBZ not_RB expected_VBN to_TO increase_VB levels_NNS of_IN drugs_NNS metabolized_VBN by_IN CYP3A4_NN ._. Other_JJ Drug_NN Interaction_NN Information_NN Digoxin_NNP :_: Studies_NNS in_IN healthy_JJ volunteers_NNS have_VBP shown_VBN that_IN TIKOSYN_NN does_VBZ not_RB affect_VB the_DT pharmacokinetics_NNS of_IN digoxin_NN ._. In_IN patients_NNS ,_, the_DT concomitant_JJ administration_NN of_IN digoxin_NN with_IN dofetilide_NN was_VBD associated_VBN with_IN a_DT higher_JJR occurrence_NN of_IN torsade_FW de_FW pointes_FW ._. It_PRP is_VBZ not_RB clear_JJ whether_IN this_DT represents_VBZ an_DT interaction_NN with_IN TIKOSYN_NN or_CC the_DT presence_NN of_IN more_RBR severe_JJ structural_JJ heart_NN disease_NN in_IN patients_NNS on_IN digoxin_NN ._. structural_JJ heart_NN disease_NN is_VBZ a_DT known_JJ risk_NN factor_NN for_IN arrhythmia_NN ._. No_DT increase_NN in_IN mortality_NN was_VBD observed_VBN in_IN patients_NNS taking_VBG digoxin_NN as_IN concomitant_JJ medication_NN ._. Other_JJ Drugs_NNS :_: In_IN healthy_JJ volunteers_NNS ,_, amlodipine_NN ,_, phenytoin_NN ,_, glyburide_NN ,_, ranitidine_NN ,_, omeprazole_NN ,_, hormone_NN replacement_NN therapy_NN -LRB-_-LRB- a_DT combination_NN of_IN conjugated_VBN estrogens_NNS and_CC medroxyprogesterone_NN -RRB-_-RRB- ,_, antacid_NN -LRB-_-LRB- aluminum_NN and_CC magnesium_NN hydroxides_NNS -RRB-_-RRB- and_CC theophylline_NN did_VBD not_RB affect_VB the_DT pharmacokinetics_NNS of_IN TIKOSYN_NN ._. In_IN addition_NN ,_, studies_NNS in_IN healthy_JJ volunteers_NNS have_VBP shown_VBN that_IN TIKOSYN_NN does_VBZ not_RB affect_VB the_DT pharmacokinetics_NNS or_CC pharmacodynamics_NNS of_IN warfarin_NN ,_, or_CC the_DT pharmacokinetics_NNS of_IN propranolol_NN -LRB-_-LRB- 40_CD mg_NN twice_RB daily_RB -RRB-_-RRB- ,_, phenytoin_NN ,_, theophylline_NN ,_, or_CC oral_JJ contraceptives_NNS ._. Population_NNP pharmacokinetic_JJ analyses_NNS were_VBD conducted_VBN on_IN plasma_NN concentration_NN data_NNS from_IN 1445_CD patients_NNS in_IN clinical_JJ trials_NNS to_TO examine_VB the_DT effects_NNS of_IN concomitant_JJ medications_NNS on_IN clearance_NN or_CC volume_NN of_IN distribution_NN of_IN dofetilide_NN ._. Concomitant_JJ medications_NNS were_VBD grouped_VBN as_IN ACE_NN inhibitors_NNS ,_, oral_JJ anticoagulants_NNS ,_, calcium_NN channel_NN blockers_NNS ,_, beta_NN blockers_NNS ,_, cardiac_JJ glycosides_NNS ,_, inducers_NNS of_IN CYP3A4_NN ,_, substrates_NNS and_CC inhibitors_NNS of_IN CYP3A4_NN ,_, substrates_NNS and_CC inhibitors_NNS of_IN P-glycoprotein_NN ,_, nitrates_NNS ,_, sulphonylureas_NNS ,_, loop_NN diuretics_NNS ,_, potassium_NN sparing_VBG diuretics_NNS ,_, thiazide_JJ diuretics_NNS ,_, substrates_NNS and_CC inhibitors_NNS of_IN tubular_JJ organic_JJ cation_NN transport_NN ,_, and_CC QTc-prolonging_JJ drugs_NNS ._. Differences_NNS in_IN clearance_NN between_IN patients_NNS on_IN these_DT medications_NNS -LRB-_-LRB- at_IN any_DT occasion_NN in_IN the_DT study_NN -RRB-_-RRB- and_CC those_DT off_IN medications_NNS varied_VBD between_IN -16_CD %_NN and_CC +3_CD %_NN ._. The_DT mean_NN clearances_NNS of_IN dofetilide_NN were_VBD 16_CD %_NN and_CC 15_CD %_NN lower_JJR in_IN patients_NNS on_IN thiazide_JJ diuretics_NNS and_CC inhibitors_NNS of_IN tubular_JJ organic_JJ cation_NN transport_NN ,_, respectively_RB ._. The_DT potential_NN for_IN clinically_RB significant_JJ drug-drug_JJ interactions_NNS posed_VBN by_IN dolasetron_NN and_CC hydrodolasetron_NN appears_VBZ to_TO be_VB low_JJ for_IN drugs_NNS commonly_RB used_VBN in_IN chemotherapy_NN or_CC surgery_NN ,_, because_IN hydrodolasetron_NN is_VBZ eliminated_VBN by_IN multiple_JJ routes_NNS ._. Blood_NN levels_NNS of_IN hydrodolasetron_NN increased_VBD 24_CD %_NN when_WRB dolasetron_NN was_VBD coadministered_VBN with_IN cimetidine_NN -LRB-_-LRB- nonselective_JJ inhibitor_NN of_IN cytochrome_NN P-450_NN -RRB-_-RRB- for_IN 7_CD days_NNS ,_, and_CC decreased_VBD 28_CD %_NN with_IN coadministration_NN of_IN rifampin_NN -LRB-_-LRB- potent_JJ inducer_NN of_IN cytochrome_NN P-450_NN -RRB-_-RRB- for_IN 7_CD days_NNS ._. Dolasetron_NNP has_VBZ been_VBN safely_RB coadministered_VBN with_IN drugs_NNS used_VBN in_IN chemotherapy_NN and_CC surgery_NN ._. This_DT observed_VBN increase_NN in_IN the_DT bioavailability_NN of_IN fexofenadine_NN may_MD be_VB due_JJ to_TO transport-related_JJ effects_NNS ,_, such_JJ as_IN p-glycoprotein_NN ._. in_FW vivo_FW animal_NN studies_NNS also_RB suggest_VBP that_IN in_IN addition_NN to_TO enhancing_VBG absorption_NN ,_, ketoconazole_NN decreases_VBZ fexofenadine_NN gastrointestinal_JJ secretion_NN ,_, while_IN erythromycin_NN may_MD also_RB decrease_VB biliary_JJ excretion_NN ._. Drug_NN Interactions_NNS with_IN Antacids_NNPS Administration_NNP of_IN 120_CD mg_NN of_IN fexofenadine_NN hydrochloride_NN -LRB-_-LRB- 2_CD x_CC 60_CD mg_NN capsule_NN -RRB-_-RRB- within_IN 15_CD minutes_NNS of_IN an_DT aluminum_NN and_CC magnesium_NN containing_VBG antacid_NN -LRB-_-LRB- Maalox_NNP -RRB-_-RRB- decreased_VBD fexofenadine_NN AUC_NN by_IN 41_CD %_NN and_CC cmax_NN by_IN 43_CD %_NN ._. ALLEGRA_NNP should_MD not_RB be_VB taken_VBN closely_RB in_IN time_NN with_IN aluminum_NN and_CC magnesium_NN containing_VBG antacids_NNS ._. Interactions_NNS with_IN Fruit_NNP Juices_NNP Fruit_NNP juices_NNS such_JJ as_IN grapefruit_NN ,_, orange_NN and_CC apple_NN may_MD reduce_VB the_DT bioavailability_NN and_CC exposure_NN of_IN fexofenadine_NN ._. This_DT is_VBZ based_VBN on_IN the_DT results_NNS from_IN 3_CD clinical_JJ studies_NNS using_VBG histamine_NN induced_VBD skin_NN wheals_NNS and_CC flares_NNS coupled_VBN with_IN population_NN pharmacokinetic_JJ analysis_NN ._. The_DT size_NN of_IN wheal_NN and_CC flare_NN were_VBD significantly_RB larger_JJR when_WRB fexofenadine_NN hydrochloride_NN was_VBD administered_VBN with_IN either_CC grapefruit_NN or_CC orange_JJ juices_NNS compared_VBN to_TO water_NN ._. Based_VBN on_IN the_DT literature_NN reports_NNS ,_, the_DT same_JJ effects_NNS may_MD be_VB extrapolated_VBN to_TO other_JJ fruit_NN juices_NNS such_JJ as_IN apple_NN juice_NN ._. The_DT clinical_JJ significance_NN of_IN these_DT observations_NNS is_VBZ unknown_JJ ._. In_IN addition_NN ,_, based_VBN on_IN the_DT population_NN pharmacokinetics_NNS analysis_NN of_IN the_DT combined_JJ data_NNS from_IN grapefruit_NN and_CC orange_JJ juices_NNS studies_NNS with_IN the_DT data_NNS from_IN a_DT bioequivalence_NN study_NN ,_, the_DT bioavailability_NN of_IN fexofenadine_NN was_VBD reduced_VBN by_IN 36_CD %_NN ._. Therefore_RB ,_, to_TO maximize_VB the_DT effects_NNS of_IN fexofenadine_NN ,_, it_PRP is_VBZ recommended_VBN that_IN ALLEGRA_NNP should_MD be_VB taken_VBN with_IN wate_NN ._. Drug_NN interactions_NNS between_IN NEUPOGEN_NNP and_CC other_JJ drugs_NNS have_VBP not_RB been_VBN fully_RB evaluated_VBN ._. Drugs_NNS which_WDT may_MD potentiate_VB the_DT release_NN of_IN neutrophils_NNS ,_, such_JJ as_IN lithium_NN ,_, should_MD be_VB used_VBN with_IN caution_NN ._. No_DT drug_NN interactions_NNS of_IN clinical_JJ importance_NN have_VBP been_VBN identified_VBN ._. Finasteride_NN does_VBZ not_RB appear_VB to_TO affect_VB the_DT cytochrome_NN P450-linked_JJ drug-metabolizing_JJ enzyme_NN system_NN ._. Compounds_NNS that_WDT have_VBP been_VBN tested_VBN in_IN man_NN include_VBP antipyrine_NN ,_, digoxin_NN ,_, propranolol_NN ,_, theophylline_NN ,_, and_CC warfarin_NN and_CC no_DT clinically_RB meaningful_JJ interactions_NNS were_VBD found_VBN ._. Other_JJ concomitant_JJ therapy_NN Although_IN specific_JJ interaction_NN studies_NNS were_VBD not_RB performed_VBN ,_, finasteride_NN doses_NNS of_IN 1_CD mg_NN or_CC more_JJR were_VBD concomitantly_RB used_VBN in_IN clinical_JJ studies_NNS with_IN acetaminophen_NN ,_, acetylsalicylic_JJ acid_NN ,_, a-blockers_NNS ,_, analgesics_NNS ,_, angiotensin-converting_JJ enzyme_NN -LRB-_-LRB- ACE_NN -RRB-_-RRB- inhibitors_NNS ,_, anticonvulsants_NNS ,_, benzodiazepines_NNS ,_, beta_NN blockers_NNS ,_, calcium-channel_JJ blockers_NNS ,_, cardiac_JJ nitrates_NNS ,_, diuretics_NNS ,_, H2_NN antagonists_NNS ,_, HMG-CoA_NN reductase_NN inhibitors_NNS ,_, prostaglandin_NN synthetase_NN inhibitors_NNS -LRB-_-LRB- also_RB referred_VBN to_TO as_IN NSAIDs_NNS -RRB-_-RRB- ,_, and_CC quinolone_NN anti-infectives_NNS without_IN evidence_NN of_IN clinically_RB significant_JJ adverse_JJ interactions_NNS ._. Drug/Laboratory_JJ Test_NN Interactions_NNS Finasteride_NNP had_VBD no_DT effect_NN on_IN circulating_VBG levels_NNS of_IN cortisol_NN ,_, thyroid-stimulating_JJ hormone_NN ,_, or_CC thyroxine_NN ,_, nor_CC did_VBD it_PRP affect_VB the_DT plasma_NN lipid_NN profile_NN -LRB-_-LRB- e.g._FW ,_, total_JJ cholesterol_NN ,_, low-density_JJ lipoproteins_NNS ,_, high-density_JJ lipoproteins_NNS and_CC triglycerides_NNS -RRB-_-RRB- or_CC bone_NN mineral_NN density_NN ._. In_IN studies_NNS with_IN finasteride_NN ,_, no_DT clinically_RB meaningful_JJ changes_NNS in_IN luteinizing_VBG hormone_NN -LRB-_-LRB- LH_NN -RRB-_-RRB- ,_, follicle-stimulating_JJ hormone_NN -LRB-_-LRB- FSH_NN -RRB-_-RRB- or_CC prolactin_NN were_VBD detected_VBN ._. In_IN healthy_JJ volunteers_NNS ,_, treatment_NN with_IN finasteride_NN did_VBD not_RB alter_VB the_DT response_NN of_IN LH_NN and_CC FSH_NN to_TO gonadotropin-releasing_NN hormone_NN indicating_VBG that_IN the_DT hypothalamic-pituitary-testicular_JJ axis_NN was_VBD not_RB affected_VBN ._. In_IN clinical_JJ studies_NNS with_IN PROPECIA_NN -LRB-_-LRB- finasteride_NN ,_, 1_CD mg_NN -RRB-_-RRB- in_IN men_NNS 18-41_CD years_NNS of_IN age_NN ,_, the_DT mean_JJ value_NN of_IN serum_NN prostate-specific_JJ antigen_NN -LRB-_-LRB- PSA_NN -RRB-_-RRB- decreased_VBD from_IN 0.7_CD ng/mL_NN at_IN baseline_NN to_TO 0.5_CD ng/mL_NN at_IN Month_NNP 12_CD ._. Further_RB ,_, in_IN clinical_JJ studies_NNS with_IN PROSCAR_NN -LRB-_-LRB- finasteride_NN ,_, 5_CD mg_NN -RRB-_-RRB- when_WRB used_VBN in_IN older_JJR men_NNS who_WP have_VBP benign_JJ prostatic_JJ hyperplasia_NN -LRB-_-LRB- BPH_NNP -RRB-_-RRB- ,_, PSA_NN levels_NNS are_VBP decreased_VBN by_IN approximately_RB 50_CD %_NN ._. These_DT findings_NNS should_MD be_VB taken_VBN into_IN account_NN for_IN proper_JJ interpretation_NN of_IN serum_NN PSA_NN when_WRB evaluating_VBG men_NNS treated_VBN with_IN finasteride_NN ._. Drug_NN Interactions_NNS ._. TAMBOCOR_NN has_VBZ been_VBN administered_VBN to_TO patients_NNS receiving_VBG digitalis_NN preparations_NNS or_CC beta-adrenergic_JJ blocking_VBG agents_NNS without_IN adverse_JJ effects_NNS ._. During_IN administration_NN of_IN multiple_JJ oral_JJ doses_NNS of_IN TAMBOCOR_NN to_TO healthy_JJ subjects_NNS stabilized_VBD on_IN a_DT maintenance_NN dose_NN of_IN digoxin_NN ,_, a_DT 13_CD %_NN -19_CD %_NN increase_NN in_IN plasma_NN digoxin_NN levels_NNS occurred_VBD at_IN six_CD hours_NNS postdose_NN ._. In_IN a_DT study_NN involving_VBG healthy_JJ subjects_NNS receiving_VBG TAMBOCOR_NN and_CC propranolol_NN concurrently_RB ,_, plasma_NN flecainide_NN levels_NNS were_VBD increased_VBN about_RB 20_CD %_NN and_CC propranolol_NN levels_NNS were_VBD increased_VBN about_IN 30_CD %_NN compared_VBN to_TO control_VB values_NNS ._. In_IN this_DT formal_JJ interaction_NN study_NN ,_, TAMBOCOR_NN and_CC propranolol_NN were_VBD each_DT found_VBN to_TO have_VB negative_JJ inotropic_JJ effects_NNS ._. when_WRB the_DT drugs_NNS were_VBD administered_VBN together_RB ,_, the_DT effects_NNS were_VBD additive_JJ ._. The_DT effects_NNS of_IN concomitant_JJ administration_NN of_IN TAMBOCOR_NN and_CC propranolol_NN on_IN the_DT PR_NN interval_NN were_VBD less_JJR than_IN additive_JJ ._. In_IN TAMBOCOR_NN clinical_JJ trials_NNS ,_, patients_NNS who_WP were_VBD receiving_VBG beta_NN blockers_NNS concurrently_RB did_VBD not_RB experience_VB an_DT increased_VBN incidence_NN of_IN side_JJ effects_NNS ._. Nevertheless_RB ,_, the_DT possibility_NN of_IN additive_JJ negative_JJ inotropic_JJ effects_NNS of_IN beta_NN blockers_NNS and_CC flecainide_NN should_MD be_VB recognized_VBN ._. Flecainide_NNP is_VBZ not_RB extensively_RB bound_VBN to_TO plasma_NN proteins_NNS ._. In_FW vitro_FW studies_NNS with_IN several_JJ drugs_NNS which_WDT may_MD be_VB administered_VBN concomitantly_RB showed_VBD that_IN the_DT extent_NN of_IN flecainide_NN binding_NN to_TO human_JJ plasma_NN proteins_NNS is_VBZ either_CC unchanged_JJ or_CC only_RB slightly_RB less_RBR ._. Consequently_RB ,_, interactions_NNS with_IN other_JJ drugs_NNS which_WDT are_VBP highly_RB protein_NN bound_VBD -LRB-_-LRB- e.g._FW ,_, anticoagulants_NNS -RRB-_-RRB- would_MD not_RB be_VB expected_VBN ._. TAMBOCOR_NN has_VBZ been_VBN used_VBN in_IN a_DT large_JJ number_NN of_IN patients_NNS receiving_VBG diuretics_NNS without_IN apparent_JJ interaction_NN ._. Limited_JJ data_NNS in_IN patients_NNS receiving_VBG known_JJ enzyme_NN inducers_NNS -LRB-_-LRB- phenytoin_NN ,_, phenobarbital_NN ,_, carbamazepine_NN -RRB-_-RRB- indicate_VBP only_RB a_DT 30_CD %_NN increase_NN in_IN the_DT rate_NN of_IN flecainide_NN elimination_NN ._. In_IN healthy_JJ subjects_NNS receiving_VBG cimetidine_NN -LRB-_-LRB- 1_CD gm_NN daily_JJ -RRB-_-RRB- for_IN one_CD week_NN ,_, plasma_NN flecainide_NN levels_NNS increased_VBN by_IN about_IN 30_CD %_NN and_CC half-life_NN increased_VBN by_IN about_RB 10_CD %_NN ._. When_WRB amiodarone_NN is_VBZ added_VBN to_TO flecainide_NN therapy_NN ,_, plasma_NN flecainide_NN levels_NNS may_MD increase_VB two-fold_RB or_CC more_RBR in_IN some_DT patients_NNS ,_, if_IN flecainide_NN dosage_NN is_VBZ not_RB reduced_VBN ._. Drugs_NNS that_WDT inhibit_VBP cytochrome_NN P450IID6_NN ,_, such_JJ as_IN quinidine_NN ,_, might_MD increase_VB the_DT plasma_NN concentrations_NNS of_IN flecainide_NN in_IN patients_NNS that_WDT are_VBP on_IN chronic_JJ flecainide_NN therapy_NN ._. especially_RB if_IN these_DT patients_NNS are_VBP extensive_JJ metabolizers_NNS ._. There_EX has_VBZ been_VBN little_JJ experience_NN with_IN the_DT coadministration_NN of_IN TAMBOCOR_NN and_CC either_CC disopyramide_NN or_CC verapamil_NN ._. Because_IN both_DT of_IN these_DT drugs_NNS have_VBP negative_JJ inotropic_JJ properties_NNS and_CC the_DT effects_NNS of_IN coadministration_NN with_IN TAMBOCOR_NN are_VBP unknown_JJ ,_, neither_CC disopyramide_NN nor_CC verapamil_NN should_MD be_VB administered_VBN concurrently_RB with_IN TAMBOCOR_NN unless_IN ,_, in_IN the_DT judgment_NN of_IN the_DT physician_NN ,_, the_DT benefits_NNS of_IN this_DT combination_NN outweigh_VBP the_DT risks_NNS ._. There_EX has_VBZ been_VBN too_RB little_JJ experience_NN with_IN the_DT coadministration_NN of_IN TAMBOCOR_NN with_IN nifedipine_NN or_CC diltiazem_NN to_TO recommend_VB concomitant_JJ use_NN ._. Combination_NN Therapy_NN :_: Any_DT form_NN of_IN therapy_NN which_WDT adds_VBZ to_TO the_DT stress_NN of_IN the_DT patient_NN ,_, interferes_VBZ with_IN nutrition_NN or_CC depresses_VBZ bone_NN marrow_NN function_NN will_MD increase_VB the_DT toxicity_NN of_IN Floxuridine_NN ._. Cytosine_NN arabinoside_NN ,_, a_DT cytostatic_JJ agent_NN ,_, has_VBZ been_VBN reported_VBN to_TO inactivate_VB the_DT antifungal_JJ activity_NN of_IN flucytosine_NN by_IN competitive_JJ inhibition_NN ._. Drugs_NNS which_WDT impair_VBP glomerular_JJ filtration_NN may_MD prolong_VB the_DT biological_JJ half-life_NN of_IN flucytosine_NN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS :_: Measurement_NN of_IN serum_NN creatinine_NN levels_NNS should_MD be_VB determined_VBN by_IN the_DT Jaffe_NNP reaction_NN ,_, since_IN Ancobon_NNP does_VBZ not_RB interfere_VB with_IN the_DT determination_NN of_IN creatinine_NN values_NNS by_IN this_DT method_NN ._. Most_JJS automated_JJ equipment_NN for_IN measurement_NN of_IN creatinine_NN makes_VBZ use_NN of_IN the_DT Jaffe_NNP reaction_NN ._. The_DT use_NN of_IN FLUDARA_NNP FOR_IN INJECTION_NNP in_IN combination_NN with_IN pentostatin_NN is_VBZ not_RB recommended_VBN due_JJ to_TO the_DT risk_NN of_IN severe_JJ pulmonary_JJ toxicity_NN ._. When_WRB administered_VBN concurrently_RB ,_, the_DT following_VBG drugs_NNS may_MD interact_VB with_IN adrenal_JJ corticosteroids_NNS ._. Amphotericin_NN B_NN or_CC potassium-depleting_JJ diuretics_NNS -LRB-_-LRB- benzothiadiazines_NNS and_CC related_JJ drugs_NNS ,_, ethacrynic_JJ acid_NN and_CC furosemide_NN -RRB-_-RRB- enhanced_VBD hypokalemia_NN ._. Check_VB serum_NN potassium_NN levels_NNS at_IN frequent_JJ intervals_NNS ;_: ._. use_NN potassium_NN supplements_NNS if_IN necessary_JJ ._. Digitalis_NN glycosides_NNS enhanced_VBD possibility_NN of_IN arrhythmias_NNS or_CC digitalis_NN toxicity_NN associated_VBN with_IN hypokalemia_NN ._. Monitor_NNP serum_NN potassium_NN levels_NNS ;_: ._. use_NN potassium_NN supplements_NNS if_IN necessary_JJ ._. Oral_JJ anticoagulants_NNS decreased_VBD prothrombin_NN time_NN response_NN ._. Monitor_NNP prothrombin_NN levels_NNS and_CC adjust_VBP anticoagulant_JJ dosage_NN accordingly_RB ._. Antidiabetic_JJ drugs_NNS -LRB-_-LRB- oral_JJ agents_NNS and_CC insulin_NN -RRB-_-RRB- diminished_VBD antidiabetic_JJ effect_NN ._. Monitor_NNP for_IN symptoms_NNS of_IN hyperglycemia_NN ;_: ._. adjust_VBP dosage_NN of_IN antidiabetic_JJ drug_NN upward_RB if_IN necessary_JJ ._. Aspirin_NN increased_VBD ulcerogenic_JJ effect_NN ._. decreased_VBN pharmacologic_JJ effect_NN of_IN aspirin_NN ._. Rarely_RB salicylate_NN toxicity_NN may_MD occur_VB in_IN patients_NNS who_WP discontinue_VBP steroids_NNS after_IN concurrent_JJ high-dose_JJ aspirin_NN therapy_NN ._. Monitor_NNP salicylate_NN levels_NNS or_CC the_DT therapeutic_JJ effect_NN for_IN which_WDT aspirin_NN is_VBZ given_VBN ._. adjust_VBP salicylate_NN dosage_NN accordingly_RB if_IN effect_NN is_VBZ altered_VBN ._. Barbiturates_NNP ,_, phenytoin_NN ,_, or_CC rifampin_NN increased_VBD metabolic_JJ clearance_NN of_IN fludrocortisone_NN acetate_NN because_IN of_IN the_DT induction_NN of_IN hepatic_JJ enzymes_NNS ._. Observe_VB the_DT patient_NN for_IN possible_JJ diminished_JJ effect_NN of_IN steroid_NN and_CC increase_VB the_DT steroid_NN dosage_NN accordingly_RB ._. Anabolic_JJ steroids_NNS -LRB-_-LRB- particularly_RB C-17_JJ alkylated_VBN androgens_NNS such_JJ as_IN oxymetholone_NN ,_, methandrostenolone_NN ,_, norethandrolone_NN ,_, and_CC similar_JJ compounds_NNS -RRB-_-RRB- enhanced_VBD tendency_NN toward_IN edema_NN ._. Use_NNP caution_NN when_WRB giving_VBG these_DT drugs_NNS together_RB ,_, especially_RB in_IN patients_NNS with_IN hepatic_JJ or_CC cardiac_JJ disease_NN ._. Vaccines_NNS neurological_JJ complications_NNS and_CC lack_NN of_IN antibody_NN response_NN ._. Estrogen_NN increased_VBD levels_NNS of_IN corticosteroid-binding_JJ globulin_NN ,_, thereby_RB increasing_VBG the_DT bound_VBN -LRB-_-LRB- inactive_JJ -RRB-_-RRB- fraction_NN ._. this_DT effect_NN is_VBZ at_IN least_JJS balanced_VBN by_IN decreased_VBN metabolism_NN of_IN corticosteroids_NNS ._. When_WRB estrogen_NN therapy_NN is_VBZ initiated_VBN ,_, a_DT reduction_NN in_IN corticosteroid_NN dosage_NN may_MD be_VB required_VBN ,_, and_CC increased_VBD amounts_NNS may_MD be_VB required_VBN when_WRB estrogen_NN is_VBZ terminated_VBN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS Corticosteroids_NNS may_MD affect_VB the_DT nitrobluetetrazolium_JJ test_NN for_IN bacterial_JJ infection_NN and_CC produce_VBP false-negative_JJ result_NN ._. Interaction_NN with_IN central_JJ nervous_JJ system_NN depressants_NNS other_JJ than_IN benzodiazepines_NNS has_VBZ not_RB been_VBN specifically_RB studied_VBN ._. however_RB ,_, no_DT deleterious_JJ interactions_NNS were_VBD seen_VBN when_WRB ROMAZICON_NNP was_VBD administered_VBN after_IN narcotics_NNS ,_, inhalational_JJ anesthetics_NNS ,_, muscle_NN relaxants_NNS and_CC muscle_NN relaxant_NN antagonists_NNS administered_VBN in_IN conjunction_NN with_IN sedation_NN or_CC anesthesia_NN ._. Particular_JJ caution_NN is_VBZ necessary_JJ when_WRB using_VBG ROMAZICON_NNP in_IN cases_NNS of_IN mixed_JJ drug_NN overdosage_NN since_IN the_DT toxic_JJ effects_NNS -LRB-_-LRB- such_JJ as_IN convulsions_NNS and_CC cardiac_JJ dysrhythmias_NNS -RRB-_-RRB- of_IN other_JJ drugs_NNS taken_VBN in_IN overdose_NN -LRB-_-LRB- especially_RB cyclic_JJ antidepressants_NNS -RRB-_-RRB- may_MD emerge_VB with_IN the_DT reversal_NN of_IN the_DT benzodiazepine_NN effect_NN by_IN flumazenil_NN ._. The_DT use_NN of_IN ROMAZICON_NNP is_VBZ not_RB recommended_VBN in_IN epileptic_JJ patients_NNS who_WP have_VBP been_VBN receiving_VBG benzodiazepine_NN treatment_NN for_IN a_DT prolonged_JJ period_NN ._. Although_IN ROMAZICON_NN exerts_VBZ a_DT slight_JJ intrinsic_JJ anticonvulsant_JJ effect_NN ,_, its_PRP$ abrupt_JJ suppression_NN of_IN the_DT protective_JJ effect_NN of_IN a_DT benzodiazepine_NN agonist_NN can_MD give_VB rise_VB to_TO convulsions_NNS in_IN epileptic_JJ patients_NNS ._. ROMAZICON_NN blocks_VBZ the_DT central_JJ effects_NNS of_IN benzodiazepines_NNS by_IN competitive_JJ interaction_NN at_IN the_DT receptor_NN level_NN ._. The_DT effects_NNS of_IN nonbenzodiazepine_JJ agonists_NNS at_IN benzodiazepine_NN receptors_NNS ,_, such_JJ as_IN zopiclone_NN ,_, triazolopyridazines_NNS and_CC others_NNS ,_, are_VBP also_RB blocked_VBN by_IN ROMAZICON_NN ._. The_DT pharmacokinetics_NNS of_IN benzodiazepines_NNS are_VBP unaltered_JJ in_IN the_DT presence_NN of_IN flumazenil_NN and_CC vice_NN versa_RB ._. There_EX is_VBZ no_DT pharmacokinetic_JJ interaction_NN between_IN ethanol_NN and_CC flumazenil_NN ._. Use_NN in_IN Ambulatory_JJ Patients_NNS The_DT effects_NNS of_IN ROMAZICON_NN may_MD wear_VB off_RP before_IN a_DT long-acting_JJ benzodiazepine_NN is_VBZ completely_RB cleared_VBN from_IN the_DT body_NN ._. In_IN general_JJ ,_, if_IN a_DT patient_NN shows_VBZ no_DT signs_NNS of_IN sedation_NN within_IN 2_CD hours_NNS after_IN a_DT 1-mg_JJ dose_NN of_IN flumazenil_NN ,_, serious_JJ resedation_NN at_IN a_DT later_JJ time_NN is_VBZ unlikely_JJ ._. An_DT adequate_JJ period_NN of_IN observation_NN must_MD be_VB provided_VBN for_IN any_DT patient_NN in_IN whom_WP either_CC long-acting_JJ benzodiazepines_NNS -LRB-_-LRB- such_JJ as_IN diazepam_NN -RRB-_-RRB- or_CC large_JJ doses_NNS of_IN short-acting_JJ benzodiazepines_NNS -LRB-_-LRB- such_JJ as_IN 10_CD mg_NN of_IN midazolam_NN -RRB-_-RRB- have_VBP been_VBN used_VBN ._. Because_IN of_IN the_DT increased_VBN risk_NN of_IN adverse_JJ reactions_NNS in_IN patients_NNS who_WP have_VBP been_VBN taking_VBG benzodiazepines_NNS on_IN a_DT regular_JJ basis_NN ,_, it_PRP is_VBZ particularly_RB important_JJ that_IN physicians_NNS query_NN patients_NNS or_CC their_PRP$ guardians_NNS carefully_RB about_IN benzodiazepine_NN ,_, alcohol_NN and_CC sedative_NN use_VBP as_IN part_NN of_IN the_DT history_NN prior_RB to_TO any_DT procedure_NN in_IN which_WDT the_DT use_NN of_IN ROMAZICON_NNP is_VBZ planned_VBN ._. No_DT information_NN available_JJ ._. Do_VB not_RB take_VB this_DT medicine_NN with_IN thioridizine_NN ,_, or_CC within_IN 5_CD weeks_NNS of_IN taking_VBG fluoxetine_NN ._. Talk_NN to_TO your_PRP$ doctor_NN if_IN you_PRP are_VBP taking_VBG certain_JJ antibiotics_NNS such_JJ as_IN erythromycin_NN ,_, clarithromycin_NN or_CC azithromycin_NN ._. This_DT medicine_NN should_MD not_RB be_VB taken_VBN with_IN MAO_NN inhibitors_NNS ._. Caution_NN should_MD be_VB exercised_VBN when_WRB taking_VBG this_DT medicine_NN certain_JJ antibiotics_NNS ,_, such_JJ as_IN erythromycin_NN ,_, clarithromycin_NN ,_, or_CC azithromycin_NN ._. This_DT medicine_NN should_MD not_RB be_VB taken_VBN with_IN MAO_NN inhibitors_NNS ._. If_IN you_PRP think_VBP you_PRP are_VBP taking_VBG an_DT MAO_NNP inhibitor_NN talk_NN to_TO your_PRP$ doctor_NN or_CC pharmacist_NN ._. Do_VB not_RB take_VB this_DT medicine_NN with_IN St._NNP Johns_NNP Wort_NNP because_IN of_IN the_DT additive_JJ effects_NNS of_IN sertonin_NN ._. This_DT medication_NN should_MD not_RB be_VB taken_VBN with_IN MAO_NN inhibitors_NNS ._. Your_PRP$ doctor_NN or_CC pharmacist_NN can_MD give_VB you_PRP more_JJR information_NN on_IN MAO_NN inhibitors_NNS ._. Wait_VB 5_CD weeks_NNS after_IN stopping_VBG escitalopram_NN before_IN starting_VBG a_DT non-selective_JJ MAO_NNP inhibitor_NN ._. Wait_VB 2_CD weeks_NNS after_IN stopping_VBG an_DT MAO_NNP inhibitor_NN before_IN starting_VBG escitalopram_NN ._. 